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Depression: 
.... There is a pitch of unhappiness so great that the goods of nature mqy be entirelY 
forgotten, and all sentiment of their existence vanish from the mental field. For this 
extremity of pessimism to be reached something more is needed than observation of life and 
reflection upon death. The individual must in his own person become the prey of 
pathological melancholY .. ... Such sensitiveness and susceptibility to mental pain is a rare 
occurrence where the nervous constitution is entirelY normal; one seldom finds it in a 
healthy subject even where he is the victim of the most atrocious cruelties of outward 
fortune ... it is positive and active anguish, a sort of psychical neuralgia whollY unknown 
to healthy life. 
William lames (1968) 
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Chapter! 
Introduction 
This thesis is concerned with the pharmacotherapy of inpatients with a major 
depressive disorder. In this introduction, the background of the present study is 
discussed, subsequently the aims of the study, and finally the structure of this thesis. 
The background section is divided into four parts. Firstly, epidemiological aspects of 
major depressive disorder are described and an attempt is made to describe the 
characteristic features of depressed inpatients. Secondly, the development of 
antidepressants is described and reports on the efficacy of antidepressants in 
inpatients are evaluated. Additionally, methodological aspects of these studies are 
evaluated to estimate the available evidence. Thirdly, several aspects of lithium 
addition to antidepressant treatment for UtlIesponsive depressed patients are 
discussed. Finally, aspects of trait aIL..aety, as a possible predictor of response to 
treatment \.V'i.th antidepressants, are discussed. 
Background 
Epidemiological a.rpects of unipolar depression 
Depressive disorders are common. International public health e":perts 
acknowledge the high prevalence of unipolar major depressive disorder combined 
with the pervasive human misery and impaired general functioning, and have 
identified this disorder in 1997 as the fourth most important cause of disability and 
premature death world wide (N[urray and Lopez, 1997a). Moreover, they '""pect 
depression to become the most important cause of disability and premature death by 
2020 (N[urray and Lopez, 1997b). The world wide 1-year prevalence for unipolar 
major depression according to the DSM-III criteria (APA, 1980) ranges from 0.8% 
to 5.8%, while the lifetime prevalence ranges from 1.5% to 19% (Weissman et al., 
1996). The 1-year prevalence of unipolar major depression for the United States 
ranges from 5% in the Epidemiological Catchment Area Study (Regier et al., 1993) to 
10.3% in the National Co-morbidity Study (Kessler et al., 1994). 
In the Netherlands, the 1-year prevalence of unipolar depression in the 
community is 5.8% and the lifetime prevalence is 15.4% (Netherlands Mental Health 
Survey and Incidence Study, NEMESIS; Bijl et al., 1997). The 1-year prevalence of 
depression recognised by general practitioners is 4%-5%, of depressive patients 
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referred to psychiatric outpatient services 0.64%, and of depressive patients referred 
to inpatient services 0.15% (Onnel and Sytema, 1999). The Netherlands with 15.8 
million inhabitants, thus, counts 916,400 depressives in the commuoity across each 
I-year period. Of this number about 711,000 are identified as depressed by general 
practitioners, while about 101,120 are referred to psychiatric outpatient services of 
whom 23,700 (23%) per year are admitted in hospitals. Thus, a substantial 
percentage of all depressives stay unrecognised and, thus, untreated, while a relatively 
small percentage of those who are identified as depressed are treated in psychiatric 
servlces. 
Little is known about factors that determine whether or not medical treatment is 
obtained. Also, little is known about which factors characterise depressed inpatients 
versus outpatients. Mendlowicz et al. (1998) found that inpatients and outpatients 
differed significantly in the severity of stressors, coping abilities and history of 
previous hospitalisations, but not in mean total scores on depression rating scales. 
Inpatients more often present with melancholia and a greater risk of suicide (Stage et 
al., 1998). Besides, inpatient populations of depressed patients have a relatively high 
proportion of psychotic depressed patients, of treatment resistant patients and of 
patients with a duration of the current episode of depression longer than one year 
(Bouvy, 1997). 
The develapment oj antidepressants 
Since Kuhn (1958) introduced the tricyclic compound imipraminehydrochloride 
as an effective antidepressant, many other tricyclic antidepressants (TCAs) have been 
developed. Throughout the last 30 years, considerable efforts have been made to 
develop pharmacologically different drugs with the purpose to replace the TCAs as 
the primary treatment for depression. These efforts are understandable since the 
TCAs, although therapeutically quite efficient, pose several problems such as slow or 
delayed onset of action, side effects and toxicity when taken in overdose. Especially 
the selective serotonin re-uptake inhibitors (SSRls) have increasingly become first 
choice in the treatment of depression next to the well-established TCAs, probably 
because of their more benign side effect profile and safety. Of the many clinical trials 
comparing the efficacy of antidepressants, only very few resulted in significant 
differences between the tested compounds in treating depression in general, as well 
as in treating subtypes of depression. These observations fuelled the opinion that 
most antidepressants are equally effective, regardless of the type of depression. 
However, in spite of the many reports showing no differences in efficacy between 
the various antidepressants, there has also been growing concern during the past 20 
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years, about the evidence for therapeutic efficacy of several of the new drugs. For 
instance, Zis and Goodwin (1979) analysed the evidence from controlled clinical 
trials for the antidepressant efficacy of iprindole and mianserin. For both 
compounds they concluded that the existing reports on clinical trials suggested 
considerable methodological shortcomings in terms of design, sample size, selection 
criteria, duration, dose levels, etc., such that no valid conclusion concerning their 
antidepressant properties could be dra"m. In addition, Cording-Tommel and Von 
Zerssen (1982) and Kragh-S0rensen et al. (1983), applying a methodology more 
appropriate to detect differences, found that mianserin was virtually devoid of any 
antidepressant effect in endogenously depressed patients (Research Diagnostic 
criteria [RDCJ; Spitzer et al., 1978). Subsequently, the reports of Gram et al (1983) 
and Guy (1986) suggested that the SSRls are less effective antidepressants than the 
TCAs. These reports stressed the importance of evaluating the magnitude of the 
type-2 error problem studies comparing the efficacy of new antidepressants versus 
the TCAs. A possible difference in efficacy between the drugs may have stayed 
undetected as a result of methodological flaws and/or a too low statistical power. In 
many studies comparing a new antidepressant '\vi.th a TeA, the statistical a no 
difference" conclusion has been taken as an indication of therapeutic equivalence 
with the TCA. Pocock (1985) in his book on the methodology of clinical trials 
calculated that a very substantial number of patients are needed to establish with any 
confidence that two treatments have comparable efficacy. If, for instance, a new 
drug treatment is compared to a standard drug treatment in a randomised trial, and if 
this new treatment will only be considered acceptable if it can be demonstrated with 
95% confidence that the number of responders to this new treatment is at worst 
10% less compared to the standard treatment, then there are at least 332 patients 
needed in each treatment condition. Thus, in a clinical trial comparing two treatment 
groups, a sample size of at least 2 x 332 = 664 patients is needed. In this case, the 
degree of certainty that the a priori defined difference, if present, would be detected is 
set at 1 - 0.2 = 0.8 (0.2 = type-2 error), which is called the "power" to detect a 
difference (in this case a difference of 10% in number of responders). 
The SSRIs versus the TC4s 
The existing number of studies comparing SSRls to TCAs made it possible to 
perform meta-analyses to overcome the problem of small sample size and type-2 
error (Iyrer, 1992). Anderson and Tomenson (1994) performed a meta-analysis 
comparing the efficacy of the TCAs and the SSRls including outpatient as well as 
inpatient studies. This meta-analysis was reported more in detail for inpatient groups 
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(Anderson, 1998) and was updated recently (Anderson, 2000). Included were all 
randomised, controlled trials published up to May 1997, investigating the efficacy of 
SSRIs (fluoxetine, fluvoxamine, paroxetine, sertraline, or citalopram) against a TCA 
in patients with unipolar depressive illness. A total of 10,706 patients from 102 
studies were included in the analyses, of which 5,533 received an SSRI and 5,173 a 
TCA. Subgroup analyses were performed for older versus younger, high versus low 
severity, and high versus low dose TCA groups. There were no significant 
differences in efficacy between the SSRIs and the TCAs, both in the total patient 
population and in these subgroups. No significant difference in efficacy between the 
drug classes was observed in the subgroup containing general practice and 
outpatients. However, in the inpatient group, TCAs were found to be significantly 
more effective than SSRIs. 
A possible e'--planation for the superiority of TCAs over SSRIs in inpatients is 
that treatment compliance is better in inpatients than in outpatients, as nurses more 
closely supervise inpatients. Thus, a better compliance might reveal an e.--cisting 
difference between antidepressants among hospitalised patients, which remains 
obscure in outpatients. 
However, it also is possible that this superiority of TCAs in inpatients is related to 
differences between outpatients and inpatients that make the latter more responsive 
to TCAs. These differences cannot be related to severity of depression, as measured 
by an initial high score on the Hamilton Rating Scale of Depression (HRSD; 
Hamilton, 1960), because the benefit of TCAs in this subgroup is not related to the 
HRSD score of the patients (Anderson, 2000), and because inpatients and 
outpatients do not differ in mean total scores on depression rating scales 
(Mendlowicz et al., 1998). Apparently, other differences do playa role. As mentioned 
before, inpatients more often present with melancholia, a greater risk of suicide, 
psychotic features, treatment resistance and a relatively long duration of the cw:rent 
episode of depression than outpatients (Bouvy, 1997; Stage et al., 1998). Anderson 
(2000) gives an alternative explanation for the difference in efficacy between SSRIs 
and TCAs in inpatients. He observed that clomipramine and especially amitriptyline 
were the most effective antidepressants in inpatients. Clomipramine and 
amitriptyline are so-called dual action TCAs: they inhibit both noradrenalin and 
serotonin re-uptake. Therefore, Anderson hypothesised that this pharmacological 
property makes these TCAs more effective in these inpatient studies and stated that 
it will be important to explore the efficacy of the newer dual action antidepressants, 
such as venlafa.."cine and mirtazapine in inpatients. However, Anderson (2000) also 
stated that caution is required in the interpretation of this result, as there exists no 
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statistically significant difference in efficacy between dual action and noradrenergic 
TCAs. Furthermore, his e.'planation does not make clear why the superiority of 
these dual action TCAs did not show up in outpatients. 
Finally, another explanation might be measuring blood levels of the TCAs in 
some of the studies. Two of the three trials among inpatients that did find a 
significant difference between a SSRl and a TCA were trials with blood level control 
of clomipramine (DUAG, 1986; 1990). Another double-blind blood level controlled 
study (Roose et al., 1994), which was not included in this meta-analysis because it 
was not randomised, also showed a significant and clinically relevant difference 
between a TCA (nortriptyline) and a SSRl (fluoxetine). How relevant is measuring a 
blood level of TCAs? Dosing of TCAs without blood level control will not result in 
an adequate blood level of the antidepressant in 30%-50% of the patients (Perry et 
al., 1994; Moleman et al., 1996). In addition, fle."<ible dosing of TCAs without blood 
level control is more problematic than fi,ed dosing because disturbing side effects 
could result in doses below the therapeutic level (Gram, 1990). All this may lead to 
response rates below the real potentials of these drugs. The majority of trials 
included in the meta-analysis of Anderson (2000) used a flexible dose design without 
blood level control. This may have lowered the efficacy of the TCAs used in these 
trials, which implicates that real differences between TCAs and SSRls may have been 
missed. This also may have influenced the results of the meta-analysis considerably. 
The newer antidepressants, pharmacologically different from SSRIs, versus the TCAr 
In view of the differences in efficacy between TCAs and SSRls in inpatients, the 
question of the efficacy of the newer antidepressants in inpatients is of interest. This 
review concerns only those newer non-SSRl antidepressants that are registered in the 
Netherlands: moclobemide, trazodone, nefazodone, mirtazapine and venlafa...~e. 
Randomised controlled trials comparing the efficacy of the newer antidepressants 
against a TCA in inpatients with major depressive disorder were identified by manual 
cross-referencing and a Medline® search up to September 2000 (search terms: drug 
name; randomlsed controlled trial; controlled trial; depression; major depressive 
disorder; inpatients) without language restrictions. 
The search resulted in identifying 8 inpatient studies. There were no inpatient 
studies on nefazodone. For the 8 studies identified, sample size (power), diagnostic 
criteria, selection, and description of the study population, dosing design, duration of 
trial, dropout rate, use of concomitant psychotropic medication, outcome criteria 
and results are listed in Table 1. As can be seen, except for one (DUAG, 1993) 
showing superiority of the TCA clomipramine over mocloberoide, all studies in this 
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n 
.". 
p-
eAuthor(s) eDiagnosis 8Description of srudy population .Sample size -Design ~ ~ (l> 
eResults -Outcome eDropouts (%) • Duration of trial H 
-.Dnl~ -Concomitant medication .@:rean~ Dose mg/dar 
Guelfi ct at, 1992 DSM-lII Endogenous* 129 Flexible dose dcsib'il 
fl"Tof siguifimllt Newcastle Psychotic? Suicidal? Moclobemide 15/62 (24) during 6 weel<s 
Moc1ohemide MADRS Duration of current episode? Clomipramine 11/67 (16) i\1oclobcmidc 462 
Clomipramine lIRSD,CGI Pre-treatment? Diazepam Clomipramine 146 
Chloral-hydrate 
DUAG,1993 DUAG Endogcnous t and non-endogenous 115 Fixed dose design 
Clomipramine> Newcastle Suicidal ++. Psychotic? Moclobemide 20/57 (35) during 6 weeks 
Moclobcmidc HRSD Only duration < 1 year Imipramine 12/58 (21) Plama drug level control 
p = 0.018 Bech Pre-trC"atment described Occasional oxa%epam j\,foclobemide 400 
Clomipramine 150 
Kellams et ai., 1979 No diagnostic Endogenous* 28 Flexible dose design 
No/ sigJlifirall/ Criteria Suicidal? Psychotic? Tmzodone 3/9 (33) during 4 weeks 
'l'ra%odone HRSD,CGI Duration of current episode? Imipramine 8/10 (80) Trazodone SOD 
Clomipramine Pre-treatment? Placebo 9/9 (100) Imipramine 185 
Chloral-hydrate 
Feighner, 1980 Feigner criteria Primary depression 45 Flexible dose design 
No/ sigNificaNt HRSD Suicidal? Psychotic? Melancholic? Tmzodone7/17 (41) during 4 weeks 
Trazodone eel Pre-treatment? Imipramine 9/18 (50) Trazodone 313 
Imipramine Duration of current episode? Placebo 7/10 (70) Imipramine 160 
Chloral-hydrate 
Gershon et aI., 1981 DSM-III Endogenous* depression 263 Flexible dose design 
Not siglJifirafl/ HRSD Suicidal? Psychotic? Trazodone 34/91 (37) during 4 weeks 
Trazodone Duration of current episode? Imipramine 37/100 (37) Trazodone 215 to 370 
Imipramine Pre-treatment? Placebo 42/72 (58) Imipramine 112.5 to 190 
ehloral-h~'drate 
Table 1 continues 
~ 
'" 
Table 1 (continued) Methodological aspects of eight trials with newer antidepressants and TeAs 
.Author(s) 
.Results 
_Drugs 
Zivkov et al., 1995 
Not significant 
Mirtazapine 
Amitripyline 
Richou CUll., 1995 
Not significant 
J\Iirtazapine 
Clomipramine 
Benkert et aI., 1996 
Not significant 
Venlafaxine 
Imipramine 
.l)iagnosis 
-Outcome 
DSM-II1 
RDC 
HRSD 
BPRS, GAS 
DSM-II1 
RDC 
HltSD 
MADRS 
BPRS, GAS 
DSM-IIl-R 
IIRSD 
MADRS 
-Description of stud}' population 
} No suicidal patients 
} Melancholic? Psychotic? 
} Only duration < 6 months 
} No antidepressants allowed in 
} month before admittance 
} Pre-treatment before that 
} month? 
Suicidal? Melancholic? Psychotic? 
CGI: 65% moderate to markedly, 
35% severely to extremely ill 
85% duration < 6 months 
Pre-treatment? 
* "Endogenous" is comparable to the term "melancholic" 
_Sample size 
.Dropouts (%) 
-Concomitant medication 
244 
Mi<t.,19/133 (14) 
Am;; 22/111(19) 
Chloral-hydrate/bcnzo-
dbzepine 
174 
~1i<tazap;ne;24/87 (28) 
Clomipramine 27/87 (31) 
Chloral-hydrate 
13en7.0diazcpine 
167 
Venlafax;ne 21/85 (25) 
Imipramine 31/82 (38) 
Chloral-hydrate 
Benzodiazepine 
.Design 
.Duration of trial 
-(Mean) Dose mg/ day 
Flexible dose design 
during 6 weeks 
Mirta£.apine 48.5 
1\ mitriptyline 182.7 
Flexible dose design 
during 6 weeks 
Mirtazapine 47.3 
Clomipramine 113.7 
Fi.xed dose design 
during 6 weeks 
Venlafaxine 365 ~ 150 
Imipramine 200 
Diagnostic criteria and rating scales: DSM-III: Diagnostic Statistical Manual (APA, 1980); DUAG scale: Scale of the Danish University 
Antidepressant Group (DUAG, 1993); Feighner criteria (Feighner et al., 1972); RDe: Research Diagnostic Criteria (Spitzer et at, 1978); 
DSI\1-III-R: Diagnostic Statistical Manual, revised (APA, 1987); Newcastle scale (Roth et al., 1983); MADRS; Montgomery-Asberg 
Depression Rating Scale (Montgomery and Asberg, 1979); HRSD: Hamilton Rating Scalc for Depression (Hamilton, 1969). CGI: Clinical 
Global Imprcssion (Guy, 1976); Bech-scale (Bech ct al., 1986); BPRS: Brief Psychiatric Rating Scale (Overall and Gorcham, 1962); GAS: 
Global Assessment Scale (Endicott et 011.,1976) ~ g-
o g' 
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ovemew failed to detect a difference between the tested antidepressants. However, 
as indicated by Angst et al. (1989), a number of methodolog;cal problems concerning 
the variables listed in Table 1 may invalidate clinical trials of antidepressants. 
Sample size. The sample size of the studies ranges from 28 - 263. As discussed 
earlier, the sample size has to be at least 664 to take a "no difference" conclusion as 
an indication of therapeutic equivalence of the new drug and the reference drug, if 
the power is set at 0.8 (pocock, 1985). 
Diagnostic and outcome criteria. Most studies use internationally accepted diagnostic 
criteria except one (Kellams et al., 1979). Outcome criteria seem to be well defined 
and accepted rating scales are used in all studies. 
Study population. The description of the study population in most studies is 
incomplete. None of the studies describes whether psychotic depressed patients are 
included. This is of interest, because psychotic depressed patients have been reported 
to show a weak response to treatment with antidepressants alone (Glassman et al., 
1975; Parker et al., 1992; Schatzberg and Rothschild, 1992), and no antipsychotics 
were allowed in any of these studies. Thus, g;ven the opinion of many authors that 
psychotic depressed patients need treatment with a combination of an antidepressant 
and an antipsychotic, it is unlikely that psychotic depressed patients are included in 
these studies (Spiker et al, 1985). In 2 studies patients with actively suicidal 
tendencies were excluded (Zivkov and De Jongh, 1995; Richou et al., 1995) and only 
1 study describes inclusion of suicidal patients (DUAG, 1993); in the other 5 studies 
it is not e"plicitly mentioned. Exclusion of suicidal patients is of interest because 
suicidality is one of the characteristic features of inpatients (Stage et al., 1998). The 
same issue applies to melancholic depression. In 4 studies it is not clear which 
proportion of the patients had melancholic features (Feighner, 1980; Zivkov and De 
Jong, 1995; Richou et al., 1995 and Benkert et al., 1996). Patients with melancholic 
features are more often present in inpatient groups (Stage et al., 1998) and it is 
relevant to know their specific response to the newer antidepressants in view of their 
weaker response to treatment of SSRIs compared to treatment of TCAs (perry, 
1996). Another relevant patient characteristic is duration of the current episode, 
because there may be a substantial difference in response rates between patients with 
short and long lasting depressive episodes, and because, in addition to higher true 
response rates, higher placebo response rates are found in patients with episodes of 
short duration (Angst et al., 1989). In only 4 studies the duration of current episode 
is mentioned: DUAG (1993) excluded patients with duration of current episode 
longer than 12 months. Zivkov and De Jong (1995) and Richou et al. (1995) 
excluded patients with duration of current episode longer than 6 months. In one 
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study 85% of patients had a duration of current episode shorter than 6 months 
(Benkert et al., 1996). Additionally, it is remarkable that none of these studies 
describes pre-treatment during the current episode although adequate pre-treatment 
may be an important predictor of non-response (Bouvy, 1997). Finally, patients who 
have been adequately pre-treated during the same episode with one of the 
antidepressants investigated in a certain trial should be excluded from that trial. In 
only one study this exclusion criterion is mentioned (Benkert et al., 1996). 
Dropout rates. High di:opout rates may bias the results of a trial. Evidence-Based 
Mental Health states that a dropout rate higher than 20% is not acceptable 
(Anonymous, 2000). The higher the dropout rate, the smaller the proportion of 
patients completing treatment, resulting in weakening of the power of that study 
even when an intention to treat analysis is performed. A skewed distribution of 
dropouts is even more blurring, because the reason of mthdrawal can be related to 
properties of one of the drugs (Angst et al., 1989; DUAG, 1993). In 5 studies the 
dropout rate is high in relation to sample size (Kellams et al., 1979; Feighner, 1980; 
Gershon et al., 1981; Richou et al., 1995; Benkert et al., 1996). In 2 studies the 
dropout distribution is skewed as a consequence of inefficacy of one of the tested 
antidepressants, moclobemide (Guelfi et al., 1992; DUAG, 1993). 
Concomitant medication. If concomitant psychotropic medication is used, the 
differences in efficacy between treatment groups may be blurred (Angst et al., 1989; 
Angst, 1993). In all studies an:ciolytic and/or hypnotic medication was used. None of 
the studies described the mean dose of concomitant medication that was used. In 
only 3 studies the exact numbers of patients which used concomitant medication in 
each treatment group were described (Guelfi et al., 1992; Zivkov and De J ongh, 
1995; Richou et al., 1995). DUAG (1993) described the distribution of occasional use 
of concomitant medication between the 2 study groups. The other 4 studies reported 
neither the numbers of patients, who used concomitant medication, nor the 
distribution of this medication between the 2 treatment groups. 
Dose design. There were 2 studies ",ith a fi..;:ed dose design. At a fi..;:ed dose of 150 
mg/ day, clomipramine resulted in a therapeutic level in the majority of patients 
(DUAG, 1993). Benkert et al. (1996) also applied a fi..;:ed dose design, but without 
blood level control. In a study of Glassman et al. (1977) on the clinical implication of 
imipramine blood levels, a fi..;:ed dose of 225 mg imipramine/day resulted in a 
therapeutic blood level in only 60% of patients. Thus, it is unlikely that the fi..;:ed 
dose of 200 mg imipramine/ day in the study of Benkert et al. (1996) has resulted in 
therapeutic levels in more than 60% of patients. There were 6 studies with a flexible 
dose design (Guelfi et al., 1992; Kellams et al., 1979; Feigner, 1980; Gershon et al., 
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1981; Zivkov and De Jongh, 1995; Richou et al., 1995). As discussed earlier a flexible 
dose design can easily result in doses of the TCA below the therapeutic level. 
Duration of triaL All studies fulfilled the criterion of duration of the trial of at least 
4 weeks (Angst et al., 1989). 
In conclusion, there are only a few randomised, controlled trials comparing the 
newer antidepressants moclobernide, trazodone, rnirtazapine and venlafa...ane to 
TCAs in inpatients. Only 1 study showed a significant difference between the new 
antidepressant versus clornipramille: mocIobemide was less effective than 
clomipramine (DUAG, 1993). The study population was clearly described and the 
results seem to be generalisable to other inpatient groups with the exception of 
psychotic depressed patients. Patients in this study were treated in a fixed dose 
design with blood level drug measurements. In the other 7 studies no significant 
differences between the newer antidepressants and TeAs were found. However, the 
sample size of all of these trials in combination with a number of other 
methodological shortcomings make it impossible to take the "no difference" 
conclusion as an indication of therapeutic equivalence of the new drug and the 
reference drug. Moreover, in view of the study populations of these studies, it is 
unlikely that their results could be generalised to other inpatient groups including 
patients \N~th melancholic features, with psychotic features, with substantial 
suicidality, \N~th treatment resistance and with a relatively long duration of the current 
episode of depression. Given the low number of studies on these newer 
antidepressants and given the methodological weaknesses of most of these studies, 
the efficacy of these drugs compared to the TCAs in inpatients is still uncertain. 
From this review it is clear that there is a need for more clinical trials in inpatients 
comparing treatment with the newer antidepressants to the established standard 
treatment 'W~th TCAs. Therefore, the present study comparing mirtazapine to 
imipramine in inpatients \vith major depression is relevant. Studies on ruirtazapine as 
well as venlafa..we are of particular interest because many authors use the udual 
action" properties of these drugs as an argument for choosing these drugs in 
(treatment resistant) inpatients (Kasper, 1997; Hirschfeld, 1999; Montgomery, 1999; 
Moller, 2000) despite the lack of evidence. 
lithium addition in treatment resistant depressive patients 
In addition to the issue regarding the optimal antidepressant treatment, there is 
the question -with respect to the strategy in treatment resistant depressive patients. 
Studies have shown, that in patients with melancholic depression treatment response 
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rates are 60% to 65% when blood levels of the drugs are not used to adjust the dose, 
and 80% to 85% when the dose of the antidepressant is adjusted on the basis of 
routine measurement of blood levels (Glassman et al" 1977; Reisby et al" 1977), 
Thus, according to these results, 15% to 20% of patients with melancholic 
depression is resistant to treatment. 
Lithium addition appears to be an effective strategy in patients with treatment 
resistant depression in about 50% to 60% of cases (Schopf, 1989; Katona et al" 
1995; Austin et al" 1991; Bauer and Dopfmer, 1999), It is the treatment strategy in 
treatment resistant depression that has been investigated most frequendy in placebo 
controlled double-blind studies (Bauer and Dopfmer, 1999), In several guidelines 
regarding treatment of major depressive disorder, lithium addition is advised in case 
of non-response to a single antidepressant (DeGroot, 1995; Birkenhager and 
Moleman, 1998; Nolen and Hoogduin, 1998; Anderson et al" 2000; AP A, 2000), 
From a clinical perspective, lithium addition is an attractive alternative in a non-
responding depressed patient; there is considerable likelihood of response, the effect 
can be rapid (DeMontigny et al" 1985), and the problems associated with 
withdrawing an antidepressant and starting a new one may be avoided, 
The treatment with an antidepressant and the addition of lithium, however, are 
often regarded separate, unrelated treatment decisions (Anderson et al" 2000; AP A, 
2000), Thus, in prescribing an antidepressant, the efficacy of possible lithium 
addition to that specific antidepressant is not taken into account, This may be of 
clinical relevance, as the efficacy of lithium addition may differ between 
antidepressants (price et al" 1986), Similarly, in studies on the efficacy of lithium 
addition, non-responders to an antidepressant are mostly recruited without much 
attention for details of the treatment phase that resulted in non-response (Schopf, 
1989; Katona et al" 1995), Therefore, comparison of the overall effectiveness of 
treatment strategies of different antidepressants and subsequent lithium addition of 
the respective non-responders is of interest. 
Trait anxiety as a possible predictor of response of depressive patients to specific antidepressants 
Given the expanding array of effective antidepressant drugs with high response 
rates and with rather divergent pharmacological properties, the question of whether 
there are reliable predictors of response to a given drug or class of drugs is of 
considerable importance, To date, however, among the many possible clinical 
predictors which have been investigated, only a few have emerged with relative value 
for clinical practice (Joyce and Payke], 1989; Goodwin, 1993): melancholic features 
predict a favourable response to TeAs compared to SSRIs (perry, 1996); atypical 
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depressions show a better response to monoamine oxidase inhibitors compared to 
TCA's (Quitkin, 1990); many authors feel that psychotic features predict a poor 
response to a treatment mth a single antidepressant '\.\i'l.thout combination mth an 
antipsychotic (Schatzberg and Rothschild, 1992). In the majority of cases, however it 
is still very difficult to accurately predict the response of depressed patients to 
medication. Predictors of response, which would be useful in identifying patients 
who would best be treated with a certain antidepressant, have been scarcely 
established (Nelson, 1999). 
According to many authors major depressive disorder, although 
phenomenologically quite homogeneous, is aetiologically heterogeneous (Schatzberg 
et al., 1983; Sacchetti et al., 1987; Winol .. ur, 1999). This may be one of the reasons 
that it is difficult to find clinical predictors of response to antidepressants in 
depressive patients. Winokur (1999) hypothesises that phenomenologically 
indistinguishable depressions may be separated into a group of depressions 
secondary to emotional instability and a group without emotional instability. 
According to Winoh,'ur (1999), the emotional instability in the former is caused by 
certain pre-e.'<isting psychiatric disorders such as anxiety disorders and personality 
disorders. Akiskal (1998) concludes that patients with an.'<iety disorders not only do 
develop depressions, but also that patients with high lnlit anxiety develop 
depressions. He introduced the concept of "generalised anxious temperament", 
indicating lifelong high trait anxiety which fluctuates in reaction to stress and which 
can escalate to a full-blown generalised an.'<iety disorder. According to Akiskal 
(1998), generalised anxiety disorder is in continuum with generalised an.'<iety 
temperament. This may predispose to and is often associated with depression. Janet 
a elgersma, 1939), Hays (1964), and Van Valkenburg (1983) described similar 
concepts. Thus, patients with a history of an.'<iety often develop a depression later in 
their life, which may be phenomenologically similar to depressions of patients 
without a history of anxiety. 
Disorders with different aetiology may show differential response to specific 
treatments. Therefore, it may be useful to e':plore clinical, personality and biological 
variables which could help to distinguish patients with different levels of trait 
anxiety, and subsequently, to e':plore the predictive value of trait anxiety in 
depressive patients with respect to the specific response to different antidepressants. 
Aims of the present study 
The main purpose of this study was to compare the efficacy of mirtazapine, a 
new antidepressant with strong anxiolytic properties, to the efficacy of imipramine, a 
20 
Introduction 
standard TCA, among inpatients with a major depressive disorder, including patients 
with melancholic features, with psychotic features, with suicidality, with treatment 
resistance, and with relatively long duration of the current episode of depression. It 
was hypothesised that a high trait an.'<iety level would be predictive for response to 
mirtazapine, and that a low trait anxiety level would be predictive for response to 
imipramine in this patient group. A randomised controlled clinical trial was 
performed, which was designed to avoid methodological problems such as 
inadequate dosing of the reference drug, a high dropout rate and concomitant 
treatment with other psychotropic drugs. Thus, the purpose of this design was to 
minimise the chance of type-2 errors and to ma.ximise the chance to observe 
quantitative and qualitative differences between the treatment outcomes of the two 
drugs. 
The specific aims of this study were the following: 
Primary aims: (1) To compare the efficacy of mirtazapine and imipramine in 
inpatients with major depressive disorder. (2) To determine the value of trait anxiety 
level as a predictor for response to mirtazapine and impramine, respectively. 
Secondary aims: (3) To compare the efficacy of treatment of psychotic depressed 
patients with that of non-psychotic depressed patients in the total study population 
and in the mirtazapine and the imipramine group, respectively. (4) To compare the 
overall efficacy of 2 treatment strategies for depressed inpatients: mirtazapine and 
subsequently lithium addition for non-responders or imipramine and subsequently 
lithium addition for non-responders. (5) To determine clinical, personality and 
biological variables which could help to distinguish patients with different levels of 
trait anxiety. 
Structure of rhe rhesis 
In Chapter 2, the pharmacological properties of mirtazapine are discussed. 
Subsequently, the design of the study and the selected patient population are 
described in detaiL The results of the comparison of the efficacy of mirtazapine and 
the efficacy of imipramine in the total study population are given and discussed in 
the light of the data on this issue from the literature and in the light of the applied 
methodology. 
In Chapter 3, the treatment of mood-congruent psychotic depression with 
imipramine is discussed. The response rate of psychotic depressed patients is 
compared to the response rate of non-psychotic depressed patients. Differences with 
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data from the literature on this issue are discussed and possible causes of these 
differences are evaluated. 
In Chapter 4, the results of an analysis of different symptom clusters and their 
course during treatment with mirtazapine and imipramine, respectively, is reported. 
The implications of these results with respect to possible differences in mechanism 
of action between the two drugs are discussed. 
In Chapter 5, the comparison of 2 treatment strategies for depressed inpatients is 
reported: mirtazapine and subsequendy lithium addition for non-responders or 
imipramine and subsequendy lithium addition for non-responders. 
In Chapter 6, the effect of a single high dose of diazepam in depressed inpatients 
in relation to their trait anxiety score is discussed. Besides, the results on the relation 
of trait anxiety with neuroticism score, MAO activity in platelets, and response to the 
two drugs, respectively, are described. 
In Chapter 7. the results of the study and clinical implications are discussed, and 
finally recommendations for future research are given. 
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Chapter 2 
A double-blind, fixed blood level study comparing 
mirtazapine with imipramine in depressed inpatients. 
Abstract 
Antidepressant effects of mirtazapine and imipramine were compared in a 
randomised, double-blind, fL,ed blood level study with inpatients in a single centre. 
Patients with a DSM-III-R diagnosis of major depression and a Hamilton (17-item) 
score of;::: 18 were selected. After a drug-free and a placebo washout period of 7 
days in total, 107 patients still fulfilling the HRSD criterion of;::: 18, started on active 
treatment. The dose was adjusted to a predefined fL,ed blood level to avoid 
suboptimal dosing of imipramine. Concomitant psychotropic medication was 
administered only in a few cases because of intolerable anxiety or intolerable 
psychotic symptoms. Eight patients dropped out and 2 were excluded from analyses 
because of non-compliance; 97 completed the study. According to the main 
response criterion (50% or more reduction on the HRSD score) 11/51 (21.6%) 
patients responded on mirtazapine and 23/46 (50%) on imipramine after 4 weeks' 
treatment on the predefined blood level. Such a dramatic difference in efficacy 
between antidepressants has not been reported often before. The selection of 
(severely ill) inpatients including those with suicidal or psychotic features may have 
significance in this respect. Optimalisation of treatment with the reference drug 
imipramine through blood level control, exclusion of non-compliance for both 
drugs, exclusion of most concomitant medication and a low dropout rate may also 
have contributed. It is concluded that imipramine is superior to mirtazapine in the 
patient population studied. 
Keywords 
Mirtazapine; Imipramine; Fi.,ed blood level monitoring; Study design; 
Antidepressant effect; Major Depression; Inpatients. 
Introduction 
11.irtazapine, a new piperaz1noazepme, is a strong antagonist of central CX2-
adrenoreceptors, H 1(histarnine) receptors, 5HT2 receptors (de Boer et al., 1988) and 
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5HT3 receptors (I<:ooyman et aI., 1994) and a weaker antagonist of muscarine and Ul 
adrenoreceptors (de Boer et al., 1988). Mirtazapine has recently been registered as an 
antidepressant. Efficacy and safety have been e":plored in controlled clinical trials 
(Smith et al., 1990; Claghom and Lesem, 1995; Richou et al., 1995; Martrila et al., 
1995; Van Moffaert et al., 1995; Zivkov and De Jong, 1995). In all trials tolerance 
and safety of rnirtazapine were satisfactory. In outpatients efficacy of rnirtazapine 
was reported to be significantly superior to placebo (Smith et al., 1990; Claghom and 
Lesem, 1995) and to trazodon (Van Moffaert et al., 1995); no significant differences 
between rnirtazapine and amitriptyline (Smith et al., 1990; Zivkov and De J ong, 
1995), clomipramine (Richou et al., 1995) and doxepin (Marttila et al., 1995), 
respectively, have been found. 
Some authors have e.."(pressed doubt whether efficacy of the "newer" 
antidepressants equals the efficacy of "older" antidepressants (DDAG, 1986; Bech, 
1988; Potter and Rudorfer, 1989; DDAG, 1990), in spite of the fact that most clinical 
trials show no differences in efficacy. The methodology of such trials may not always 
be suitable to detect differences. Possible confounding factors involved include 
(Angst et al., 1989; DDAG, 1990): 
1. High placebo response rates in trials ",~thout a placebo control group; 
2. "Dnblinding" due to different side effect pro@es; 
3. Treatment with sub-optimal doses of the reference drug; 
4. Non-compliance and dropout, especially if not equally distributed over the 
different treatment groups; 
5. High error variance in multicentre trials; 
6. Concomitant treatment with other psychotropic drugs. 
We have performed a study designed to avoid these methodological problems. 
The present study, comparing mirtazapine with imipramine, included: 
1. A drug-free and a placebo washout period of 7 days, to exclude early placebo-
responders; 
2. Dose adjustment to a fixed blood level to avoid sub-optimal dosing of 
. . 
urupramme; 
3. AlloVTing no concomitant psychotropic medication except .in case of intolerable 
anxiety or intolerable psychotic symptoms; 
4. No monitoring of side effects by the investigators to avoid unblinding; 
5. Inclusion of inpatients only; 
6. Single centre design. 
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Materials and methods 
Generaloutfine (Figure 1) 
Patients on the inpatient Depression Gnit of the Department of Psychiatry of the 
Gniversity Hospital Rotterdam "Dijkzigt" were enrolled into the study from 
December 1989 to December 1993. This Unit has a regional function for treatment 
of uncomplicated depressed patients and a supra-regional function for treatment of 
therapy-resistant depressed patients. Routinely psychotropic drugs are discontinued 
after admission. Depressed patients were screened for inclusion and exclusion 
criteria. Eligible patients had to be drug-free for at least 3 days before baseline 
assessment. After giving written informed consent placebo was administered single 
blind for 4 days. At the end of this period patients were again assessed on the 
Hamilton Rating Scale for Depression (HRSD; Hamilton, 1960) and those still 
meeting inclusion criteria (HRSD ~ 18) were randomly allocated to a double-blind 
treatment with either imipramine or mirtazapine. Doses of both drugs were adjusted 
to obtain fi:,ed blood levels. Outcome was assessed 4 weeks after attaining these 
predefined blood levels. 
Variable I. 3 days 4 days 
Drug-free Placebo 
i i 
Admission BaseLne 
assessment 
Figure 1. General outline of the study design 
Patient selection 
Variable 
I 
4 weeks 
Study medication 
i 
Dose 
Adjustment 
HRSD 
218 (day 5) 
Predefined 
blood level 
i 
HRSD 
outcome 
Patients were examined for inclusion and exclusion criteria before the initial 
placebo period and the HRSD was administered again at the end of this period. 
Included were patients aged 18-65 'With a "major depressive episode" according to a 
checklist with the DSM-III-R criteria (APA, 1987) and an HRSD score ~ 18. 
Excluded were patients with psychotic depression with hallucinations, schizophrenia, 
31 
Chapter 2 
paranoid psychosis, organic brain syndrome, chronic drug or alcohol abuse, clinically 
relevant renal, hepatic, cardiovascular, or endocrine disease, presence of absolute 
contraindication for either imipramine or mirtazapine, and pregnancy or the risk to 
become pregnant. 
All assessments were done by one research psychiatrist (fB), except the SADS 
(Schedule for Affective Disorders and Schizophrenia; Spitzer and Endicott, 
1978/79), which was performed in the presence of a second psychiatrist. In a clinical 
interview demographic data (age, sex, level of professional training, profession and 
marital status), psychiatric history (previous affective disorders, course, duration and 
treatment of the current episode), and family history (depression, suicide, alcohol 
abuse, antisocial behaviour, an.""jety disorders, drug dependency and other psychiatric 
disorders) were obtained. The depression part of the S"WS was administered at 
baseline by one psychiatrist in the presence of a second psychiatrist to obtain RDC 
diagnoses (Research Diagnostic Criteria; Spitzer et al., 1978) and to confirm the 
DSM-III-R diagnosis, obtained using the checklist at inclusion; scoring was based on 
consensus benv-een both psychiatrists. To measure severity at baseline and response 
during treatment we performed 2 depression rating scales. The HRSD, which is 
internationally the most widely accepted depression scale, was scored at baseline 
(before and at the end of the placebo period) and at 2 and 4 weeks after attaining the 
predefined blood level of study medication. The MADRS (Montgomery-As berg 
Depression Rating Scale; Montgomery and Asberg, 1979), which is composed of 10 
depression symptoms which have proven to be most sensitive to change during 
treatment, was scored at baseline and weekly thereafter. 
Study medication 
Once a day at 10 p.m. either imipramine or mirtazapine was administered in 
identical capsules containing 37.5 or 75 mg of imipramine or 10 or 20 mg of 
mirtazapine, respectively. Treatment was started with either 75 mg imipramine or 20 
mg mirtazapine. After 2 days the dose was doubled unless severe side effects were 
observed. Blood levels were monitored ru,'ice a week for the first 2 weeks, and 
weekly thereafter. The results were send to an independent psychiatrist from another 
ward who adjusted the number of capsules on the basis of these blood levels. The 
predefined blood level for imipramine + desmethylimipramine was 200-300 ng/ml 
(perry et al., 1987). For mittazapine, no therapeutic levels are known. To keep the 
study double-blind, to e..,clude treatment under e..,tremely high or low blood levels, 
and to ascertain treatment compliance it was decided to adjust mirtazapine doses to 
blood levels around the mean levels obtained with 60 mg mirtazapine per day. This 
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dosage was advised at the time the study started by Organon for treatment of 
depressed patients. To obtain such levels we performed a pilot study in 20 patients 
,vith a dose of 60 mg. The mean steady-state blood levels in this pilot study were 
67.0 ng/ml (SD ± 25.4, range 33.0-123.9). On basis of these results, predefined 
blood levels of 50-100 ng/ ml of mirtazapine were chosen. The difference ,vith 
predefined imipramine levels is, however, that optimal efficacy is not proven at these 
predefined mirtazapine levels. 
Side effects '.vere not systematically rated by the investigators, to prevent 
highlighting the different side effect profiles and, thus, introducing a bias towards 
"unblinding". Side effects were observed by treating psychiatrists and nurses not 
involved in the ratings for the study. Only in some dropout patients, specific 
treatment for side effects was necessary according to these observations. 
Evaluation of blindness. After completion of the study the research psychiatrist (JB) 
guessed the medication each of the 107 patients had received. This was correct in 46 
cases and incorrect in 37 cases. In 24 cases the research psychiatrist was not able to 
decide on 1 of the 2 study medications. 
Assqy of stu4J medication. Imipramine and desipramine assays were carried out ,vith 
HPLC. Mirtazapine was assayed according to Paanakker and Van Hal (1987). 
Concurrent medication 
Drugs for somatic complaints not interfering ,vith study medication were 
continued unchanged during the study, if necessary. No psychotropic medication 
besides the study medication was allowed except for 1-6 tablets a day containing 45 
mg of an extract of valerian in case of alL-aety or insomnia. This extract was assumed 
to be ,vithout antidepressant effect. In exceptional cases lorazeparn, 1-5 mg a day for 
intolerable agitation or amiety, or haloperidol, 1-15 mg a day in case of intolerable 
psychotic symptoms, respectively, had been prescribed. 
Data-analysis and statistical methods 
The main response criterion was defined a priori as a reduction of 50% or more of 
the HRSD score 4 weeks after attaining the predefined blood level. The x2-test was 
used for comparing outcome scores between the 2 treatment groups; the t-test for 
comparing continuous outcome variables. In order to increase precision of the 
estimated treatment effects, AL'\iCOV A's, using multiple linear regression analyses, 
were also a priori planned for comparing the MADRS and HRSD post-treatment 
scores between the 2 treatment groups with the following co-variables potentially 
taken into account MADRS and HRSD pre-treatment scores (baseline severity), 
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duration of the present episode, number of previous depressions, manic episodes, 
personality, family history, previous treatments during current episode, melancholic 
type, psychotic features and type of depression according to RDC criteria. Adequate 
pre-treatment during the current episode was defined as an adequate dose of an 
antidepressant during at least 4 weeks (potter and Rudorfer, 1989). 
The difference in time-trend of the MADRS during 6 weeks of treatment 
between the 2 treatment groups was tested in a random coefficient model using rm-
"-\NOVA. 
Because efficacy of antidepressants may be less in the subgroup of psychotic 
patients, separate analysis of this subgroup was planned a priori. 
Ethical considerations 
The protocol was approved by the Ethics Committee of the University Hospital 
Rotterdam "Dijkzigt" and the Medical Faculty of the University of Rotterdam and 
was carried out in accordance ""th the ethical standards laid do",." in the declaxation 
of Helsinki. 
Results 
Patient population and drop-outs 
One hundred and seven depressed inpatients were randonllsed to either 
mirtazapine (n = 54) or imiprarnioe (n = 53) (Table 1). Eight patients dropped out, 
while 2 patients were excluded from analyses because monitoring of blood levels 
showed non-compliance (Table 2). Five dropouts on imiprarnioe were due to side 
effects, compared to none on mirtazapine. Thus, 97 patients (51 taking mirtazapine 
and 46 taking imiprarnioe) completed the study. 
Blood level.s and &lses 
The mean time to reach the predefined blood levels was 10.9 days (SD ± 3.5, 
range 5-21) for mittazapine and 13.6 days (SD ± 4.6, range 7-25) for imiprarnioe. 
Including the 4-week treatment on this blood level, the mean total period on study 
medication was 38.9 days (SD ± 3.5, range 33-49) for mirtazapine and 41.6 days (SD 
± 4.6, range 35-53) for imipramine. The mean daily dose during the 4 weeks on the 
predefined blood level for mirtazapine was 76.2 mg (SD ± 17.6, range 40-100) with a 
mean blood level of 69.3 ng/ml (SD ± 10.0, range 48.8-92.8), and for imipramine 
235.5 mg (SD ± 90.8, range 37.5-450) with a mean blood level of imipramine + 
desmethyl-imipramine of267.1 ng/ml (SD ± 35.9, range 199.0-400.3). Within this 
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Table 1. Total population (II = 107) 
Age: mean ± SO (range) 
Sex: male/ female 
Diagnosis: I1major depressive episode II (DSf\'f-III-R) 
*Ullipo/ar 
Non-psychotic, 1 st episode 
Non-psychotic, recurrent 
Psychotic, 1st episode 
Psychotic, recurrent 
*Bipolar 
Non-psychotic 
Psychotic 
f..'felancholic type 
Major Depressive episode (RDC) 
Retarded Depression (RDC) 
Agitated Depression (RDC) 
Endogenous Depression (RDC) 
Suicidal 
HRSD baseline 
f"lADRS baseline 
Duration current episode 
< 1 year 
> 1 year 
Adequate pre-treatment with antidepressants 
Family history (1st/2nd degree) 
Depression 
Suicide 
Personality disorder 
Mirtazepine (II = 54) 
45 ± II (23-64) 
12/42 
54 
47 
54 
16 
16 
53 
28 
49 
5 
19 
IS 
9 
6 
4 
1 
26.1 ± 4.5 (19-37) 
37.5 ± 6.0 (25-51) 
34 
20 
28 
28 
10 
II 
Imipramine (II = 53) 
47 ± 10 (27-65) 
11/42 
53 
45 
52 
16 
19 
50 
32 
52 
23 
14 
10 
5 
I 
o 
26.5 ± 5.0 (18-37) 
36.2 ± 6.8 (16-54) 
32 
21 
27 
33 
9 
7 
f 
~ 
~. 
" j 
[ 
5' 
g: 
1-
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sum the mean blood level of imipramine was 119.13 ng/l (SD ± 44.48, range 44.6-
235.0) and the mean desmethyl-imipramine was 148.01 ng/l (SD ± 54.6, range 45.0-
310.3). 
Table 2. Drop-outs and non-completers by non-compliance (n = 10) 
Treatment Reason Day of Day after attaining 
study predefined blood 
medication level 
~azapine 1. Transfer to other ward 14 
2. Refuse to take medication 12 
3. Non-compliance (blood level~) 31 14 
Imipramine 4. Mania 18 4 
5. Orthostasis 9 
6. Deterioration 19 2 
7. Fever and delirium 12 2 
8. Allergic reaction 21 7 
9. ~AJlergic reaction 36 22 
10. :--Jon-compliance (blood level~) 28 7 
Concomitant medication 
Nine mirtazapine and 7 imipramine patients were treated with the valerian 
extract. There were no significant differences between the 2 treatment groups with 
respect to dose and duration of valerian medication. Lorazeparn. was administered to 
6 patients (4 taking mirtazapine and 2 taking imipramine), which has been ignored in 
the analyses because of the small number of patients (6/107). Nine of the 31 
psychotic patients were treated with haloperidol, 7 taking mirtazapine and 2 taking 
imipramine. Only 1 of those patients (taking mirtazapine) was a responder; the other 
8 patients were non-responders. This indicates, that haloperidol was not instrumental 
in the recovery in those patients. 
Treatment effeas 
According to the maID response criterion, II/51 (21.6%) patients were 
responders on mirtazapine and 23/46 (50%) on imipramine; a significant difference 
C:t..' = 7.38; df= 1; P = 0.007). In addition, the mean HRSD score after 4 weeks of 
predefined blood levels (Table 3) of the imipramine group was significantly lower 
than that of the mirtazapine group (mean difference = 5.1; SE = 1.8; t = 2.83; df= 
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95; P = 0.006). "Intent to treat" analysis (n = 107) with the last HRSD score carried 
forward showed 11/54 (20.4%) responders with the mirtazapine and 23/53 (43.4%) 
with the imipramine group &.' = 5.5; c!f= l;p = 0.019). 
Table 3 ?vfean HRSD scores at baseline and endpoint (after 4 weeks of predefined blood 
level) 
Intention to treat Completers 
1Iirtazapine Imipramine 1firtazapine Imipramine 
(n = 53) (n = 54) (n = 46) (n = 51) 
Baseline HRSD 26.1 ± 4.5 26.5 ± 5.0 26.1 ± 4.4 26.7 ± 4.9 
Endpoint HRSD 19.6 ± 8.7 15.8 ± 9.6 19.2 ± 8.6 14.1 ± 9.0 
Since 9 of the 31 psychotic patients were treated with haloperidol and since more 
patients on mirtazapine received haloperidol, we have analysed the results omitring 
patients receiving haloperidol. The response on imipramine: 23/44 (52.3%), differed 
significantly from the response on mirtazapine: 10/44 (22.7%) &.' = 6.7; c!f= 1;p = 
O.OOS). 
Figure 2A (completers) and 2B (ITT with LOCF) show the mean MADRS scores 
for the 2 groups during 6 weeks of treatment. According to the rm-ANOVA the 
time-trends were significantly different between the 2 treatment groups (completers: 
P = 0.003; ITT: P = 0.026). Regression analyses ",-jth severity (HRSD score at 
baseline), suicidal or psychotic features (DSM-III-R), duration of current episode, 
previous adequate treatment of current episode with imipramine, with other classical 
tricyclics or with modern antidepressants, number of psychiatric admissions before 
the current depression, positive family history for depression and/or suicide, and 
personality disorder as co-variables did not improve the precision of the estimated 
difference between the 2 drugs to an appreciable extent. 
In the subgroup of 31 psycbotic patients 4 dropped out (2 patients taking 
mirtazapine and 2 taking imipramine), so 27 psycbotic patients completed the study. 
According to the main response criterion, 4/14 (2S.6%) responded on mirtazapine 
and 9/13 (69.2%) on imipramine &.' = 2.98; c!f= l;p = 0.OS4). The mean HRSD 
scores after 4 weeks of predefined blood levels were significantly lower for the 
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imipramine group than for the rnirtazapine group (mean difference = 9.8; SE = 3.8; t 
= 2.56; df= 25;p = 0.017). "Intent to treat" analysis in the subgroup of 31 psychotic 
patients showed 4/16 (25%) responders with the mirtazapine and 9/15 (60%) with 
the imipramine group ex' = 2.59; df = 1; P = 0.11). If patients treated with 
haloperidol were regarded as dropouts, an "intent to treat" analysis showed the 
following results: 3/16 (18.8%) responders with the mirtazapine group and 9/15 
(60%) with the imipramine group. This is a significant difference ex' = 3.95; df= 1; P 
= 0.046). Figure 3A (completers) and Figure 3B (ITT with LOCF) show the 
MADRS scores for the 2 groups of psychotic patients during 6 weeks of treatment. 
According to the rm-ANOVA the time-trends were significandy different between 
the two treatment groups (completers: p = 0.001; ITT: p = 0.019). 
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Mean total scores on the Montgomery-Asberg depression rating scale. 
A Completers (n = 97); B all patients (n = 108, LOCF) 
MiItazapine compared to imipramine 
The overall response rate to treatment ".vas rather low (50% on imipramine and 
22% on mirtazapine). For this reason we performed subgroup analyses. Excluding 
patients with duration of the depression longer than 1 year, the response rate on 
imipramine was 63.3% (19/30) and 31.3% (10/32) on mirtazapine. Excluding in this 
subgroup also patients 'With adequate pre-treatment of the current episode, response 
rates were even higher: 69.6% (16/23) on imipramine and 37.5% (9/24) on 
mirtazapine. These differences between the imipramine and mirtazapine group are 
not significant, most likely because of the low number of patients. 
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Figure 3A, B Mean total score on the Montgomery-Asberg depression rating scale of the 
psychotic patients. 
A Completers (n = 27); B all psychotic patients (n = 31, LOCF). 
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Discussion 
The most obvious result in this study is the considerable difference in 
antidepressant efficacy between mirtazapine and imipramine. Such a difference has 
not been reported in previous studies (Smith et al., 1990; Claghom and Lesem, 1995; 
Richou et al., 1995; Marttila et al., 1995; Van Moffaert et al., 1995; Zivkov and De 
Jong, 1995). A possible explanation may be found in differences between the present 
and other trials with mirtazapine. 
Previous studies on mirtazapine (Smith et al., 1990; Claghom and Lesem, 1995; 
Richou et al., 1995; Marttila et al., 1995; Van Moffaert et al., 1995; Zivkov and De 
Jong, 1995) used a flexible dose design. This may lead to inappropriate dosing 
especially with tricyclic antidepressants because side effects preventing dose 
increments may occur at sub-therapeutic doses/blood levels (Dawling, 1982; 
D"L'AG, 1990). In at least 2 previous studies (Smith et al., 1990; Richou et al., 1995) 
the mean dose of the tricyclic reference drug was rather low; 111 mg amitriptyline 
and 113.7 mg clomipramine, respectively. In the present patient group the mean 
daily dose of imipramine was 235.5 mg with a very wide range (37.5-450 mg). No 
fewer than 9 (20%) patients were on a dose of 112.5 mg or less, and 17 (37%) 
patients received 300 mg imipramine per day or more. This illustrates the range of 
doses necessary to obtain therapeutic blood levels. It is not very likely that such 
doses would have been administered without blood level control. With mirtazapine it 
was not possible to predefine an optimal blood level because therapeutic blood levels 
of mirtazapine are not available. The mean mirtazapine dose of 76 mg/ day was 
above the dose used in other studies: 53 mg/ day (Zivkov and De J ong, 1995) and 47 
mg/day (Richou et al., 1995) in other inpatient studies. The predefined blood level of 
mirtazapine was based on steady-state blood levels of patients on 60 mg/ day of 
mirtazapine, which was the recommended dose in the previous inpatient mirtazapine 
studies (Richou et al., 1995; Van Moffaert et al., 1995; Zivkov and De Jong, 1995). 
It cannot be excluded that mirtazapine has a curvilinear blood level response 
curve, as is the case with nortriptyline (Perry et al., 1987), and that the present dose 
was less effective for that reason. Dose fmding or blood level response studies to 
clarify this point are not available. Thus, the imipramine dose in the present study 
Vlas in the therapeutic range for all patients, but this is not certain for all patients on 
mirtazapine, which could be one e,:planation for the difference in efficacy between 
both drugs in this study. 
In the present study only a minority of patients was treated with co-medication, 
and the difference in efficacy between imipramine and mirtazapine remained 
significant if these patients were excluded. In the earlier mirtazapine studies (Smith et 
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al., 1990; Claghom and Lesem, 1995; Richou et al., 1995; Marttila et al., 1995; Van 
Moffaert et al., 1995; Zivkov and de Jong, 1995) short acting benzodiazepines were 
allowed for the first 2 weeks and chloral hydxate (0.5-3 gr) during the entire study. It 
was not reported whether the co-medication was equally divided between the 2 
treatment groups. Angst (1993) has argued that co-medication with benzodiazepines 
increases response to placebo treatment and decreases the power of a comparative 
trial considerably. It may be of significance, therefore, that other studies with 
mirtazapine reported response percentages as high as 72% (Zivkov and de J ong, 
1995),80% (Richou et al., 1995), and 78% (Van Moffaert et al., 1995), respectively. 
The dxopout rate in the present study was low: 9.1% versus 17-35% in other 
mirtazapine studies (Smith et al., 1990; Claghom and Lesem, 1995; Martrila et al., 
1995; Van Moffaert et al., 1995; Richou et al., 1995; Zivkov and De Jong, 1995). A 
high dxopout rate may bias results of clinical trials even if analyses are based on 
"intent to treat" samples (Angst et ai, 1989). 
Patient selection may also play an important role in treatment outcome (Ansseau, 
1992). Similar to the present trial, 3 trials of mirtazapine were performed with 
inpatients, comparing it 'With amitriptyline, clomipramine, and trazodone, 
respectively (Richou et al., 1995; Van Moffaert et ai, 1995; Zivkov and De Jong, 
1995). However, other selection criteria differed. Patients with active suicidal 
tendencies were excluded (Smith et al., 1990; Claghom and Lesem, 1995; Richou et 
al., 1995; Marttila et al., 1995; Van Moffaert et al., 1995; Zivkov and de Jong, 1995). 
It is not clear whether patients with psychotic depressions and patients with a 
"melancholic type" -depression had been included in these studies. In the present 
study 29% (31/107) of the patients had psychotic depressions and 86% (92/107) 
fulfilled criteria for melancholic type, respectively. Outpatients (Smith et al., 1990; 
Claghom and Lesem, 1995) or in and outpatients (Marttila et al., 1995) were studied 
in some trials, while in the 3 trials with inpatients (Richou et al., 1995; Van Moffaert 
et al., 1995; Zivkov and De Jong, 1995) those with a duration of the depression 
longer than 6 months were excluded. In 3 studies (Richou et al., 1995; Marttila et al., 
1995; Van Moffaert et al., 1995) none of the patients had been treated with an 
adequate dose of an antidepressant in the month preceding the trial. 
The present results are in some respects comparable to those of the DUAG-
studies (DUAG, 1986; DUAG, 1990), in which the serotonine re-uptake inhibitors 
citalopram and paroxetine, respectively, were compared \.Vith clomipramine. 
Differences in favour of clomipramine were reported in both studies. The authors 
suggested that this may be related to inclusion of only inpatients, rigid adherence to a 
fi:<ed dose schedule and control of drug compliance by blood level monitoting. 
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The subgroup of psychotic patients showed an even larger supenonty of 
imipramine over mirtazapine, response percentages being around 60-70% for 
imipramine and around 20-30% for mirtazapine, depending on the analysis 
performed. Most of these results were significant, even 'With the small number of 
psychotic patients studied. Seven patients treated with haloperidol were talting 
mirtazapine and only 2 were taking imipramine, also hinting at a better efficacy of 
imipramine. Thus, the inclusion of psychotic patients may have contributed to the 
superiority of imipramine. 
The response rate in this study was relatively low; 50% on imipramine compared 
to 70-80% in other studies (potter and Rudorfer, 1989). This is probably due, at least 
in part, to a lower response rate of patients "\N;th a current depressive episode of long 
duration and of patients that had been pre-treated with antidepressants, since with 
the exclusion of these patients, the response rate was 70% (16/23) on imipramine. 
In conclusion, the present study shows a considerable difference in 
antidepressant efficacy between the new antidepressant mirtazapine and imipramine. 
Optimalisation of treatment with the reference drug imipramine through blood level 
control, exclusion of non-compliance for both drugs, exclusion of most concomitant 
medication and a very low dropout rate may have contributed to this result. Also, the 
selection of severely ill inpatients, including those with suicidal or psychotic features, 
may be significant in this respect, although it is difficult to ascertain differences 
between patient characteristics in different studies. In the patient population studied 
imipramine is superior in efficacy to mirtazapine. 
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Abstract 
Most studies report a poor response of psychotic depressed patients to tricyclic 
antidepressants in comparison "vith non-psychotic depressed patients and in 
comparison '-vith treatment ",vith tricyclic antidepressants in combination v.rith 
antipsychotics. However, the issue of optimal treatment of psychotic depressed 
patients has not been resolved as yet. Previously, '\ve reported a significant difference 
in response to mirtazapine compared to imipramine in a randomised, double-blind, 
fL"ed blood level study with inpatients 'W~th major depression. In the current study 
\.ve focus on the response to imipramine in a group of patients with psychotic 
depression and compare this to patients without psychotic features. Our aim in 
presenting these fmdings '.vas to contribute to the discussion on the optimal 
treatment of psychotic depressed patients. Fifty two patients with a unipolar major 
depression (DSy[-III-R), comprising 15 patients with mood-congruent psychotic 
features and 37 '\vith no psychotic features, were commenced on treatment '\vith 
imipramine. The dose was adjusted to a predetermined blood level. After 4 weeks of 
treatment on predetermined blood leve~ there were 45 completers, 9/13 (69.2%) 
psychotic and 14/32 (43.8%) non-psychotic patients were responders. The patients 
with psychotic features demonstrated a lower mean final HRSD score, togedler ,,~th 
a greater fall in MADRS score over time, compared to the non-psychotic group. In 
this group of patients with mood-congruent psychotic depression, imipramine used 
on its own together with strict control of blood drug levels produced a high 
treatment response rate of 70%. 
Keywords: 
Imipramine; Fixed blood level monitoring; Study design; Antidepressant effect; 
Major depression with psychotic features. 
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Introduction 
As reviewed by Schatzberg and Rothschild (1992) most studies report that 
depressed patients with psychotic features respond poorly to treatment ,,~th an 
antidepressant alone. However, the question of which treatment is optimal for 
patients diagnosed '\vith psychotic depression remains as yet unresolved. In a meta-
analysis of 44 studies looking at physical treatments for psychotic depression (parker 
et al., 1992) combination therapy of tricyclic and antipsychotic drugs ranked as more 
effective than antidepressant therapy alone, but the difference was not statistically 
significant. The authors conclude that there is a need to re-examine the ",~dely held 
view that combination thexapy \vith an antipsychotic drug and an antidepressant 
preparation is superior to treatment with an antidepressant alone. One factor that 
may affect treatment results (the conclusions reached by research on this subject) is 
that diagnostic criteria for psychotic depression frequently differ from study to 
study. Maj et al. (1990) suggested that the inclusion in some studies of depressed 
patients ,vith psychotic features that were mood-incongruent could account in part 
for the differences in treatment response observed between psychotic depressed 
patients and depressed patients without psychotic features. A second factor that may 
exert an lmportant influence on results is the dose and duration of drug treatment. 
Quitkin et al. (1978) reported that the presence of delusions did not predict a poor 
response to imipramine provided that patients were treated with adequate doses for 
a sufficient period of time. Glassman et al. (1975, 1977), however, reported a poor 
response to 4 weeks of treatment v.;th a fix:ed dose of imipramine in depressed 
patients when psychotic features were present. The one available double-blind study 
(Spiker et al., 1985) found the combination of amitriptyline and perphenazine clearly 
superior to amitriptyline alone. 
The present paper forms part of a double-blind study comparing mirtazapine and 
imipramine in a group of depressed inpatients. The results of this comparative trial 
have been reported elsewhere (Bruijn et al., 1996) and indicated a considerable 
difference in efficacy in favow: of imipramine over mirtazapine for depressed 
patients both ,vith and ",~thout psychotic features. In the current study, we focus on 
the treatment response to imipramine in a group of patients with psychotic 
depression and compare this to patients who manifest no psychotic features. Our 
aim in presenting these findings is to contribute to the discussion on the optimal 
management for this patient group. 
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Methods 
General outline 
For a detailed description of the study the reader is referred to our previous 
report (Eruijn ct aI., 1996). The general outline is shown in Figure 1. Eligible patients 
had to be drug-free for at least 3 days before baseline assessment. Included were 
patients aged 18-65 ,vith a DS\1-III-R diagnosis "major depressive episode" 
(American Psychiatric Association, 1987) and a Hamilton Rating Scale for 
Depression score "= 18 (HRSD; Hamilton, 1960). Excluded were patients with visual 
hallucinations, schizophrenia, paranoid psychosis, organic brain syndrome, chronic 
drug or alcohol abuse, and clinically relevant somatic disease. Patients were given a 
detailed outline of the study, followmg which "Titten consent was obtained and a 
single-blind placebo was administered for 4 days. At the end of this period of 
placebo treatment, patients '-vere assessed again on the HRSD and those still meeting 
the mclusion criteria including a HRSD "= 18 were randomly allocated to double-
blind treatment ,vith either imipramine or mirtazapine. 
Variable I 3 days 4 days Variable 1 4 weeks 
Drug-free Placebo Study medication 
Dose Predefined 
adjustment Blood level 
T T T T 
Admission Baseline HRSD HRSD 
assessment ;>;18 (day 5) outcome 
Figure 1. General outline of the study design 
Blood levels were monitored at weekly intervals. Dosing was adjusted for all 
subjects to obtain a predetermined blood level of imipramine plus desmethyl-
imipramine, of 200-300 "gil. lill assessments were done by one research psychiatrist 
GB), except for the section of the Schedule for Affective Disorders and 
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Schizophrenia (SADS; Spitzer and Endicott, 1978/79) which relates to depression, 
which was performed in the presence of a second psychiatrist. This standardised 
interview was administered at the start of the trial to obtain Research Diagnostic 
Criteria (RDC; Spitzer et al., 1978) diagnoses and scoring was based on a consensus 
between both psychiatrists. Psychotic features were assessed during this interview. 
Extreme feelings of hopelessness and worthlessness were not by themselves 
considered sufficient for inclusion within the psychotic group. A diagnosis of 
psychotic depression was made only when the subject was found to be suffering 
from definite mood-congruent delusions as defined by the SADS. Two depression 
rating scales were used: the Hamilton Rating Scale for Depression, (HRSD; 
Hamilton, 1960) and the Montgomery Asberg Depression Rating Scale (lVlADRS; 
Montgomery and Asberg, 1979). Both the HRSD and MADRS were performed at 
the start of the study to record a baseline depression score. Thereafter, the HRSD 
was scored at 2 and 4 weeks after attaining the predefined blood level of imipramine 
and desmethyl-imipramine; and the 11.ADRS at weekly intervals. No concurrent 
psychotropic medication was allowed except up to 6, 45 mg tablets of valerian per 
24-hour period in the case of anxiety or insomnia. This extract was assumed to be 
"\vi.thout antidepressant effect. In 3 exceptional cases other co-medications were 
administered (see Results). 
Data ana!)isis and statistical methods 
Response was defined a pn"on" as a reduction of 50% or more of the HRSD score 
from baseline measurement at the start of the study to the endpoint, at 4 weeks post 
attaining the predetermined blood imipramine level. Patients ",ith an outcome 
HRSD score of less than 10 were determined for the purposes of this study to be "in 
remission". The x2-test was used for comparing categorical variables; 950/0 
confidence intervals are also reported. The I<olmogorov-Smirnov goodness of fit 
test was performed on all continuous variables to measure deviation from the curve 
of normal distribution. Variables which showed an approximate normal distribution 
'\vere eXamlned using independent samples t-tests; othenvise~ Mann-W'hitney tests 
were performed. 
Since this analysis is post-hoc, it can be regarded as an observational study. 
Therefore, we controlled for all currendy acknowledged possible confounding 
factors relating to the efficacy of antidepressants that may have had an impact on the 
difference in endpoint HRSD scores between the non-psychotic and psychotic 
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groups of patients (l<:ocsis et al., 1990; Scott, 1994). These factors were: age, 
duration, and severity (taken as baseline HRSD score) of present episode, 
psychomotor retardation, number of previous episodes of depression, and family 
history of affective disorder. Thus, we performed an ANCOV A using a multiple 
linear regression analysis: with the outcome HRSD score as the dependent variable, 
the presence of psychotic symptoms as the independent variable and the 
aforementioned possible confounding factors as co-variables. A p value < 0.05 (two 
sided) was considered statistically significant. 
The MADRS score over time was measured at weekly intervals during 6 weeks of 
treatment. The difference in time-trend of this score between the 2 groups of 
subjects was tested in a random coefficient model using rm-ANOV A (mi..,<ed model 
A.,.1\JOVA, using SAS statistical software package). The previously mentioned co-
variables and their effects on the time-trend were again taken into account. Hence, 
the difference in time-trend of the MADRS score between psychotic and non-
psychotic patients is adjusted for the possibly confounding effects of the above 
mentioned factors on the time-trend. 
Ethical considerations 
The protocol was approved by the Ethics Committee of the "Dijkzigt" 
University Hospital Rotterdam and the Medical Faculty of the University of 
Rotterdam and has been carried out in accordance with the ethical standards laid 
down in the declaration of Helsinki. 
Results 
Patient population, attrition and concomitant medication 
Of the total of 107 depressed in-patients entered into the study, 53 were 
randomised to imipramine treatment. Of these, 15 were diagnosed with psychotic 
depression. 
There were significant differences between the psychotic and non-psychotic 
groups of patients regarding sex, frequency of RDC diagnosis "retarded depression", 
total mean HRSD and mean MADRS scores at baseline, and the HRSD items 
"feelings of guilt!!, "somatic anxiety", and "insight". The difference between the 2 
groups regarding the HRSD items "depressed mood", "work and activities" and 
"hypochondriasis" (fable lA and IB) was found to be just below levels of 
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Table 1A. Total population (II ::: 53); Patient characteristics 
"" ~
rt 
---- rI Psychotic % Non-psychotic % Sign." 
'" (II = 15) (II = 38) 
Age: Mean ± SD (range) 49 ± 10 (34-65) 48 ± 11 (27-65) 0.57 
Sex: ~'fale 7 47 4 10 0.007 
Female 8 53 34 90 
Diagnosis: Umajor depressive episode" (DS:rvf-III-R) 15 100 38 100 
Ullipolar 15 37 1.00 
1st episode 10 67 23 60 1.00 
Recurrent 5 33 14 37 
Bipolar a 3 1.00 
:Melancholic type 13 87 32 84 1.00 
Major Depressive episode (RDC) 15 100 37 97 1.00 
Retarded Depression (RDC) 8 53 8 21 0.04 
Agitated Depression (RDC) 6 40 13 34 0.76 
Endogenous Depression (RDe) 15 100 35 92 0.55 
Suicidal 7 47 25 66 0.23 
IIRSD baseline 29.1 ± 5 (22-37) 25.5 ± 5 (18-37) 0.02 
MADRS baseline 39.6 ± 8 (27-54) 35.0 ± 6 (16-47) 0.03 
Duration current episode 
< 1 year 11 73 21 55 0.35 
> 1 year 4 27 17 45 
Family history (1st/2nd degree) 
Depression 10 67 23 61 0.76 
Suicide 2 13 7 18 1.00 
Adequate pre-treatment l 5 33 17 45 0.54 
"~~ __ ~'~ ____ ~"T"~_~_~"C~~ __ "_"_'''~_~ 
1 Prc-treatment of prescnt episode with an adequate dose of an antidepressant drug during at least four weeks (potter 
and Rudorfcr, 1989) 
Table lB. Total population (II = 53); HRSD items 
----~-~. 
Factor Psychotic (II - 15) Non-psychotic (II - 38) Sign.p 
mean (range) mean (range) 
Depressed mood 3.47 (34) 3.03 (2-4) 0.05 
Feelings of guilt 2.80 (0-4) 1.42 (0-4) 0.004 
Suicide 1.73 (0-4) 1.63 (0-4) 0.87 
Insomnia early 1.60 (0-2) 1.66 (0-2) 0.80 
Insomnia middle 1.73 (1-2) 1.74 (0-2) 0.75 
Insomnia late 1.67 (0-2) 1.71 (0-2) 0.99 
\'\'ork and activities 2.80 (2-4) 2.39 (2-4) 0.05 ~ 
Retardation 1.07 (0-3) 0.61 (0-2) 0.16 ~. 
Agitation 0.93 (0-3) 1.13 (0-3) 0.50 H 
" Anxiety, psychic 1.93 (0-3) 2.24 (0-4) 0.16 § 
Anxiety, somatic 1.20 (0-2) 1.89 (0-3) 0.006 (1) 
Somatic symptoms 5 
Gastro-intestinal 1.40 (0-2) 1.16 (0-2) 0.20 >tJ ~ 
'<1 Somatic symptoms g. 
General 1.27 (0-2) 1.34 (02) 0.66 0 
". Genital symptoms 1.73 (0-2) 1.79 (0-2) 0.58 n 
I Iypochondriasis 1.33 (0-4) 0.58 (0-3) 0.07 CL 
.g 
Loss of weight 1.00 (0-2) 0.92 (0-2) 0.77 H (1) 
Insight 1.40 (0-2) 0.26 (0-2) <.000 ~ ~ 
" HRSD total score 29.07 (22-37) 25.50 (18-37) 0.02 CL 
__ ~ __ '_____ '_~~~_~,_'~'=m_~~,~ __ ,~,'_' ______ ~~~_~" __ 
~~~~"~" __ ~"~=_~~~c=~_~=, __ , ___ >tJ 
" ". (1) 
~ 
'-" 
~ 
'-" 
~ 
v, n 
.J>. 
,Table ~. Delusional s~..?!£~l:~:J:)~~~~~! (11 "~,~~,~''""/~~_~'"'~_~~ '"_",,~""_"~~,"=~.,~_'_."==~_,~~ _________ p-" 
"" Case#/ Delusional symptoms as aChlally reported by the patient Delusions according to SADS score rt fl 
Age/Sex Guilt/Sin Persecutory Somatic ,,> 
1/53/m Is a criminal, is not worth to live, is a sinner, does not deserve to Definite Absent Absent 
drink or to eat, has always played a game 
2/45/m Goes to hell, is guilty of a lot of sins, deserves punishment, is being Definite Definite Absent 
eavesdropped, does not tmst anyone, is convinced that we read his 
mind and know everything of him. 
3/37/f Everything around her goes wrong and it is her fault; has smashed Definite Suspect or Absent 
everybody, feels a dirty lazy pig; we playa game and know likely 
everything already, we laugh at her and cut her up 
4/34/f Is a bad christian; it is all her fault; wants to give herself up to the Definite Suspect or Absent 
police, deserves a lifelong sentence, is being eavesdropped likely 
5/62/m Deserves death, caused the death of another patient, is in a Definite Definite Absent 
concentration camp, suspects a conspiracy against himself 
6 /38/f Is ugly, is already dead, has no stomach, no heart anymore, is an Definite Absent Suspect or 
evil person, deserves no food and no visitors likely 
7/49/f Cannot do anything anymore, is already dead, is in prison eternally; Absent Absent Definite 
her brain is irreparably damaged, her limbs melt 
8/51/f Has no money anymore, has ruined her family, deserves Definite Suspect or Definite 
punishment, is already dead, has no heartbeat anymore, cannot do likely 
anything and knows nothing anymore 
9/64/m Has cancer and aids, is a piece if dead flesh, has no intestines and Suspect or Absent Definite 
no bladder anymore, is being punished likely 
10/63/m Has no money anymore, is bankrupt, ruined his family! is Deftnite Absent Absent 
worthless, thus is not allowed to eat, to drink or to urinate 
"-~. ~~="=~~=--~~,=~-==-~~~~~",-~~~,~-. ~"~~.~~-.~-~,===-~~~.~~----
Table 2 continues 
'-" u. 
~! able 3j,~?11 ~~~_~1p~~~_~~~.~sX~~,~,~,~~~~,~E~L:,~~~:~J?~ld~~~~'~'"~"'>~_,~}"~,~. 
Case#/ Delusional symptoms as actually reported by the patient Delusions according to SADS score 
"gc/Sex Ci-uilt/Sin Persecutory Somatic 
12/45/ m-=--;C---C---:C' .---,---,--------~-~------------- --- ------~,---,-----.--~-~-----------Il1e pOlice is after him; has big financial debts, the admission is a Def11lite Absent 
punishment for all of his crimes; cannot pay food 
13/44/f [ ... fakes everybody ill, is a devil, is guilty of everything, is already 
dead; family hates her and will punish her 
14/46/m Is a criminal, has killed his wife, evaded taxes, the hospital is a 
prison, his house is burned down as a punishment 
15/52/f Deserves to go to prison, did everything wrong, has deceived 
everybody; everybody thinks she is crazy and evil 
Definite Absent 
Definite Definite 
Definite Absent 
()uspect or 
likely 
Suspect or 
likely 
Absent 
Absent 
H 
~' 
~, 
co 
13' 
OJ 
.", g-
o 
0, 
n 
,g 
a 
~ 
co 
0.. 
OJ 
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significance. Each patient given a diagnosis of psychotic depression was shown to 
manifest at least one mood-congruent delusional belief as defined by the SADS. 
The delusions in the psychotic patients consisted of delusions of guilt or sin, 
persecutory delusions or somatic delusions (Table 2). One of the non-psychotic 
subjects who did not respond to treatment had a diagnosis of a bipolar disorder. Six 
patients dropped out and 1 patient was excluded from analyses because blood levels 
revealed poor compliance (Table 3). Thus, 45 subjects were able to complete the 
study, of which 13 were diagnosed with psychotic depression. Seven patients, 5 non-
psychotic and 2 psychotic, '\vere treated '-\11th valerian extract. Three patients were 
treated ,,"vith concomitant psychotropic medication; 1 non-psychotic patient 'With 
lorazepam, 1 psychotic patient with haloperidol and 1 psychotic patient ",~th 
lorazepam and haloperidol. All 3 did not respond to treatment: thus, neither 
haloperidol nor lorazapam could have been instrumental in the recovery of patients. 
No other sedatives, hypnotics or other psychotropics were used by any of the 
patients. 
Table 3. Dropouts and completers by non~compliance (n = 7) 
Reason 
Psychotic Deterioration 1 
F eve! and delirium 1 
Non-psychotic Mania 1 
Orthostasis 1 
Allergic reaction 2 
Non-compliance (blood levell) 1 
Treatment periods, blood levels and doses 
Predefined blood levels of imipramine were achieved after 12.8 days (mean SD ± 
5.2, range 7-25) for the psychotic patients, and after 14.0 days (mean SD ± 4.4, range 
7-24) for the non-psychotic patients. Thus, the mean total period of imipramine 
treatment (including 4 weeks of treatment at predefined blood levels) waS 40.8 days 
(SD ± 5.2, range 35-53) for the psychotic patients, and 42 days (SD ± 4.4, range 35-
52) for the non-psychotic patients (i.e. a mean of almost 6 weeks for both groups). 
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The mean daily dose after attaining the predefined blood level for the psychotic 
patients was 211 mg (SD ± 103.5, range 37.5-337.5) with a mean blood level of 270 
f.lg/l (SD ± 31.5, range 213.5-320.3; sum of imipramine and desmethyl-imipramine). 
The mean daily dose for the non-psychotic patients was 247 mg (SD ± 85.5, range 
112.5-450) with a mean blood level of 265 f.lg/l (SD ± 38.3, range 199.0-400.3). 
Treatment effects 
Nine of the 13 (69.2%) psychotic patients and 14 of the 32 (43.8%) non-
psychotic patients responded to treatment according to the 50% response criterion 
(:x2 = 1.5; 4= 1; P = n.s.). (95%-confidence interval comparing the psychotic group 
and non-psychotic group of subjects -4.9%; +55.9%). 
Eight of the 13 (61.5%) psychotic patients and 9 of the 32 (28%) non-psychotic 
patients were reported as "in remission" (HRSD <10; Fisher's Exact Test: p = 0.048) 
(95% confidence interval: 2.8%; 64.2%). 
Multiple regression analysis controlling for potential confounding factors showed 
a significant lower mean outcome HRSD score in the psychotic group compared to 
the non-psychotic group of patients (-6.6; SE B = 2.91; 95% CI (-12.5; -0.70); t = 
-2.27; 4 = 37; P = 0.03) (Table 4). Furthermore, the relationship between mean 
outcome HRSD score and the duration of the present episode of illness was also 
sho'C11t1 to be statistically significant. Subjects whose current episode of illness had a 
duration of less than or equal to 1 year were found to have a significantly lower 
mean outcome HRSD score (6.79; SE B = 2.78; 95% CI (1.16; 12.42); t = 2.44; 4= 
37; P = 0.02). 
Figure 2 shows the mean :MADRS scores of all completers for the 2 groups 
during 6 weeks of treatment. According to the rm-ANOVA there was a difference in 
change in M.ADRS scores over time between psychotic and non-psychotic patients 
controlled for confounding factors (p = 0.011), which indicated a statistically 
significant steeper decline in MADRS scores for the group of patients diagnosed 
with psychotic depression. In the psychotic patients, the trend was found to be 1.75 
(SE = 0.680) MADRS units per week lower than in the non-psychotic patients, 
adjusted for the earlier mentioned co-variables. The difference in mean MADRS 
scores at baseline between psychotic and non-psychotic subjects who completed this 
study was not significant (p = 0.22). 
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Table 4. Results of a multiple regression analysis concerning the effect of psychotic 
features and possibly confounding variables in the HRSD-outcome score. The 
regression coefficient (B) indicates the increase (B: +) or decrease (B: -) of the 
HRSD outcome score for each unit increase in the variable 
Variable (units) B (SE) 95% CI P 
Psychotic features (no - 0, yes - 1) -6.60 (2.91) -12.50; - 0.70 0.03 
Age (years) 0.01 (0.13) 0.25; 0.28 0.92 
Duration of present episode 6.79 (2.78) 1.16; 12.42 0.02 
(:0 1 year =0, >1 year =1) 
Number of previous depressions 1.96 (2.74) - 3.60; 7.52 0.48 
Family history (no = 0, yes = 1) 3.36 (2.68) - 2.06 ; 8.79 0.22 
BaseIlle severity (HRSD score) 0.35 (0.29) - 0.24; 0.93 0.24 
Retarded depression (RDC) 5.28 (3.08) - 0.97 ; 11.53 0.10 
(no = 0, yes = 1) 
Discussion 
In this study a high response rate of approximately 70% was observed in our 
patients with psychotic depression who were treated v.rith imipramine VTith no 
adjuvant antipsychotic medication. This contrasted '\\11th a much lo'\ver response rate 
of about 40% to the sarne treatment in our non-psychotic patients. Tlu:oughout the 
entire treatment period the steeper response curve of the psychotic depressed 
patients in the present study was clear (Figure 2). Possible confounding factors did 
not account for this result. On the contrary, the difference in response between 
psychotic and non-psychotic groups of patients was mo.re pronounced afte.r 
potential confounding factors had been controlled for. The only co-variable that was 
sho'\\.Tn to contribute significantly to the difference in treatment response observed 
bet\\leen psychotic and non-psychotic patients, was "duration of the present 
episode", i.e. a longer duration of the present episode was related to a poorer 
treatment response in line with the literature (Scott, 1994). The fact that our patients 
with psychotic depression had a shorter duration of the present episode (Table 1A) 
and a better treatment response (Table 4) might suggest that "duration of the 
episode" and not psychosis status e:A-plains oU.! obse:rv-ed differences in treatment 
response. This, however, is refuted by the fact that the effect of psychosis status in 
the mean HRSD outcome was even more significant in the analysis adjusting for 
"duration of the present episode" as a confounder (Table 4). 
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The fact that the present results form part of a randomised double-blind trial 
comparing imipramine with mirtazapine helps clarify another alternative explanation 
of the results. Imipramine was shown to be significantly superior to mirtazapine in 
the treatment of our psychotic as well as non-psychotic patients (Bruijn et al" 1996); 
this rules out possible explanation of our results being related to high placebo 
response in both or either of the comparison groups. 
Most studies report a low response rate (23-40%) for patients with psychotic 
depression when treated with tricyclic antidepressants alone (Schatzberg and 
Rothschild, 1992; Chan et al., 1987), The difference in response rate observed in the 
present study could be accounted for by variations in methodology. Optimal dosing 
in our study may explain our high treatment response rates, Earlier studies 
frequently did not provide a clear report of dosage and duration of the drug 
treatment and most did not control for blood levels of the studied tricyclic 
antidepressant. Considering the extreme range of doses (37.5-450 mg) which we 
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found to be necessary to adjust tbe dose to tbe predefined, adequate, blood level of 
imipramine in this study, an otber way of dosing could not have resulted in 
treatment witb adequate blood levels of imipramine in all patients. This raises tbe 
possibility of sub-optimal dosing of antidepressants in otber studies. Since psychotic 
depressed patients may show a lower placebo response tban non-psychotic 
depressed patients (Schatzberg and Rotbschild, 1992), sub-optimal dosing could 
reduce tbe response in psychotic patients more tban in non-psychotic patients. 
There are, however, otber studies of psychotic depressed patients using 
measurement of blood antidepressant levels, which report a lower treatment 
response rate for psychotic depressed patients. Glassman et al. (1975) found a 
considerable and significant response difference between psychotic and non-
psychotic depressed patients treated witb imipramine. Patients were treated during 4 
weeks witb a fi:,ed dose of 3.5 mg of imipramine per kg body weight (average daily 
dose for men 250 mg, for women 200 mg). The blood levels obtained witb this 
treatment regimen, however, were not reported. In a report on the possible clinical 
implications of plasma imipramine levels for tbe management of depressive illness, 
Glassman et al. (1975) could not detect a relationship between tberapeutic response 
and antidepressant blood level in tbe psychotic patients in contrast to his findings 
for tbe non-psychotic group of patients. However, of tbe 17 psychotic patients in 
this study, only 9 patients had an imipramine plus desipramine blood level in ,,-,cess 
of 180 ng/ml. 
Quitkin et al. (1978) have reported a satisfactory treatment response by patients 
with psychotic depression to tricyclic medication alone (i.e. not combined witb an 
antipsychotic preparation), and argued tbat otber autbors found a difference in 
favour of non-psychotic depressed patients, because the duration of their treatment 
period was only 4 weeks. This argument is not supported by our results, however, 
because the therapeutic response in the present study after a mean of ca. 4 weeks of 
treatment was not found to be worse for psychotic patients than for non-psychotic 
patients (Figure 2). 
The results of tbe double-blind blood level controlled study of Spiker et al. 
(1985), in which patients were randomly assigned to amitriptyline alone, to 
perphenazine alone or to amitriptyline plus perphenazine, are also not in line witb 
our results. Spiker et al. did report tbe mean blood level of antidepressant during tbe 
35 days of treatment, but tbey did not report how many days tbe patients were 
treated on an adequate blood level of amitriptyline plus nortriptyline (Spiker et al., 
1985; Spiker et al., 1986). Also, in this study tbe patient group witb combination 
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treatment had a higher mean blood level of the antidepressant than the patient 
group treated with the antidepressant alone. Nevertheless, it is not clear whether this 
could e..\:plain the difference in results. 
Comparison of results also raises the question wbether the patients selected in 
different studies are comparable. In this regard the classification of psychotic and 
non-psychotic patients is important. In the present study all psychotic patients have 
mood-congruent delusions as is also the case in the study by Glassman et a1. (1975). 
In other studies the qualification I!mood-congruence" in terms of delusions is not 
explicitly mentioned. Thus) it is not clear whether the patients are comparable to our 
subjects '\vi.th respect to this characteristic. Depressed patients "'."\Iith delusions, which 
are not mood-congruent, may be less likely to respond to treatment v.rith 
antidepressants alone compared to combination therapy of antidepressant and 
antipsychotic medication (M:ay et al., 1990; Parker et al., 1992). 
Another possible difference between patient populations in different studies, may 
be the mean age of patients recruited: in Glassmans' study the mean age of subjects 
was about 10 years higher than in our study. 
A further difference may be the almost complete lack of concomitant medication 
in our srody, which is in contrast to other studies. It is conceivable that other 
medications - such as anxiolytic preparations - improve treatment response :in non-
psychotic, but not in psychotic depressed patients (Schatzberg and Rothschild, 
1992). 
Glassman et al. (1975) made reference to the issue of severity as a confounding 
factor in the comparison of the response rates of psychotic depressed and non-
psychotic depressed patients. Kocsis et al. (1990) reported that the treatment 
response of severely depressed patients with no psychotic features did not differ 
significantly from the response of those with psychotic depression and that both 
groups fared worse than the group of moderately depressed patients with no 
psychotic features. Kocsis suggested the difference in response noted between the 
groups was more being related to severity of illness than to the psychotic / non-
psychotic dichotomy. In the present study this is not the case, because our group of 
non-psychotic patients showed a lesser treatment response compared to the more 
severe group of psychotic patients (Tables lA, IB). 
The fact that only 15 of the 52 patients recruited into this study were psychotic 
may caution against generalisation of the results. However, there are no well-
controlled studies with substantially larger numbers of psychotic depressed patients. 
In no way, however, does this restricted number explain away the high response rate 
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to imipramine mono-therapy that we observed in our group of patients with 
psychotic depression. 
Most reports in the literature conclude that combillation of an antidepressant 
'With a neuroleptic drug is the treatment of cboice in psychotic depressed patients in 
view of the poor response to mono-therapy VJith an antidepressant. In our patient 
group, however, the first choice treatment is mono-therapy Vlith imipramine "Xith 
blood level control because of the high success rate, the more so since subsequent 
lithium addition for psychotic depressed patients with unsatisfactory response 
increased the response rate from 69% to 1 00% (Bruijn et al., 1998). 
Our belief is that our fIndings need to be tested further in a prospective study 
and further double-blind, randorrllsed controlled studies, comparing combination 
therapy with antidepressant mono-therapy in psychotic depressed patients similar to 
our study population, are also warranted to clarify the issues discussed in this paper. 
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Effect on different symptom dusters 
Chapter 4 
Depressed inpatients respond differently to imipramine and 
mirtazapine 
Abstract 
Tricyclic antidepressants and more recent antidepressants are generally 
considered to have equivalent efficacy in the treatment of depression. After a 
previous report of a marked difference in the response to mirtazapine compared to 
imipramine, we report here an analysis of different symptom dusters. One hundred 
and seven consecutive inpatients with major depression (Diagnostic and Statistical 
Manual III-R, DSM-III-R) and a Hamilton Rating Scale for Depression (HRSD) 
score of 18 points or more were randomly assigned to double-blind treatment. Two 
and 4 weeks after predefined blood levels had been obtained, the severity of 
depression was assessed using the HRSD. The mean dosages used were 235 mg/ day 
of imipramine and 77 mg/ day of mirtazapine, the latter being in excess of the 15-45 
mg/ day range currently advised. Total HRSD scores and 7 symptom dusters were 
analysed in the 85 patients (79%) who were not receiving any co-medication. 
Imipramine was more effective against the dusters related to core symptoms of 
depression: "depression and guilt", "retardation" and "melancholia", respectively. 
11irtazapine showed a biphasic response with regard to the clusters "sleep" and 
"anxiety/agitation", respectively, which consisted of a marked response after 2 weeks 
of predefined blood level, but with a waning of this effect at 4 weeks. Imipramine 
produced a more gradual response on these clusters, which was more pronounced at 
4 weeks than with mirtazapine. Two aspects of the present study could be related to 
this finding: blood level control resulted in optimal treatment with imipramine but 
not mirtazapine and - most importantly - the patients were not receiving any 
anxiolytic or hypnotic co-medication. These findings suggest that mirtazapine may 
have anxiolytic and sedative properties and fewer antidepressant properties than 
imipramine in severely depressed inpatients. 
Introduction 
It is generally considered that different antidepressants have similar efficacy 
(Burke and Preskom, 1995; Song et al., 1993). Efforts to identify patient 
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characteristics capable of predicting the response to a specific serotonin re-uptake 
inhibitor (SSRI), for example - compared with mi."ed re-uptake inhibitors such as 
tricyclic antidepressants - have been unsuccessful (Burke and Preskom, 1995). The 
same applies to efforts to identify specific symptoms responsive to a single 
antidepressant (Danish University Antidepressant Group, 1986; 1990; 1993). 
In a previous report on this study, we described a significant difference in 
response in favour of imipramine in a double-blind, fL"ed blood level study 
comparing imipramine 'With mirtazapine in depressed inpatients (Bruijn et al., 1996). 
Mirtazapine is a new antidepressant related to mianserin and pharmacologically 
different from the tricyclic antidepressant imipramine. It is a strong antagonist of 
centralIX2 adrenoreceptors, serotonin SHT2 and 5HT3 receptors, and histamine HI 
receptors and a weaker antagonist of muscarine and (Xl adrenoreceptors (De Boer et 
al., 1995). Imipramine is a strong mi."ed (norepinephrine, serotonin) re-uptake 
inhibitor 'With strong anticholinergic properties and weaker antagonism of HI and ell 
receptors. In a more detailed analysis of the course of the Hamilton Rating Scale for 
Depression (HRSD) total scores (Hamilton, 1960) and of symptom clusters over 
time during treatment, we detected differences in patterns of response between the 2 
drugs, which might be indicative of differences in the drugs' mechanism of action. 
Patients and methods 
Genera! outline (Figure 1) and patient population 
Patients included were aged 18-65 with a Diagnostic and Statistical Manual III-R 
(DSM-III-R) diagnosis of "major depressive episode", which was assessed by 2 
psychiatrists on the basis of the depression section of the Schedule for Affective 
Disorders and Schizophrenia (SADS; Spitzer and Endicott, 1978/79) and with a 
HRSD score of 18 or more. Patients with hallucinations, schizophrenia, paranoid 
psychosis, organic brain syndrome, chronic drug or alcohol abuse, and clinically 
relevant somatic diseases were excluded. 
After written informed consent had been received, a single-blind placebo was 
administered for 4 days. On the 5th day, patients were assessed agsin on the HRSD, 
and those still meering the inclusion criterion of an HRSD score of 18 or more were 
randomly allocated to double-blind treatment with either imipramine or mirtazapine. 
Blood levels were monitored weekly, and dosages of both drugs were adjusted (by an 
independent psychiatrist, to preserve blindness) to obtain fi."ed blood levels (200-300 
"g/l for imipramine + desmethyl-imipramine (perty et al., 1987) and 50-100 f.lg/l for 
mirtazapine). The blood level of mirtazapine was based on a pilot study with 20 
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patients receiving 60 mg/day of mirtazapine (Bruijn et al., 1996). The HRSD was 
assessed 2 and 4 weeks after this blood level was reached. No psychotropic 
medication apart from the study medication was allowed except for 1 to 6 tablets a 
day each containing 45 mg of an extract of valerian, in case of anxiety or insomnia. 
This extract was presumed to be without antidepressant effect. 
Variable I 3 days 4 days 
Drug-free Placebo 
i i 
Admission Baseline 
assessment 
Figure 1. General outline of the study design 
Variable 
I 
4 weeks 
Study medication 
Dose 
adjustment 
i 
HRSD 
;0,18 (day 5) 
I 
Predefined 
blood level 
i 
HRSD 
outcome 
One hundred seven depressed inpatients were randomly assigned to active 
treatment. Eight patients dropped out, and 2 patients were excluded from analyses 
because blood levels showed non-compliance (Table 1); 97 patients (51 taking 
mirtazapine and 46 taking imipramine) completed the study. All patients were drug-
free when they started on the study medication. Nine mirtazapine and 7 imipramine 
patients were treated '\vith valerian extract. There were no significant differences 
between the 2 treatment groups vvi.th respect to the dose and duration of valerian 
medication. The protocol allowed for co-medication only in case of intolerable 
agitation or anxiety, and/or intolerable psychotic symptoms. Nine of the 51 patients 
taking mirtazapine (18%) and 3 of the 46 patients taking imipramine (7%) were 
treated with lorazepam 1-5 mg/day and/or haloperidol 1-15 mg/day (Table 1), 
respectively, for these reasons. 
As this report is concerned with differences in the patterns of response to the 2 
antidepressants investigated, it describes the results of the group of 85 completers 
(79%) who had no concomitant medication (Table 2). PredefIned blood levels in the 
42 mirtazapine patients were achieved after 11.3 days (mean SD ± 3.5, range 5-21), 
and for the 43 imipramine patients after 13.5 days (mean SD ± 4.5, range 7-25), 
respectively. Thus, the mean total period on study medication (including 4 weeks on 
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predefined blood levels) was 39.3 days (SD ± 3.5, range 33-49) for mirtazapine and 
41.5 days (SD ± 4.5, range 35-53) for imipramine, i.e. almost 6 weeks. The daily dose 
after the predefined blood level for mirtazapine was reached, was 77.4 mg (mean SD 
± 17.6, range 40-100) with a blood level of 69.0 fJ-g/1 (mean SD ± 8.8, range 52.3-
89.0), and for imipramine 235.5 mg (mean SD ± 90.8, range 37.5-450) with a blood 
level of 267.6 f.lg/l (mean SD ± 36.5, range 195.0-400.3; sum of imipramine and 
desmethyl-imipramine), respectively. 
Table 1. Drop-outs, non-completers by non-compliance, and protocol violation by 
concomitant medication (n :;:;: 22) 
Reason Mirtazapine (n - 12) Imipramine (n - 10) 
Drop-out/non- Transfer to other waxd 1 Mania 1 
compliance Refusal to take medication 1 Orthostasis 1 
Non-compliance 1 Deterioration 1 
(blood level L) 
Fever and delirium 1 
.A.llergic reaction 2 
Non-compliance 1 
(blood level L) 
Concomitant Lorazepam 2 Lorazepam 1 
medication Haloperidol 5 Haloperidol 1 
Lorazepam + haloperidol 2 Lorazepam + haloperidol 1 
Data analysis and statistical methods 
During the pre-planned statistical analysis of this study, reported elsewhere 
(Bruijn et al., 1996), we observed differences in the time course of the HRSD total 
scores during treatment (Figure 2). These differences between mirtazapine and 
imipramine were analysed using repeated measures-ANOV A for unbalanced data 
(BMDP software program). The following HRSD symptom clusters were analysed in 
the same way: "depression + guilt" (items 1 + 2 + 3), "sleep disturbances" (items 4 
+ 5 + 6), "retardation" (items 7 + 8), "an...aety/agitation" (items 9 + 10 + 11), 
"somatic complaints" (items 12 + 13), and "others" (items 14 + 15 + 16 + 17) 
(Danish University Antidepressant Group, 1986; 1990; 1993), along with the HRSD 
factor "melancholia" (items 1 + 2 + 7 + 8 + 10 + 13) (Bech et al., 1975). 
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Table 2. Characteristics of the patient population (II = 85) 
Age: mean ± SD (range) 
Sex: male/ female 
Diagnosis (DS:rvI-III-R) nmajor depressive episoden 
* Unipolar 
Non-psychotic, 1st episode 
Non-psychotic, recurrent 
Psychotic, 1 st episode 
Psychotic, recurrent 
* Bipolar Non-psychotic 
Melancholic type 
fvfajor Depressive episode (RDC) 
Retarded Depression (RDC) 
Agitated Depression (RDC) 
Endogenous Depression (RDC) 
Suicidal (RDC) 
HRSD-baseline ± SD (range) 
MADRS-baseline ± SD (range) 
Duration current episode 
< 1 year 
> 1 year 
Adequate pre-treatment with antidepressants 
Famil)' history (1st/2nd degree) 
Depression 
Suicide 
Mirtazapine (II = 42) 
44 ± 10 (26 - 65) 
9/33 
42 
36 
42 
31 
30 
41 
22 
38 
4 
18 
13 
4 
3 
25.3 ± 4.1(19 - 37) 
36.1 ± 5.5(25 - 48) 
25 
17 
25 
22 
7 
Imipramine (II = 43) 
~~~--~-,--.-,,--.--~-
49 ± 10 (29 - 65) 
8/35 
43 
38 
42 
31 
28 
40 
25 
42 
19 
12 
7 
4 
26.3 ± 4.8(18 - 37) 
36.3 ± 5.8(27 - 54) 
27 
16 
19 
23 
7 
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Figure 2 Mean total scores on the 17 item-HRSD ± 1 SD (vertical a.xis) of the 42 
mirtazapine completers and 43 imipramine completers \.Vithout co-medication, at 
baseline and 2 and 4 weeks after attaining the predefined blood level of the study 
medication (horizontal a.xis). Solid line :;;: m.irtazapine; dotted line :;;: imipramine. 
The time course is significantly different between mirtazapine and imipramine 
according to repeated meaSilles AN OVA (p < 0.005). 
There were 3 repeated measurements of these dependent variables: 1 at baseline 
(measurement 0) and 2 measurements during the trial- measurement 1 after 2 weeks 
and measurement 2 after 4 weeks of the predefined blood level of the antidepressant. 
The between-subject factor was treatment "vith 2 levels: "mirtazapine" and 
"imipramine". Firsdy, a restricted model was fitted, only including a categorical 
within-subject time factor, with the following coefficients: ~o for the baseline level, ~I 
for the difference from baseline at measurement 1, and ~2 fOI the difference from 
baseline at measurement 2. Secondly, the restricted model "\-vas extended to a :full 
model by adding interactions between the within-subject time factor and the 
dichotomous between-subjects treatment factoI, thus allowing the coefficient ~I and 
~2 to be different between the 2 treatment groups. Because the treatment factor is 
72 
Effect on different symptom clusters 
randomised, the baseline coefficient ~o is by definition the same in both treatment 
groups. The effect of treatment was tested by comparing the full model with the 
restricted mode~ using a likelihood ratio test with 2 degrees of freedom. The 3 x 3 
within-subject co-variance matrix of the residuals was left completely unstructured. 
The likelihood ratio test thus assessed whether the 2 coefficients ~, and [32 were 
different simultaneously between the 2 treatment groups; hence, the difference in the 
time-cow:se between the 2 treatment groups during treatment was tested. As a co-
variate, the time from baseline to reach the predefined blood level of mirtazapine or 
imipramine was included in all the models considered, which adjusted the results for 
between-subject difference in this time. 
Ethical considerations 
The protocol was approved by the Ethics Committees of the University Hospital 
"Dijkzigt" and of the Medical Faculty of the University of Rotterdam. 
Results 
The scores on all symptom clusters appeared to decrease steadily between 
baseline and 2 and 4 weeks of predefined blood level for imipramine, while for 
mirtazapine 2 different patterns appeared. On the one hand (Figure 3), the scores 
for the symptom clusters "depression and guilt", "retardation" and "melancholia!! 
decreased less for rnirtazapine than for imipramine at both time points. On the other 
hand (Figure 4), the scores for the symptom clusters "sleep disturbances" and 
"an.uety/agitation" decreased more for rn1rtazapine than for imipramine up to 2 
weeks of predefined blood levels, while these scores increased again between 2 and 4 
weeks of predefined blood levels, in contrast to the scores for imipramine. 
Table 3 shows the mean and 95% confidence intervals for the difference between 
the HRSD total scores and the symptom clusters between the 2 treatment groups at 
measurement 1 and measurement 2, respectively, estimated by the model. The time 
course of the HRSD total scores was significantly different between the 2 drug 
groups according to the repeated-measures ANOV A (X' = 11.0, degrees of freedom 
(dj) = 2, P < 0.005, Figure 2). The time course of most HRSD symptom clusters 
analysed was also significantly different between imipramine and mirtazapine; 
"depression and guilt" X2=8.44, d[=2,p < 0.025, "retardation" X2 = 14.48, df= 2,p < 
0.001, "melancholia" X2 = 6.43, df= 2,p < 0.05, "sleep disturbances" X2 = 9.36, df= 
2,p < 0.01, "anxiety/agitation" X2 = 7.09, df= 2,p < 0.05. However, there was no 
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significant difference for the symptom clusters "somatic complaints" Xz = 0.97, df= 
? p' . d" th " - 6 O? df- ? p' _, . n.S., an 0 ers X2 ......, - ..... ,. n.s. 
To avoid the pitfall of these results being artefacts of selecting only the patients 
completing the study "vithout taking any co-medication, we carried out the same 
analyses with the group of all 107 patients (intent to treat, with last observation 
carried forward) also including dropouts and patients with co-medication, and with 
the group of all 97 completers excluding dropouts, but including all patients with co-
medication. The results of these analyses were similar to the results of the group of 
8S completers Vlithout any co-medication. 
Table 3. Mean (D) and 95% confidence intervals (95% CI) of the difference between the 2 
treatment groups at measurement 1 and measurement 2, respectively, estimated by 
the model HRSD total scores and symptom clusters (negative values indicate 
superiority of imipramine). 
Measurement 1 Measurement 2 
D 95% CI D 95%CI 
HRSD total scores -0.2 - 3.6/+3.3 - 4.8 - 8.5/- 1.1 
Depression and guilt -0.8 - 2.0/ +0.4 - 1.8 - 2.9/- 0.6 
Retardation -0.2 - 0.6/ +0.2 - 0.7 - 1.1/- 0.4 
Melancholia -0.8 - 2.4/ +0.8 - 2.0 - 3.6/- 0.4 
Sleep disnu:bances +0.6 -0.4/+1.5 - 0.9 - I.7 /- 0.0 
_""---ciety / agitation +0.5 - 0.3/+1.4 - 0.4 - 1.3/+0.5 
Somatic complaints -0.2 - 0.7/+0.3 - 0.3 - 0.8/+0.3 
()thersymptoms +0.3 - 0.4/ +1.0 -0.5 -1.3/+0.3 
Discussion 
Differences in response patterns bet\Veen imipramine and mirtazapine were 
identified in depressed inpatients. Imipramine was more effective for symptoms such 
as depression, guilt, and retardation, which can be regarded as the core symptoms of 
depression (Bech et al., 1975) and it had an effect on all of the symptoms, which 
progressively increased during treatment. Mirtazapine, on the other hand., had a more 
restricted effect on sleep and anxiety symptoms, to which tolerance developed. 
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Differences in the response patterns have not previously been observed in studies 
comparing antidepressants, despite the wealth of such studies and numerous efforts 
to discover differences between antidepressants (Burke and Preskom, 1995; Danish 
University Antidepressant Group, 1986; 1990; 1993; Song et al., 1993). We believe 
that two aspects of this study contributed to the differences found. 
First, the problem of correct dosing of imipramine was solved by adjusting the 
dose to obtain a fi.'(ed blood level. Other studies did not apply this methodology, and 
used either gradual titration or aggressive dosing. It has been pointed out that the 
former frequently results in inadequate antidepressant doses, in contrast to the latter, 
whicb results in large dropout rates (Burke and Preskom, 1995). Thus, the present 
study appears to stand out from other studies in that it adjusted adequate dosage of 
imipramine in all patients, together with a low dropout rate. With mirtazapine, it was 
not possible to predefine an optimal blood level, because therapeutic blood levels of 
mirtazapine are not available. The predefined blood level of mirtazapine was based 
on steady-state blood levels of 20 patients receiving 60 mg/ day of mirtazapine 
(Bruijn et al., 1996). This dosage was advised by Organon for the treatment of 
depressed patients at the time when the study started. By adjusting mirtazapine doses 
to this predefmed blood level, we excluded treatment under extremely high or low 
blood levels, and ascertained treatment compliance. The mean mirtazapine dose of 
77 mg/ day was above the dosages used in other inpatient studies - 47 mg/ day 
(Richou et al., 1995) and 53 mg/day (Zivkov and De Jong, 1995), respectively. The 
dose currently advised by Organon is 15-45 mg/day. No dose-response studies ",~th 
mirtazapine are available that show reduced effectiveness at higher dosages, but it 
cannot be ruled out that this higher dosage influenced our results. 
Secondly, the 85 patients described here did not receive any concomitant 
an....aolytic, hypnotic, or sedative medication, except for the few who were treated 
with the supposedly inactive valerian extract. It has been suggested that a co-
medication ",~th benzodiazepines may mask differences in efficacy between 
antidepressants (Angat, 1993), and this certainly would apply to differences in 
symptom clusters involving sleep and anxiety. 
Tricyclic antidepressants such as imipramine may be more effective in severely 
depressed inpatients (Burke and Preskom, 1995; Danish University Antidepressant 
Group, 1986; 1990; 1993) sucb as our patient population, in which 47 patients were 
suicidal and 18 patients were psychotic in the total of 85. Typical patients included in 
clinical trials during drug development form a heterogeneous group of outpatients 
suffering from mild to moderate depression without suicidal or psycbotic features 
(Burke and Preskom, 1995). It would seem prudent not to generalise the present 
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findings to populations of depressed patients. The analyses of response patterns 
were carried out post hoc, and require replication. If replicated, the results would 
imply that mirtazapine has sedative and anxiolytic properties, and fewer 
antidepressant properties than imipramine. This must be related to the different 
pharmacological properties of the drugs. Mirtazapine is a strong antihistaminic, in 
contrast to imipramine (Richelson, 1982). Histamine antagonists are sometimes 
prescribed for the treatment of anxiety (Rickels and Schweizer, 1987), they shorten 
sleep latency (Roehrs et al., 1993), and histamine has been implicated in the control 
of the waking state (Monti, 1993). Mirtazapine has been shown to have hypnotic 
properties (Ruigt et al., 1990). Development of tolerance to the effects of histamine 
antagonists has been described (Tinklenberg, 1977). Mirtazapine is also a strong 
antagonist of serotonin-2/1C receptors (De Boer et al., 1995), in contrast to 
imipramine (Rich elson, 1982). Antagonism of these receptors has been associated 
'With an.:ciolytic effects in patients with dysthymia or generalised an..--ciety disorder 
(Blackburn 1992). Imipramine is a potent inhibitor of serotonin and norepinephrine 
re-uptake (Rickels and Schweizer, 1987), in contrast to mirtazapine (De Boer et al., 
1995). \X.Ihether one or more of these properties can e'--plain the differences observed 
remains to be investigated. 
Imipramine, mirtazapine, SSRIs and other antidepressants in one way or another 
stimulate serotonergic neurotransrnlssion via SHT1A receptors in the hippocampus 
(Blier and DeMontigny, 1994; Haddjeri et al., 1996). This is assumed to be related to 
the clinical antidepressant effects (Blier and De..'v!ontigny, 1994; Haddjeri et al., 
1996). The results of the present study point to a difference between imipramine and 
mirtazapine, specifically 'With regard to antidepressant properties. This argues against 
the view that their commOn stimulation of serotonergic neurotransmission was 
related to the clinical antidepressant effects observed in our patients. 
The findings of this study my have implications for the way in which clinical trials 
with antidepressants should be carried out and the theories about which properties 
are related to the antidepressant effects of drugs. Before we reach that point, 
however, similar results must be obtained elsewhere and with other antidepressants 
in trials using fi.,ed blood levels and without concomitant medications. 
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ChapterS 
Comparison of two treatment strategies for depressed 
inpatients: Imipramine and lithium addition or mirtazapine 
and lithium addition. 
Abstract 
Background: The purpose of this study was to compare the overall effectiveness of 
two treatment strategies for inpatients with severe major depressive episode (DSM-
III-R: (1) Mirtazapine (phase 1) and subsequent lithium addition (phase 2) or (2) 
imipramine (phase 1) and subsequent lithium addition (phase 2). We previously 
reported the results of phase 1. 
Method: In phase 1, patients were randomly assigned to treatment with either 
mirtazapine or imipramine, and doses were adjusted to obtain predefined blood drug 
levels. Non-responders had lithium added to the double-blind mirtazapine or 
imipramine medication. The dose was adjusted to obtain a blood level of 0.5 to 1.0 
mmo1/1. Treatment effects were evaluated weekly by the Montgomery-Asberg 
Depression Rating Scale for up to 2 weeks on this lithium blood level. 
Results: Data for 100 patients were available for comparison of the 2 treatment 
strategies. Eighty patients received no co-medication. By the end of phase 2, 24 
(48%) of 50 had responded to mirtazapine and 32 (64%) of 50 had responded to 
imipramine (intent-to-treat analysis). A survival analysis of the total patient group 
intent-to-treat showed a significant difference in favour of the treatment strategy 
with imipramine and subsequent lithium addition. 
Conclusion: Efficacy of imipramine and subsequent lithium addition for non-
responders is superior to the same treatment strategy with mirtazapine. This applies 
to the patient sample studied, which consisted of 100 severely depressed inpatients, 
29 of whom were psychotically depressed. More serious side effects of imipramine, 
however, led to discontinuation of imipramine in 5 patients. No serious side effects 
were observed during the phase of lithium addition to either imipramine or 
mirtazapine. We, therefore, prefer to start treatment mtb. imipramine and test for 
fi.,ed blood drug levels, and, if necessary, add lithium. In the case of prohibitive side 
effects, patients are sVlitched to a modern antidepressant such as mirtazapine and, if 
necessary, lithium is added to this antidepressant. 
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Introduction 
Many clinical reports and open studies and a few double-blind studies suggest 
lithium addition to be an effective strategy for treatment resistant depression in 
about 50% to 60% of cases (Schopf, 1989a). Although most double-blind studies 
deal with small numbers of patients (De Montigny et al., 1983; Heninger et al., 1983; 
I<antor et al., 1986; Katona et al., 1995; Schopf et al., 1989b; Stein and Bernadt, 
1988; Zus1-] et al., 1988) 2 meta-analyses of these studies confirm the effectiveness 
of lithium addition (Austin et al., 1991; Katona et al., 1995). 
As a resuIt, it is quite common in clinical practice to add lithium to an 
antidepressant in the case of non-response to the latter. The treatment with an 
antidepressant and the addition of lithium to it, however, are seen as separate, 
unrelated treatment decisions; e.g., in prescribing an antidepressant, clinicians do not 
take into account the efficacy of a possible lithium addition with that particular 
antidepressant, although resuIts of lithium addition may differ between 
antidepressants. Similarly, in studies of lithium addition, non-responders to an 
antidepressant are mostly recruited ",ithout much attention for details of the 
treatment phase that resuIted in non-response (Schopf, 1989a; Katona, 1995). 
In the present study, lithium was added to the treatment of inpatients that were 
treatment-resistant in a randomised, double-blind, fi."ed blood level study comparing 
mirtazapine with imipramine. Mittazapine is a new antidepressant of the group of 
the piperazinoazepines, related to m1anserin. It is a strong antagonist of central (;(2-
adrenoreceptors, serotonin SHTz and SHT3 receptors, and hista.rnme H1 receptors 
and is a weaker antagonist of muscarine and C(1 adrenoreceptors (De Boer et al., 
1995). The resuIts of the comparative n-ial, before lithium addition, indicated a large, 
statistically significant and clinically relevant difference in efficacy in favour of 
imipramine (Bruijn et al., 1996). 
The purpose of the present study was to compare the overall response of a two-
step treatment strategy with a standard tricyclic antidepressant and lithium addition 
for non-responders with a similar treatment strategy with mirtazapine and 
subsequent lithium addition. 
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Methods 
Phase 1: Double-blind study-medication period 
For a detailed description of the double-blind part of the study the reader is 
referred to our previous report (Bruijn et a!., 1996). The general oudine is presented 
in Figure 1. The study was performed at the inpatient depression unit of the 
Department of Psychiatry of the University Hospital Dijkzigt Rotterdam, where 
uncomplicated depressed patients as well as treatment-resistant depressed patients 
are treated. Included were patients aged 18-65 years who had a DSM-III-R diagnosis 
"major depressive episode" (American Psychiatric Association), which was assessed 
by two psychiatrists performing the depression part of the Schedule for Affective 
Disorders and Schizophrenia (SADS; Spitzer and Endicott, 1977), and a Hamilton 
Rating Scale for Depression (HRSD; Hamilton, 1960) score 2: 18. Patients with 
hallucinations, schizophrenia, paranoid psychosis, organic brain syndrome, chronic 
drug or alcohol abuse, or clinically relevant somatic disease were excluded. 
After giving ",Titten informed consent patients were randomly allocated to 
double-blind treatment. Treatment was started with either 75 mg/day of imipramine 
or 20 mg/ day of mirtazapine. After 2 days, the dose was doubled unless severe side 
effects were observed. Blood levels were monitored weekly, and doses of both drugs 
were adjusted (by an independent psychiatrist to preserve blindedness) to obtain 
fLxed blood levels (200-300 flg/l for imipramine + desmethyl-imipramine and 50-100 
flg/l for mirtazapine). Response was assessed weekly with the Montgomery-Asberg 
Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979). No 
psychotropic medication besides the study medication was allowed except for 1 to 6 
tablets per day containing 45 mg of an extract of valerian in case of anxiety or 
insomnia. This extract was assumed to be ~thout antidepressant effect. In 
exceptional cases, lorazepam, 1 to 5 mg/ day, for intolerable agitation or anxiety, or 
haloperidol, 1 to 15 mg/ day, in case of intolerable psychotic symptoms was 
prescribed. 
Phase 2: Lithium addition period 
Four weeks after attainment of the predefined blood level of mirtazapine or 
imipramine, non-responders had lithium added to the double-blind medication. After 
screening for contraindications (thyroid, cardiac, or renal disease), lithium was started 
at a daily dose of 200 to 800 mg at 8 p.m. After 5 to 7 days, the blood lithium level 
was monitored at 8 a.m.) and weekly thereafter at 8 a.m. The dose was adjusted to 
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amount 
of time 
t t 
Study medication 
(1firtazapine / Imipramine) 
Variable amount 4 weeks 
of time'l 
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adjustment blood dmg 
level 
t 
, Variable amount 
of timea 
Screening for 
contraindications 
Admission Baseline 
assessment 
HRSD Weekly assessment (1{ADRS) 
2:18 (day 5) 
a See the section titled {<Results: Patient population and dropouts" 
Figure 1 General outline of the study design 
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Lithium addition 
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adjustment lithium level 
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Weekly assessment (MADRS) Outcome 
assessment 
(MADRS) 
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obtain as soon as possible a blood level of 0.5 to 1.0 mmol/l. The effect of lithium 
addition was evaluated weekly by assessment with the MADRS, up to 2 weeks after 
reaching the blood level of 0.5 to 1.0 mmol/l. The mirtazapine/imipramine 
medication was kept blind throughout the trial period. 
Data analysis and statistical methods 
The results of the sequential treatment strategies were evaluated with survival 
analysis using the Cox proportional hazards model. Duration of treatment until 
meeting the response criterion was the survival time variable. Response was defined 
as a 500/0 or more reduction in the baseline lvf.ADRS score. During phase 1} the last 
time this response was assessed was at 4 weeks after attainment of the predefined 
blood level, unless the response criterion was met earlier. During lithium addition, 
the last time response was assessed at 2 weeks after attainment of the blood lithium 
level of 0.5 to 1.0 mmol/l, unless the response criterion was met earlier. Dropouts 
were censored at the time of dropout. Eventual non-responders were censored at the 
end of the treatment strategy, i.e., 2 weeks after attaining the blood lithium level of 
0.5 to 1.0 mmol/l. As planned a priori (Bruijn et al., 1996), the analyses for testing 
differences in response rates between the 2 treatment strategies were adjusted for the 
following co-variables and their possible interactions with type of treatment: 
MADRS pre-treatment scores (baseline severity), duration of the current episode, 
adequate pre-treatment during current episode, number of previous depressive 
episodes, bipolar type, melancholic type, psychotic features, type of depression 
according to Research Diagnostic Criteria, and time to attain pre-defined blood level 
of study medication. A survival analysis with start time of haloperidol as time-
dependent co-variable was performed to take into account the possible influence of 
haloperidol co-medication on response. Each co-variable and, consecutively, this co-
variable ",ith its interaction with type of treatment were entered in a model 
containing type of treatment only. A p value < .05 (2-sided) was considered 
statistically significant. Eventually, a model was fitted containing all co-variables and 
interactions that had thus appeared to be significant. Hazard ratios with 95% 
confidence intervals (CIs) are presented. The hazard ratio is the factor by which the 
response rate is multiplied for each unit increase in the co-variable. Thus, if the co-
variable is dichotomous (e.g., treatment type), then the hazard ratio is the ratio of the 
response rate in one group (e.g., mirtazapine with lithium addition) relative to the 
other (e.g., imipramine with lithium addition). 
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Variable Mirtazapine (II - 50) Imipramine (II = 50) 
Age: years, mean ± SD (range) 
Sex: male/ female 
Diagnosis: "major depressive episodc ll (DS1\.f-III-R) 
* Ullipolars 
Non-psychotic, 1st episode 
Non-psychotic, recurrent 
Psychotic, 1 st episode 
Psychotic, recurrent 
* Bipolars 
Non-psychotic 
Psychotic 
l\,felancholic type 
r..hjor depressive episode (RDC) 
Retarded Depression (RDC) 
Agitated Depression (RDC) 
Endogenous Depression (RDC) 
Suicidal 
IIRSD-baseline, total score, mean ± SD (range) 
1.1ADRS-baseline, total score, mean ± SD (range) 
Duration current episode 
< 1 year 
> 1 year 
Adequate pre-treatment with antidepressants 
Family history (1st/2nd degree) 
Depression 
Suicide 
Personality disorder 
----
45 ± 11 (23-64) 
12/38 
50 
46 
50 
15 
16 
50 
25 
45 
5 
16 
15 
8 
6 
4 
1 
26.3 ± 4.6 (19-37) 
37.6 ± 6.0 (25-51) 
32 
18 
21 
27 
10 
10 
47 ± 10 (27-65) 
11/39 
SO 
42 
49 
15 
17 
47 
31 
50 
22 
14 
10 
4 
26.3 ± 5.08 (18-37) 
36.0 ± 6.9 (16-54) 
30 
20 
21 
32 
9 
7 
n 
~ 
~ 
en 
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Adequate pre-treatment during current episode was defined as an adequate dose 
of an antidepressant received for at least 4 weeks (potter and Rudorfer, 1989). 
The efficacy of lithium addition as such (the effect in phase 2) in non-responders 
was not analysed separately because the difference in efficacy between imipramine 
and mirtazapine in phase 1 makes non-responders taking imipramine and non-
responders taking mirtazapine no longer representative of the same pool of patients. 
Results 
Patient population and dropouts 
One hundred seven depressed inpatients were randomly assigned to either 
mirtazapine (n = 54) or imipramine (n = 53). Seven patients (4 taking mirtazapine 
and 3 taking imipramine) did not receive lithium addition although they were non-
responders; 1 patient recovered shortly after addition of haloperidol, 1 patient was 
discharged without our consent, and 5 patients were continued on double-blind 
medication without ever receiving lithium addition. Thus, 100 patients were available 
for analysis (Table 1). During phase 1, 8 patients dropped out, while 2 patients were 
excluded from analyses because monitoring of blood levels showed non-compliance 
(Table 2). 
Table 2. Drop-outs and non-completers by non-compliance (n :;:: 13) during mirtazapine or 
imipramine monotherapy (phase 1), and during lithium addition (phase 2). 
Treatment 
11:irtazapine 
Phase 1 
Phase 2 
Imipramine 
Phase 1 
Phase 2 
Reason for leaving study 
Transfer to other ward 
Refuse to take medication 
~ on-compliance (blood level l) 
Deterioration -- ECT 
Non-compliance 
Mania 
Orthostasis 
Deterioration 
Fever and delirium 
}Jlergic reaction 
Non-compliance (blood level t) 
Discharge mthout OUI consent 
N 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
1 
1 
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Thus, 90 patients (47 taking mirtazapine and 43 taking imipramine) remained after 
phase 1. The mean ± SD time to reach the predefined blood levels was 10.9 ± 3.5 
days (range 5-21) for mirtazapine and 13.6 days ± 4.6 days (range 7-25) for 
imipramine. Including the 4-week treatment at this blood leve~ the mean ± SD 
total period on study medication (phase 1) was 38.9 ± 3.5 days (range 33-49) for 
mirtazapine and 41.6 ± 4.6 days (range 35-53) for imipramine. 
According to the main response criterion at 4 weeks after attaining the predefined 
blood level, 33 (37%) of 90 were responders and 57 (63%) of 90 were non-
responders. Thus, 57 non-responders (35 taking mirtazapine and 22 taking 
imipramine) were started on lithium addition. Lithium was added to the study 
medication after a mean lag time of 3.5 days. During phase 2, no patients dropped 
out because of adverse effects. Three patients dropped out for other reasons: 1 
taking nill:tazapine was treated with electro-convulsive therapy after 10 days of 
lithium addition, because of worsening of the depression, and 1 patient taking 
imipramine was discharged without our consent after 11 days of lithium addition. A 
third patient had to be excluded from analyses because the monitored blood levels of 
mirtazapine showed non-compliance. Thus, 54 patients completed phase 2; 33 taking 
nill:tazapine and 21 taking imipramine. The mean ± SD total period of lithium 
addition, including the time to reach the lithium blood level of 0.5-1.0 mmo1/l, was 
22.4 ± 5.0 days (range 13-32) for patients receiving nill:tazapine and 23.2 ± 5.0 days 
(range 18-33) for those receiving imipramine. 
Co-medication (Table 3) 
Twenty patients received co-medication (8 received haloperido~ 3 haloperidol 
and lorazepam, and 9 lorazepam). Before lithium addition, lorazepam was 
administered to 6 patients (4 taking nill:tazapine and 2 taking imipramine). Before 
lithium addition, 11 of the 29 psychotic patients (7 taking mirtazapine and 4 taking 
imipramine) were treated ",~th between 4 and 12 mg/ day of haloperidol during 9 to 
40 days. Only 2 of those patients (1 taking nill:tazapine and 1 taking imipramine) 
were responders; the other 9 were non-responders. The J:v1ADRS score after 
haloperidol addition with these 9 patients was the same as or higher than before 
haloperidol addition. Thus, none of these patients benefitted from haloperido~ and 
all were subsequendy treated with lithium addition. One of these patients, taking 
imipramine, entered the lithium addition period with this co-medication, which was 
continued during the entire period of lithium addition. 
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Table 3. ~umber of patients receiving co-medication during mirtazapine or imipramine 
monotherapy (phase 1) and during lithium addition (phase 2) 
, 
b 
Ivfirtazapine Imipramine 
Lorazepam 
Phase 1 4 2 
Phase 2 S 3' 
Total S 4 
Haloperidol 
Phase 1 7 4 
Phase 2 0 lb 
Total 7 4 
One patient stopped taking lorazepam before entering phase 2, and 1 patient continued 
this co-medication. 
One patient who received haloperidol in phase 1 entered phase 2 Mth this co-medication. 
Treatment effects: 
Survival analyses: The survival analysis of the total patient group (n = 100) with 
type of treatment as independent variable showed a significant difference between 
the 2 treatment groups (bazard ratio = 1.75; 95% CI = 1.03 to 3.00;p = .04). The 
results of the survival analyses with several co-variables are presented in Table 4. The 
co-variables "duration of present episode!!, "adequate pre-treatment during current 
episode" and "psychotic features!! showed a significant contribution to treatment 
results. No other co-variable was significant, although "melancholic type" 
approached significance (see Table 4). There were no significant interactions of co-
variables with treatment, although the interaction of "psychotic features" with 
treatment type almost reached statistical significance (p = .06). 
N e.:,t, we tested a model containing only the significant co-variables in addition to 
type of treatment together (Table 5, Model 1). From this model we deleted 1 co-
variable with the highest p value ("adequate pre-treatment"). This led us to the final 
model containing the co-variables "duration of present episode" and "psychotic 
features" in addition to type of treatment; both co-variables did improve the 
precision of the estimated difference between the 2 treatment groups (Table 5, 
Model 2). 
The probability of non-response (Kaplan-Meier curve) of the 2 treatment groups 
in time is shown in Figure 2. 
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Table 4. Results of sun,..,ival-analyses comparing the h,vo treatment strategies...-vith each co-
variable separately*' 
Co-variable 
Baseline severity (HRSD score) 
Duration of present episode (> 1 year) 
~umber of previous depressions 
Bipolar type (yes) 
Adequate pre-treatment (yes) 
Melancholic type (yes) 
Psychotic features (yes) 
Retarded depression (RDC) (yes) 
Agitated depression (RDC) (yes) 
Endogenous depression (RDC) (yes) 
Haloperidol (time-dependent) (yes) 
Time to attain predefined blood 
level of antidepressant (days) 
Hazard 
ration 
1.01 
0.32 
1.04 
1.40 
0.45 
2.40 
2.16 
0.89 
0.71 
1.89 
1.24 
0.99 
95% Confidence p 
interval 
0.95-1.06 0.582 
0.17-0.60 0.000 
0.90-1.19 0.597 
0.42-4.72 0.585 
0.25-0.79 0.005 
0.86-6.96 0.093 
1.23-3.83 0.008 
0.49-1.69 0.695 
0.40-1.26 0.241 
0.44-8.08 0.390 
0.52-2.92 0.629 
0.93-1.06 0.784 
* The hazard ratio is the factor by which the response rate is multiplied for each unit increase 
in the co-variable. 
Table 5. Two models of survival analyses comparing the 2 treatment strategies, using the 
significant co-variables from Table 4. 
Variable Hazard 95% p 
ratio Confidence 
interval 
Modell: 
Type of treatment (Imipramine) 2.04 1.18-3.51 0.010 
Duration of present episode (> 1 year) 0.39 0.21-0.76 0.005 
Adequate pre-treatment (yes) 0.58 0.32-1.05 0.074 
Psychotic features (yes) 1.71 0.96-3.03 0.068 
Model 2: 
Type of treatment (imipramine) 2.08 1.21-3.58 0.009 
Duration of present episode (>1 year) 0.35 0.19-0.66 0.001 
Psychotic features (yes) 1.82 1.03-3.22 0.040 
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Figure 2: Probability of non-response (Kaplan-Meier curve) of the 2 treatment groups in 
time: Mirtazapine plus lithium addition (n = 50, bold line), and imipramine plus 
lithium addition (n = 50, thin line). p = 0.04 
Numbers oj responders: in order to obtain some insight into the contribution of each 
of the significant co-variables separately, the proportion and percentage of 
responders at the end of each treatment phase are presented in Table 6. These 
numbers illustrate the result of the survival analysis. Both long duration of the 
present episode and adequate pre-treatment are related to poor response, although as 
much in the imipramine group as in the mirtazapine group. It must be pointed out 
that these co-variables are highly related, as 26 (68%) of 38 patients with a duration 
of the present episode > 1 year had an adequate pre-treatment of the present 
episode, compared with 16 (26%) of 62 with a duration of:S 1 year. Table 6 also 
illustrates that the superiority of imipramine is more pronounced in the group of 
psychotic patients. 
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" H Table 6. Number and % of responders at the end of phase "1 and phase 2 by co-variables that contributed significantly to the results tn 
in the survival analysis. 
__ ~ ___ ~=A=~'"~'~~~"~,~"."~=~, __ ,,~~,~m~_"~_~~_~~ ___ ~_~~@~ •• ~ __ "=",_~, 
Intent-ta-treat Completers 
j\1irtazapinc Imipramine l'\'lirtazapinc Imipramine 
Phase 1 Phase 2 Phase 1 Phase 2 Phase 1 Phase 2 Phase 1 Phase 2 
Variable N % n % n % n % n % n % n % n % 
---
Total group 12/50 24 24/50 48 21/50 42 32/50 64 12/45 27 24/45 52 21/42 50 32/42 76 
Psychotic 
Yes 4/15 27 7/15 47 9/14 64 12/14 86 4/12 33 7/12 58 9/12 75 12/12 100 
No 8/35 23 17/35 49 12/36 33 20/36 56 8/33 24 17/33 52 12/30 40 20/30 67 
Duration 
::; 1 year 9/32 28 19/32 59 18/30 60 24/30 80 9/27 33 19/27 70 18/27 67 24/27 89 
> 1 year 3/18 17 5/18 28 3/20 15 8/20 40 3/18 17 5/18 28 3/15 20 8/15 53 
Pre-treattnent 
Not adequate 10/29 34 15/29 52 16/29 55 23/29 79 110/25 40 15/25 60 16/27 59 23/27 85 
Adequate 2/21 10 9/21 43 5/21 24 9/21 43 2/20 10 9/20 45 5/15 33 9/15 60 
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Discussion 
The purpose of the present study was to compare the overall effectiveness of a 2-
step treatment strategy with a standard tricyclic antidepressant and subsequent 
lithium addition 'W~th a similar treatment strategy with a modem antidepressant and 
subsequent lithium addition. For the clinician, it is important to know which of these 
2 strategies results in an optimal chance for the patient to recover in the shortest 
period of time. The results of the survival analysis, in which all patients started on 
treatment are included (intent-to-treat), indicate a significant difference in favour of 
imipramine and subsequent lithium addition. According to the analyses that used 
several baseline variables as co-variables, "duration of present episode", "adequate 
pre-treatment" and "psychotic fearures" are significant predictors for response (see 
Table 4). In 2 different models, these co-variables improved the precision of the 
estimation of the difference between the 2 treatment strategies (see Table 5). 
The fact that no significant interaction between any of the 3 significant co-
variables and treatment type was observed indicates that these baseline variables did 
not contribute significantly to the difference between the 2 treatments. Thus, both 
treatment strategies show less effect in patients '\.Vlth a duration of present episode> 
1 year and in patients with adequate pre-treatment of present episode (baseline 
variables that often go hand in hand), as also reported in the analysis of phase 1 of 
this study (Bruijn et al., 1996). However, there was an almost significant interaction 
bet\\leen the baseline variable "psychotic features It and treatment type. Thus, it is 
possible that psychotic patients profited more than non-psychotic patients from the 
superiority of imipramine. These results emphasise the value of lithium addition to 
tricyclics, especially for patients 'W~th psychotic depressions, as has been suggested in 
earlier reports (price et al., 1983; Pai et al., 1986; Stein and Bemadt, 1993). 
No other co-variables were significant in these analyses. This was especially of 
importance for the unequally divided baseline variable "bipolar"; the 5 bipolar 
patients were by chance all included in the mirtazapine group (Tables 1 and 4), but 
according to the analysis, this fact did not influence the response rate in the 
mirtazapine group. 
It may be argued that the overall response was influenced by haloperidol, 
received by 7 patients taking mirtazapine and 4 patients taking imipramine. However, 
of these 11 patients, only 2 (1 taking mirtazapine and 1 taking imipramine) were 
responders before lithium addition, indicating that haloperidol was not instrumental 
in the recovery in those patients. Moreover, a survival analysis with haloperidol 
intake as time-dependent co-variable showed no significant contribution to the 
results (Table 4). 
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Thus, in a group of severely depressed inpatients, the treatment strategy of 
imipramine administration with subsequent lithium addition for non-responders is 
more effective than the same strategy with mirtazapine and lithium addition (76% vs. 
53% responders, respectively), as is also evident from the intent-to-treat analysis 
(64% vs. 48% responders). The advantage of imipramine is in part offset by the 
higher number of treatment failures due to side effect-related dropout; during phase 
1, 6 of 7 dropouts that occurred Vit-1th imipramine treatment were caused by adverse 
effects as compared '\vi.th none of 3 that occurred '\.Vith mirtazapine treatment. 
Most open and double-blind studies with respect to lithium addition have 
involved non-responders to antidepressants for which response and dropout 
percentages of phase 1 are not reported (Schopf, 1989a); in fact, the antidepressants 
involved often were not listed. Thus, the overall effectivec'ess of treatment with the 
antidepressant and of subsequent lithium addition can not be estimated. The present 
results illustrate the importance of this issue: the comparison between the results of 
lithium addition to imipramine non-responders and to mircazapine non-responders, 
respectively (i.e., analysis of the results of phase 2 without taking into account phase 
1), could suggest equal efficacy of lithium addition to both antidepressants. 
However, this is not an appropriate comparison, since in our study mirtazapine is 
less effective than imipramine, and the patient populations entering the lithium 
addition phase are not therefore comparable. 
Regarding the difference in effectiveness between mirtazapine and imipramine in 
phase 1, one could argue that adjusting the dose of both drugs to attain fi:<:ed blood 
levels could have influenced the results because this procedure is not a validated one 
for mirtazapine as it is for imipramine. However, the mean mirtazapine dose of 76 
mg/ day (range 40-100 mg) was above the dose used in other inpatient studies (Bruijn 
et al., 1996), which does not make probable a reduced response rate due to the fixed 
blood level. 
l! must be emphasised that our results can not be generalised to patient 
populations other than this group of severely ill inpatients, of whom many (29%) 
were psychotic. Trials similar to the present one in other patient populations are 
needed for further generalisation. 
Taking into account the literature on the efficacy of tricyclic antidepressants in 
severely depressed inpatients (Bruijn et al., 1996; Danisch University Antidepressant 
Group, 1986, 1990) we translate our results into clinical practice as follows. We start 
with imipramine treatment at fixed blood levels and, if necessary, add lithium, which 
is sufficient and effective for the majority of patients. The risk of more common as 
well as more severe adverse effects is accepted, because this risk does not offset the 
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superior overall effectiveness of imipramine. In the case of troublesome or severe 
side effects the patient is shifted to a modem antidepressant such as mirtazapine 
without losing much time in treatment, and, if necessary, lithium is added to this 
antidepressant. 
Drtlg names: 
Haloperido' (Haldol and others), imipramine (Tofranil and others), lorazepam 
(Ativan and 0rhers), mirtazapine (Remeron). 
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Chapter 6 
TRAIT ANXIETY AND THE EFFECT OF A SINGLE 
HIGH DOSE OF DIAZEPAM IN UNIPOLAR 
DEPRESSION 
Abstract 
In this cross-sectional study we explored in 101 depressive inpatients (DSM-III-
R) the association between level of trait anxiety and variables that have been 
inves~o-ated previously to discern primary and secondary depression, respectively. 
Besides, '\ve explored the influence of trait anxiety level on difference in treatment 
response to either imipramine or mirtazapine. \Ve found no relation bet\.veen trait 
anxiety level and treatment response to either imipramine or mirtazapine. 
The most important fmding of this study is the significant differential response 
to the diazepam test: Depressive patients "vith high trait anxiety sho\.ved 
predominantly disappearance of depressive symptoms without sedation and 
depressive patients Vlith low trait anxiety showed predominantly sedation "mtheut 
disappearance of depressive symptoms. The opposite response to the diazepam test 
in patients with a different history of trait anxiety in spite of similar depressive 
symptomatology is suggestive for differences in underlying pathophysiologic 
mechanisms. 
Keywords: 
Depression; Trait Anxiety; Diazepam test; M..A.O-activity; Neuroticism; 
Treatment response. 
Introduction 
Patients with a history of anxiety often develop a depression later in their life. 
This applies to an.:ciety disorders (Clancy et al., 1978, Dealy et al., 1981, Moras & 
Barlow 1992, Schatzberg et al., 1990) proper as well as to chronic anxiety symptoms 
not fulfilling the diagnostic criteria for anxiety disorder. Van Valkenbu.rg et al. 
(1983) e.g., found differences between depressive patients with chronic lifelong 
nervousness preceding the onset of depression (anxiety as a trait, without having a 
diagnosable preceding anxiety disorder) and patients without this pre-morbid 
nervousness. 
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The concept of depression secondary to chronic anxiety may be related to the 
"psychasthenia" concept of Janet Gelgersma, 1939): in addition to patients with 
melancholia (primary depression) he observed patients who had a lifelong 
vulnerability, a trait, to develop various complaints such as phobias, compulsions, 
doubt, shame, fear for the future, depersonalisation and fatigue. 
A related concept was proposed by Akiskal (1998): "Generalised anxious 
temperament" (GAT) with lifelong high trait anxiety which fluctuates in reaction to 
stress and which can escalate to a full-blown generalised anxiety disorder. According 
to Akiskal, "Generalised anxiety disorder" (GAD) is in continuum with GAT. 
Generalised anxiety temperament may predispose to and is often associated with 
depression. The view of generalised anxiety being a personality trait, which can 
exacerbate into an anxiety disorder and which predisposes to depression, is in line 
with the evidence from longitudinal studies that chronic anxiety disorders are not 
infrequently accompanied by secondary depression, whereas chronic depression 
rarely is associated with a secondary anxiety disorder (Cloninger et al., 1981). 
Nuller et al. (1982) reported that the reaction to the diazepam test distinguished 
primary depressions from depressions secondary to anxiety and predicted a good 
response to treatment with an antidepressant or to treatment with a benzodiazepine, 
respectively. We performed a cross-sectional study in depressed patients e':ploring 
clinical, personality and biological variables, which could help to distinguish patients 
with different levels of trait anxiety. 
Material and Methods 
General Outline 
The study was performed on the inpatient depression unit of the Department of 
Psychiatry of the Dniversity Hospital "Dijkzigt" Rotterdam. Eligible patients had to 
be drug free for at least 3 days before baseline assessment. Included were patients 
aged 18-65 with a "major depressive episode" (DSM-III-R; American Psychiatric 
Association, 1987) with a Hamilton Rating Scale for Depression (HRSD) score ~18 
(Hamilton, 1960). Excluded were patients with schizophrenia, paranoid psychosis, 
organic brain syndrome, chronic drug or alcohol abuse, clinically relevant renal, 
hepatic, cardiovascular, or endocrme disease, presence of absolute contraindication 
for either imipramine or mirtazapine, and pregnancy or the risk to become 
pregnant. Patients were given a detailed outline of the study, following which 
written informed consent was obtained and a single blind placebo was administered 
for 4 days. 
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The variables to be e:<amined because of their possible relationship with trait 
anxiety were neuroticism (Stavrakaki and Vargo, 1986), MA.O-activity in platelets 
(Davidson et aI., 1980), response to a single high dose of diazepam (diazepam test, 
Nuller er. aI., 1982) and response to treatment. 
At the end of the placebo period MAO-activity in platelets was measured and a 
provocation test "vith diazepam was performed, and subsequently patients ,\vere 
randomly allocated to double-blind treatment ,,~th either imipramine or 
mirtazapine. Doses of both drugs were adjusted to obtain fi:<ed blood levels as 
described previously (Bruijn et al., 1996). Outcome measurement ",~th the HRSD 
was performed 4 weeks after atraining this predefined adequate blood level. 
Response was defined a priori as a reduction of 50% or more of the outcome HRSD 
score. 
Assessments 
All assessments "\vere done by one research psychiatrist GB), except tl1.e section 
of the Schedule for Affective Disorders and Schizophrenia (SADS; Spitzer and 
Endicott, 1981), which relates to depression, which was performed in the presence 
of a second psychiatrist. This standardised interview was administered before the 
start of the placebo period to obtain RDC diagnoses (Research Diagnostic Criteria, 
Spitzer et aI., 1978) and to assess state anxiety symptoms. Scoring was based on 
consensus between both psychiatrists. During the baseline period there ,-vas an 
interview \."\Tith the partner or a Erst degree relative of the patient to evaluate the 
patients history of possible anxiety disorders administering a questionnaire which 
comprised the SADS questions on anxiety disorders (to identify patients ~th a 
history of anxiety disorders), and to assess the level of trait anxiety, using a 
questionnaire "\-vith 34 questions pertaining to trait anxiety. These questions on trait 
anxiety were both related to aspects of psychic anxiety (e,g., nervousness, anxious 
feelings, fear of dying, irritability, impatience, concentration disturbances, 
depersonalisation, indecisiveness) and to aspects of somatic anxiety (e.g., 
restlessness, trembling, muscle tension, insomnia, shortness of breath, chest pain, 
palpitations, abdominal distress, dizziness, sweating). Presence as well as intensity 
and frequency of items were quantified (score of each question: 0-4, i.e., absent, 
mild, moderate, severe; range of total score: 0 - 136). 
MA.0-activity ().l.mol/l/hour) was measured in whole blood ~th kynuramine as 
the substrate (Van Kempen et al., 1985) and calculated per platelet. The diazepam 
test was applied according to Nuller et al. (1982) by giving 40 mg diazepam by 
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"'" Table 1. Patient population (II = 101): Relation between trait anxiety sum score (TA, mean ± SD) and other 
variables*' 
Categorical variables 
Comparison of differences regarding '1'A per variable, 
---.--~ .. ,-- .~---""-.---,-,-,------.---,- - --- ------- -
Sex: Male 
Female 
DSM-III-R diagnosis 
Psychotic: 
Recurrent: 
Melancholic type 
Retarded depression (lille) 
Agitated depression (lillC) 
Endogenous depression (RDC) 
Suicidal 
Dumtion current episode 
BCllzodiazepine use before admittance during 
current episode 
History of one or more anxiety disorders (RDC) 
Yes 
No 
Yes 
No 
Yes 
No 
Yes 
No 
Yes 
No 
Yes 
No 
Yes 
No 
> I yenr 
~ 1 year 
Yes 
No 
Yes 
No 
23 
78 
30 
71 
40 
61 
86 
IS 
30 
71 
34 
67 
97 
4 
56 
45 
39 
62 
52 
49 
11 
90 
Trait anxiety 
(univariate) 
23 17 .18 
18 ± 16 
16 ± 13 .25 
21 ± 17 
24 ± 15 .02 
17 ± 16 
20 ± 17 .90 
18 ± 14 
20 ± 16 .44 
18 :t 18 
20 ± 15 .77 
19 ± 17 
19 ± 16 .80 
17:t 18 
22 ± 17 .03 
16 ± 15 
16 ± 14 .16 
21 :t 17 
22 ± 17 .09 
16 ± 15 
35 ± 23 .01 
18:t 14 
Table 1 continues 
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Table 1 (co1ltinued) Patient population (n;;::: 101): Relation between trait anxiety sum scorc (TA, mean ± 
SD) and other variables:1 
~_."~'~_"',.~,~~_~_,_, ___ ~ W".~_,_~ __ ~~_ 
Categorical variables 
Comparison of differences regarding T;-\ per variable 
Diazepam test 
Negative 
Intermediate 
Positive 
Outcome measurement 50% response 
Responders with mirtazapine 
Responders with imipramine 
Interaction f.,Jedication / Trait Anxiety 
Numeric variables 
Spcannan Rank correlation with trait anxiety 
-----~--~-~-.------ -,-----~ -----_._-
Age 
Age of onset of first depression 
HRSD baseline 
Sum scorc trait anxiety questionnaire (rA) 
Sum score state anxiety symptoms (SADS) 
MAO-activity: ~mol/l/ 10'platelets*hr 
Neuroticism score (AB'V) 
Outcome measurement HRSD score: 
I-IRSD score after mirtazapine 
HRSD score after imipramine 
Interaction r.ledication / Trait Anxiety 
r Data for some are missing. 
;;;;;1; ~~;--' ","",' , '1; ;;;Tt'" '~~;;; ""--"'~~-N· p-vJ.lue 
36 
28 
36 
11/47 (23%) 
23/45 (51%) 
not sign,(p=,32) 
[vfean ± SD (range) 
4T±iI(2365)--
40 ± 12 (16-63) 
26 ± 5 (18-37) 
19 ± 16 (0-67) 
21 ± 5 (6-36) 
11 ± ,05 (03-.26) 
68 ± 32 (13-123) 
19± 9 (1,34) 
14± 9 (1-32) 
not sign, (p = ,64) 
anxiety 
13 ± II 
19 ± 19 
25 ± 16 
CoefE. 
(univariate) 
,005 
p~value 
,~- ---" --,--~- --
,158 ,11 
-,010 .92 
.093 .36 
,11O 27 
,027 .80 
.106 ,31 
,044 ,77 
.179 .24 
::;J 
~, 
M 
§ 
p, 
" ~
§ 
0-
S'-
" ~ 
i:l 
" 
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rectiole. At baseline and 1 and 4 hours after administration of diazepam the reaction 
of the patient to the diazepam test was assessed by scoring 7 items from the 
Comprehensive Psychiatric Rating Scale (CPRS, Asberg and Perris, 1978): observed 
sadness, psychic anxiety, somatic anxiety, pessimistic thoughts, observed affect, 
somnolence. There were 3 possible clinical reactions: 
1) 1".,Tegative: Symptoms like observed sadness and pessimistic thoughts underurent 
no change and there was pronounced somnolence for several hours from "\vruch 
awakening was difficult. 
2) Intermediate. Incomplete reduction of observed sadness and pessimistic thoughts 
and varying degrees of somnolence from which awakening was not difficult. 
3) Positiv~ Complete disappearance of all symptoms, sometimes with euphoria, 
'\vithout any somnolence, this reaction persisting for several to 24 hours. 
To quantify neuroticism the 'Amsterdamse Biografische Vragenlijst' (~AJ3V; 
Wilde, 1970) was administered when the depression was in remission to minimise 
the chance of measuring 'state' instead of the intended measurement of the 'trait'. 
For all patients this assessment was made in the period from shortly before 
discharge until 3 months after discharge. 
Data ana!!sis and statistica! methods 
The Kolmogorov-Smirnov goodness of fit test was performed to test normality 
of the distribution of all continuous variables. Independent samples t-tests or one 
way ANOVA's were used on variables approximately normally distributed and 
otherwise Mann-Whitney tests or Kruskal-Wallis tests were performed. To analyse 
the relationship between the sum score of the trait anxiety questionnaire and other 
continuous variables Spearman rankorder correlations were applied. 
The relationship between trait anxiety and the diazepam test was analysed 'W-ith 
multiple linear regression analysis in order to adjust for possibly confounding 
variables (Table 1). For this purpose all variables which showed differences 
regarding trait anxiety level with a significance level < .20 were kept in the 
regression model after bach.--..:vard elimination, and the variable "sum score of state 
an....aety symptoms" was always entered to control for state an.-xiety. In the regression 
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model which was performed to calculate the adjusted means of the trait anxiety sum 
scores in the 3 diazepam test groups, the co-variables were set at their mean value. 
To analyse the possible influence of the level of trait an:ciety on the difference in 
treatment response to either rnirtazapine or imipramine, multiple linear regression 
analysis was performed vrith the outcome HRSD score as dependent continuous 
variable and study medication, the sum score on the trait an....aety questionnaire and 
its interaction "vith study medication as independent variables. Similarly, logistic 
regression analysis was performed ,,~th the 50% responders as dependent 
dichotomous variable. All tests were performed two-sided. Each analysis was 
performed mth all available data excluding missing data per analysis. 
Ethical considerations 
The protocol was approved by the Ethics Committee of the Gniversity Hospital 
"Dijkzigt" and of the Medical Faculty of the University of Rotterdam. 
Results 
Patient population 
One hundred and one unipolar depressed inpatients were included (fable 1). 
Data were missing for some patients as outlined in Table 2; data were complete for 
77 of the 1 01 patients. 
The relation between trait anxie(y and other variables 
Table 1 shows the patient characteristics at baseline and the univariate relation 
between each of the variables and trait anxiety. The sum score of the trait an...aety 
questionnaire was significantly higher in "recurrent" versus 'Tsingle episode", 
"suicidal" versus "not suicidafT and "history of one or more anxiety disorders Tt 
versus "no history of anxiety disorders". There was no significant correlation 
between the sum score of the trait anxiety questionnaire and the total score of 
anxiety symptoms (SADS) during the depressive episode (state anxiety), MAO-
activity, and neuroticism score, respectively. Regression analyses '\v:ith the HRSD 
score and logistic regression analyses mth the 50% responders showed no 
significant interaction mth study medication (p = 0.64 and p = 0.32, respectively). 
Thus, the level of trait anxiety appeared to have no relation to the difference in 
treatment response 'i-"Vith mirtazapine or imipramine, respectively. 
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Table 2. Reasons for missing data (n = 24); in some subjects more than one variable was 
IDlSSlllg 
Variable n 
YLA..O-activity missing 12 
Diazepam test miss:ing 1 
Neuroticism (ABV) missing 7 
Dropout mirtazapine treatment 2 
Dropout imipramine treatment 7 
Reason 
Logistic 
Refusal 
Logistic (3), refusal (3), treatment-resistant (1) 
Refusal (1), non-compliance (1) 
Deterioration (1), non-compliance (1), side 
effects (5) 
A significant positive relation was found between the sum score of the trait 
anxiety questionnaire and response in the diazepam test (Table 1~ one way 
ANOV A: P = 0.005). Tills seems to be a robust finding, because after adjusting for 
possible confounding variables the relation between trait aIL-ciety level and the 
response to the diazepam test remained significant (p = 0.022, Tables 3 and 4). 
There was no significant relation between the sum scores of state anxiety 
symptoms (SADS) and the results of the diazepam test (Tables 3 and 5). 
Table 3. Results of a multiple regression analysis (n ;;;: 100) conce:rning the relation 
between trait an.-..ciety level and the results of the diazepam test, adjusted for 
possibly confounding- factors. 
Variables Coefficient Standard error Significance 
Constant 
Se., (female) 
Psychotic (yes) 
Suicidal (yes) 
Duration current episode (> 1 year) 
Benzodiazepine use before admittance 
During current episode (yes) 
Diazepam test: 
Negative 
Intennedlate 
Positive 
i\.ge (year) 
Swn score state amciety symptoms (S_WS) 
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(B) 
- 4.90 
- 6.16 
- 5.16 
8.72 
- 5.48 
6.52 
o 
6.81 
9.42 
0.37 
0.38 
(SE) 
13.08 
3.60 
3.33 
3.17 
3.06 
2.93 
3.66 
3.47 
0.14 
0.31 
} 
(P) 
0.090 
0.130 
0.007 
0.076 
0.029 
} 0.022 
} 
0.009 
0.222 
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Table 4. :yrean sum score of trait an...aety questionnaire .in the 3 diazepam test groups 
unadjusted and adjusted for possible confounding factors (see Table 3) 
Diazepam test result 
(n) 
Negative (36) 
Intermediate (28) 
Positive (36) 
11ean trait an..~ety sum score (SE) 
Unadjusted Adjusted 
13.33 (2.56) 
18.57 (3.87) P = .005 
25.33 (3.62) 
13.82 (2.40) 
20.63 (2.76) P = .022 
23.24 (2.44) 
Table 5. Mean sum scores of the state an..xiety symptoms (S~IDS) in the 3 diazepam test groups 
Diazepam test Sum score of state an..x.iety symptoms 
Mean ± SD (range) 
Negative 
Intermediate 
Positive 
Discussion 
21 ± 6 ( 6-36) 
20 ± 5 (13-30) 
22 ± 4 (15-31) 
In this study we explored the relation of level of trait anxiety in depressive 
patients to neuroticism score, age of onset of first depression, reaction to diazepam 
test, MAO activity in platelets, and response to different antidepressants. We found 
no significant relation bet\veen trait anxiety and each of these factors except for the 
results of the diazepam test. ll. high trait anxiety level correlated with a positive 
response to the diazepam test and a low trait anxiety~ level wi.th a negative response 
to diazepam. 
There was no correlation bet\\7een neuroticism scores and trait anxiety level. The 
neuroticism score may have been biased by the depressive state, as has been 
observed before (Svrakic and Cloninger, 1994). The significant correlation (p = 
0.04) between the outcome HRSD score and the neuroticism score done shordy 
after the treatment period points to such a bias. Thus, a possible relation between 
neuroticism and trait anxiety may have been obscured by the depressive state. 
We did not reproduce the results of Davidson et al. (1980) who found higher 
MAO activity in platelets of patients with depression secondary to anxiety disorders 
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than in platelets of patients with primary depression. It is possible that MAO 
activity is more related to the level of state anxiety symptoms than to trait anxiety 
(Thase and Howland, 1995). The level of state anxiety symptoms differed between 
the groups of primary and secondary depressions in the study by Davidson (1980) 
but not between patients with high trait anxiety and patients with low trait anxiety in 
ours. 
The most important finding of this study is the relation between trait anxiety 
level and the reaction to the diazepam test. Thus, depressive patients with high trait 
anxiety showed predominantly disappearance of depressive symptoms without 
sedation and depressive patients with low trait anxiety showed predominantly 
sedation (somnolence) to the high dose of diazepam used in the test. These results 
can not be e.'plained by differences in state anxiety, because there were no 
significant differences between high trait anxiety patients and low trait anxiety 
patients regarding anxiety symptomatology during depression (sum scores of the 
state anxiety items (Table 1); an analysis adjusting for this variable and other 
possible confounding variables did not weaken the relation between trait anxiety 
level and the diazepam test (Tables 3 and 4) and the subgroups of the diazepam test 
showed no differences in mean sum scores of the state anxiety items (Table 5). 
The only clinical variables in our patient group which showed significant 
differences regarding trait anxiety were "suicidality" and "recurrent depression" 
(Table 1), hinting at a more severe and recurrent character of depressions with a 
high trait anxiety leveL This finding is in line with the literature on patients with 
coexistent anxiety and depressive syndromes, which indicates that there is increased 
chronicity of the illness and a poorer prognosis (Stavrakaki and Vargo, 1986). 
However, there are no other obvious symptomatological differences between 
depressive patients with high trait an.:6ety and low trait amiety in our patient group. 
The fact that patients with a different history of trait am.iety and similar 
depressive symptomatology show a totally opposite response to the diazepam test is 
suggestive for differences in underlying pathophysiologic mechanisms. Although 
this is not to infer from current symptomatology, depressive patients with high trait 
an.xiety may be more aroused than depressive patients "'W'ith low trait an.xiety. 
Townsend et al. (1998) reported a heightened autonomic arousal evidenced by 
cardiovascular measures in patients v"ith major depressive disorder secondary to a 
panic disorder compared to patients with primary major depressive disorder. 
Akiskal (1985) reported greater arousal in patients with anxiety disorders as well as 
in patients with depressions secondary to an:6ety compared to patients with primary 
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depressions. He suggests that anxiety, even when complicated by depression, is 
psychophysiologicallya distinct disorder ftom primary depression. 
In conclusion, the results of the present study show differences in response to 
diazepam in patients with high versus low trait anxiety. The results are in line with 
the postulates of Janet (Jelgersma, 1939) and Akiskal (1998) on the differences 
between primary depressions and depressions secondary to anxiety, respectively. 
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Discussion 
The main aim of this study waS (1) to compare the efficacy of mirtazapine to the 
efficacy of imipramine, a standard treatment, among inpatients '\vith major depressive 
disorder, including patients 'With melancholic features, with psychotic features, with 
suiciciality, with treatment resistance and '\v'ith relatively long duration of the current 
episode of depression. We hypothesised that a high trait am:iety level would be 
predictive for response to mirtazapine and that a low trait anxiety level would be 
predictive for response to imipramine in this patient group. In addition to the 
comparison of mirtazapine and imipramine in the total study population, and the 
investigation of the possible relation between trait anxiety level and response, more 
specifically the following issues were investigated: (2) the efficacy of treatment in 
psychotic depressed patients compared to non-psychotic patients in the total study 
population as well as in the two treatment groups separately; (3) the overall efficacy 
of the treatment strategy: mirtazapine and subsequently lithium addition for non-
responders to mirtazapine alone, compared to the efficacy of treatment strategy: 
imipramine and subsequently lithium addition for non-responders to imipramine 
alone; (4) the value of certain clinica~ personality and biological variables in 
distinguishing patients with different levels of trait anxiety. In the previous chapters, 
these specific issues have been extensively introduced, described, and discussed. The 
purpose of this final chapter is to integrate the results from these parts of the study, 
to discuss the findings and clinical implications of the study, and finally to discuss 
recommendations for future research. 
Summary of results 
(1) Diffirence in efficacy between mirtazapine and imipramine. In the total study 
population of the present study there was a considerable difference in antidepressive 
efficacy between the new antidepressant mirtazapine and the standard TCA 
imipramine (Chapter 2, Figure ZA) in favour of the last. This difference was 
significant according to all a priori defined outcome criteria. 
115 
Chapter 7 
(2) Differences in response patterns. In addition, we found differences in response 
patterns between the two drugs (Chapter 4, Figures 3 and 4). Imipramine was more 
effective than mirtazapine for symptoms such as depression, guilt and retardation, 
and it had an effect on all of the symptoms, which progressively increased during 
treatment. 11irtazapine, on the other hand, had a more restricted effect on sleep and 
anxiety symptoms, to which tolerance developed. 
(3) Psychotic depressed patients. The difference in efficacy between mirtazapine and 
imipramine was even more pronounced in the subgroup of psychotic depressed 
patients (Chapter 2, Figure 2B). In the patients who were treated ",~th imipramine 
without adjuvant antipsychotic medication, a high response rate of approximately 
70% was observed in the psychotic depressed patients. 
(4) Lithium addition. The efficacy of imipramine and subsequent lithium addition 
for non-responders was superior to mirtazapine followed by lithium addition in non-
responders (Chapter 5, Figure 1), indicating that patients who are starting treatment 
with an antidepressant and who are treated with lithium addition to that 
antidepressant in case of non-response, have a higher probability to recover and also 
recover sooner when started on imipramine. 
(5) Trait anxiety. No relation was found between trait anxiety level and treatment 
response to either imipramine or mirtazapine. Our hypothesis that rntttazapine, an 
antidepressant "\v-1.th supposed strong anxiolytic properties, would be more effective 
in patients with a high trait anxiety level and that the standard antidepressant 
imipramine would be more effective in patients '\.\t1th a low trait anxiety leve~ was not 
confumed. In addition, no variables were found which could help to distinguish 
patients with different levels of trait anxiety, except for the diazepam test. 
Why did we detect differences not found before? 
Mirtazapine compared to imipramine 
The most important finding in the present study is the considerable difference in 
efficacy between miItazapine and imipramine. In addition, we found significant 
differences in the response patterns between the two drugs. Such differences 
beween antidepressants have not been reported before, both in wo other studies 
comparing mirtazapine to TCAs in inpatients (Zivkov and De Jongh, 1995; Richou 
et al., 1995), and in most studies with SSRIs and other newer antidepressants 
compared to TCAs in inpatients (Kellams et aI., 1979; Feighner, 1980; Gershon et al., 
1981; Guelfi et aI., 1992; Benkert et al., 1996; Anderson, 2000). 
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\Vhy did we detect these differences which have not been found before? There 
are a number of differences regarding selection of study population, and regarding 
methodological issues including dose design, use of concomitant psychotropic 
medication and dropout rate between the present study and other studies. 
(1) Study population. The study population of the present study comprised severely 
depressed inpatients with typical inpatient characteristics, including suicidality, 
melancholic and/or psychotic features, and long duration and/or adequate pre-
treatment with an antidepressant during the current episode. As described in Chapter 
1, the study population of the two other inpatient studies on mirtazapine (Pichou et 
al., 1995; Zivkov and De Jongh, 1995) were different. Suicidal patients, psychotic 
depressed patients, and patients Vlith long duration of the current episode were 
excluded in these studies, while it was not clear whether the patients in these studies 
had melancholic features. The characteristics of patients in these study populations 
are more similar to those of outpatients than of inpatients. That is, they are not 
suicidal, and not psychotic, and have a duration of the current episode no longer 
than SL'\: months. To test the efficacy of antidepressants in inpatients it is essential 
that study populations include patients with typical inpatient characteristics. It is 
important to describe study populations in terms of these characteristics (Chapter 2, 
Table 1), because they appear to have more weight in predicting response than 
severity defined by the total HRSD score (Anderson, 2000). The placebo response 
rates in patients "\vith a long duration of the current episode, patients -with 
melancholic features and patients with psychotic features, are usually low (Angst et 
al., 1989; Peselow et al., 1992; Schatzberg and Rothschild, 1992), which makes the 
finding of true drug/ drug differences more probable (Angst et al., 1989). 
(2) Dose design. Comparison studies with TCAs such as imipramine are technically 
difficult to perform due to the narrow therapeutic and tolerability ranges of these 
drugs (Burke and Preskorn, 1995). If the study permits gradual titration of the dose, 
as in a flexible dose design, most patients on TeAs \.vill finish on doses that are too 
low to test the effIcacy of these drugs. The reason is that many patients simply 
cannot or will not tolerate such doses. The majority of studies comparing SSRIs or 
newer antidepressants to TCAs in inpatients were performed with a flexible dose 
design (I<:ellams et al., 1979; Feigner, 1980; Gershon et al., 1981; GuelfI et al., 1992; 
Zivkov and De Jongh, 1995; Richou et al., 1995; Anderson, 2000). With some TCAs, 
for instance clomipramine, a fLxed dose design may result in a therapeutic blood level 
for most patients (DUAG, 1986; DUAG, 1990; DUAG, 1993). However, a daily 
dose of 200 mg imipramine, as in the study of Benkert et al. (1996), will result in a 
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therapeutic blood level of imipramine in only 60% of patients (Glassman et aI., 
1977). Moleman et aI. (1996) have shown that no fi..,ed dose of imipramine will result 
in more than 30% of the patients treated with that fi..,ed dose having a therapeutic 
blood level and not having an unacceptable risk of having toxic side effects. If a 
study calls for aggressive dosing of the TCA as in a fi..,ed dose design 'With a higher 
dose, then there will be a large dropout rate, undermining the adequacy of the test of 
efficacy of the TCA. Thus, it is not surprising that there are compelling data to 
suggest that response rates to TCAs can be markedly increased by adjusting drug 
dose based on blood level determinations (Glassman et aI., 1977; Reisby et aI., 1977; 
Perry et aI., 1994). In the present study, adjusting of the dose to a predefined fi..,ed 
blood level resulted in a mean daily dose of imipramine of 235.5 mg with a very wide 
range (37.5 - 450 mg). t-Jo fewer than 9 (20%) patients were on a daily dose of 112.5 
mg or less, and 17 (37%) patients received 300 mg imipramine or more. It is unlikely 
that such doses would have been administered without blood level control. One 
could argue that this dose design is less suitable for mirtazapine because adjusting the 
dose to a predefined blood level is not a validated procedure. In fact, therapeutic 
blood levels of mirtazapine are not known. This indeed is one of the limitations of 
the present study. However, we do not believe that this really is a problem in our 
study, as the dose adjustments in the present study, based on predefined blood levels 
of mirtazapine, resulted in a mean dose of 76 mg/ day, which is higher than the mean 
dose in previous inpatient mirtazapine studies: 47 mg/day (Richou et aI., 1995), and 
53 mg/ day (Zivkov and De J ongh, 1995). In addition, there are no data suggesting 
that mirtazapine has a curvilinear blood level response curve, as is the case with 
nortriptyline (Asberg, 1974), and there were not many dropouts in the present study, 
which could have been another drawback of a possible high dose. 
(3) Concomitant psychotropic medication. It has been suggested that concomitant 
medication 'With benzodiazepines may mask differences in efficacy between 
antidepressants (Angst, 1993), and this certainly would apply to our findings 
regarding symptom clusters involving sleep and anxiety (Chapter 4), which have 
given us more insight in the specific properties of the tested drugs. As discussed in 
Chapter 1, in most inpatient studies concomitant psychotropic medication is 
permitted, probably because restriction of these drugs is practically difficult. 
However, "With the intensive support of trained nurses as in the present study it is 
feasible: only a minority of patients was treated with anxiolytic, hypnotic or sedative 
concomitant medication, and the difference in efficacy between mirtazapine and 
imipramine remained significant if these patients were excluded. 
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(4) Dropout rate. A high dropout rate may bias results of clinical trials even if 
analyses are based on "intent to treat" samples (Angst et al., 1989; Chapter 1). The 
dropout rate in the present study was low (9.1%). The previous studies '\V~th 
mirtazapine including inpatients had higher dropout rates (17 - 30%). Evidence-
Based Mental Health states that a dropout rate higher than 20% is not acceptable in 
clinical trials (Anonymous, 2000). One of the reasons for the low dropout rate in the 
present study may be the adjustment of the dose to therapeutic blood levels 
preventing dropout as a result of side effects by too high blood levels of the drug 
(Burke and Preskorn, 1995). In addition, special attention and training has been 
allocated to staff at all levels of the research-ward where the present trial was 
conducted, to ensure proper medical and psychological care for the patients. 
In conclusion, the combination of the methodological strengths regarding study 
population, dose desigo, concomitant medication and dropout rate appear to have 
resulted in the finding of true drug/drug differences which othen,~se might have 
been missed. Adjustment of the dose to therapeutic blood levels seems to be the 
most important aspect in this respect. Burke and Preskom (1995) and Sanathanan 
and Peck (1991) suggested performing such a trial appears to be very efficient due to 
the large inter-individual variability in plasma drug concentration of TCAs at a given 
dose. The few studies, which also showed significant differences in efficacy between 
the tested drugs, were all performed with therapeutic blood levels of the TCA 
involved in most patients (DUAG, 1986, 1990, 1993; Roose et al., 1994). DUAG 
applied a fi.."ed dose design of 150 mg daily of the reference TCA clomipramine with 
blood plasma control afterwards. This design resulted, perhaps by chance, in a 
therapeutic blood level for most patients. Roose et a1. (1994) applied a dose design 
'W~th adjustment of the nortriptyline dose to therapeutic blood levels, but this study 
was not randomised. Thus, the present study is the first double-blind randomised 
controlled trial with dose adjustment of imipramine to therapeutic blood levels. It is 
not surprising this being the first such trial, because a plasma controlled trial with any 
drug class is difficult to perform especially under double-blind conditions 
(Sanathanan and Peck, 1991; Johnson and Holt, 1995). However, the present study 
shows that such trials are feasible in severely depressed inpatients, but similar 
methodology has also been applied in a long term trial on preventive treatment of 
bipolar patients (Moleman et al., 2000). 
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Psychotic depressed patients 
The difference in efficacy between mirtazapine and imipramine in the present 
study was even more pronounced in the subgroup of psychotic depressed patients 
(Chapter 2, Figure 2B). In the mirtazapine group there was no significant difference 
in efficacy between the psychotic and the non-psychotic patients. However, the 
patients who were treated with imipramine without adjuvant antipsychotic 
medication, a high response rate of approximately 70% was observed in the 
psychotic depressed patients against a response rate of about 40% in the non-
psychotic patients. As discussed in Chapter 3, this result was contrary to most studies 
on the treatment of psychotic depressed patients (Glassman et aI., 1975; Spiker et al., 
1985; Chan et aI., 1987; Parker et al., 1992; Schatzberg and Rothschild, 1992). A 
major difference between the present study versus other studies on the 
pharmacotherapy of psychotic depressed patients was the treatment of all patients 
with therapeutic blood levels for a sufficient long period in the present study. 
Differences in patient characteristics between the study populations may also playa 
role. In our study, the psychotic depressed patients had a shorter duration of the 
current episode, and this feature may have contributed significandy to the more 
favourable response of the psychotic patients. Nevertheless, an analysis adjusting for 
this co-variable showed an even more pronounced difference bet\"\leen psychotic and 
non-psychotic patients in their response to imipramine (Chapter 3, Figure 2). 
Another difference between the present study and other studies was that in the 
present study all psychotic patients had mood congruent delusions, while in some 
other studies patients with mood incongruent delusions may have been included, 
although this is not always clearly described (Spiker et aI., 1985; Chan et aI., 1987; 
Kocsis et aI., 1990; Schatzberg and Rothschild, 1992). Psychotic depressed patients 
with mood incongruent delusions are less likely to respond to treatment mth 
antidepressants alone compared to combination therapy of antidepressant and 
antipsychotic medication (May et al., 1990; Parker et aI., 1992). 
Lithium addition 
The efficacy of imipramine and subsequent lithium addition for non-responders 
was superior to mirtazapine followed by lithium addition in non-responders (Chapter 
5, Figure 1). This is the [lIst study comparing the overall effectiveness of two 
treatment strategies \N~th lithium addition for non-responders As discussed in 
Chapter 5 most open and double-blind studies ",~th respect to lithium addition 
comprised non-responders to antidepressants for which response and dropout 
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percentages of the preceding antidepressant phase were not reported (Schopf, 1989; 
Austin et al., 1991; Bauer and Dopfmer, 1999). Thus, the overall effectiveness of 
treatment "vith the antidepressant and subsequent lithium addition in case of non-
response can not be estimated. The present results illustrate the importance of this 
issue: the comparison between the results of lithium addition to imipramine non-
responders and to mirtazapine non-responders, respectively (i.e., analysis of the 
results of lithium addition phase without talting into account the results of the 
preceding antidepressant phase), could suggest equal efficacy of lithium addition to 
both antidepressants. However, this is not an appropriate comparison, since in our 
study mirtazapine is less effective than imipramine, and the patient populations 
entering the lithium addition phase are, therefore, not comparable. 
Clinical implications 
(1) To which depressed inpatients do the results apply? The results apply to unipolar 
depressed inpatients with typical inpatient characteristics such as suicidality, 
melancholic and psychotic features, long duration of the current episode and/or 
adequate pre-treatment "vith an antidepressant during the current episode. In other 
studies patients Vlith these characteristics were excluded. Thus, our study more so 
than other studies seems to reflect the typical depressed inpatient population. 
However, it is stressed that it is unknown to what extend the findings of the present 
study can be generalised, because the study population was restricted to one centre. 
These results can not be applied to bipolar depressed patients in view of the low 
number of these patients in the present study and in view of the different 
recommendations for acute bipolar depression (Halpern and Glassman, 1990; Nolen 
and Bloemkolk, in press). 
(2) Which is the treatment of choice Jor unipolar depressed inpatients? The present study 
shows a considerable difference in antidepressant efficacy between the newer 
antidepressant mirtazapine and the standard antidepressant imipramine in inpatients. 
Adding the results of the present study to the results of studies on the efficacy of the 
SSRIs and the newer antidepressants as reviewed in Chapter 1, it can be concluded 
that treatment 'W~th a TCA with dose adjustment to therapeutic blood levels is the 
treatment of choice for unipolar depressed inpatients, because this treatment is most 
evidence based and probably the most effective pharmacotherapy in depressed 
inpatients. This result is remarkable because since the introduction of imipramine as 
an antidepressant (I<uhn, 1958), many new antidepressants came to the market. 
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Considering the difference between mirtazapine and imipramine in the present study, 
no supportive evidence was found for the suggestion that inpatients can be 
effectively treated with mirtazapine because of its "dual action" properties (Kasper, 
1997; Hirschfeld, 1999; Montgomery, 1999; Moller, 2000). Compared to imipramine, 
no rapid onset of action of mirtazapine was found as suggested by Montgomery 
(1999). The apparent rapid onset of action of mirtazapine in the present study was 
explained by the temporary stronger anxiolytic effect of this drug (Chapter 4, Figures 
3 and 4). 
Although the investigators did not systematically rate side effects, only in some 
dropout patients specific treatment for side effects was necessary according to the 
observations of treating psychiatrists and nurses. The dropout rates regarding side 
effects were low 5/53 (9%) for imipramine compared to 0/54 (0%) for mirtazapine. 
Although this is a non-significant difference, these results do not rule out that the 
tolerability of rniItazapine is somewhat better than of imipramine. However) the 
intention to treat analysis taking into account all dropouts resulted in a significant 
difference of the overall efficacy in favour of imipramine. Thus, the lower efficacy of 
mirtazapine is not offset by the better tolerability of this drug. 
In the light of these findings it is remarkable that, in contrast to the Dutch 
guidelines for treatment of depression (De Groot, 1995; Birkenhager and Moleman, 
1998; Nolen and Hoogduin, 1998), the official guidelines of the American Psychiatric 
Association (AP A, 2000) and of the British Association of Psychopharmacology 
(Anderson et al., 2000) do not mention explicitly the superiority of TCAs at 
therapeutic blood levels for inpatients. 
(3) Which is the place of lithium addition? The present study shows superiority of 
imipramine plus lithium addition. Regarding the question whether the lithium 
addition effect is limited to any class of antidepressant, to date no sufficient 
information is available (Bauer and Dopfmer, 1999). Most double-blind studies 
concerning lithium addition were performed on TCAs, and there are only few data 
available of double-blind placebo controlled studies concerning lithium addition to 
SSRIs or other newer antidepressants in inpatients (Schopf, 1989; Katona et al., 
1995; Austin et al., 1991; Baumann et al., 1996; Bauer and Dopfmer, 1999). The 
results of the present study emphasise the value of lithium addition to tricyclics, 
especially for patients ",~th mood congruent psychotic depressions, as has been 
suggested in earlier reports (price et al., 1983; Pai et al., 1986; Stein and Bernadt, 
1993). Although this has to be tested as yet, lithium addition to a TCA may be a 
good alternative for the combination of an antidepressant and an antipsychotic in the 
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treatment of these patients. \V'hiJ.e the Dutch guidelines advocate the addition of 
lithium to a TCA in the light of the available data, it is remarkable that the US and 
UK guidelines advocate lithium addition in case of non-response without 
mentioning to which antidepressant lithium should be added. 
Recommendations for future research 
In view of the design and the results of the present study, it is essential to 
perform double-blind randomised studies ,,~th dose adjustment of, at least, the 
reference drug to therapeutic blood levels, and with control of use of concomitant 
psychotropic medication and dropout rate among large inpatient samples that are 
representative of inpatients. Actually, the same principles also apply to outpatient 
groups. These aspects minimise the chance of type-2 error and maximise the 
probability to detect true drug/drug differences. The persistent lack of trials ,,~th 
such a methodology may ultimately lead to more and more antidepressants being 
used in certain groups of depressed patients although they in fact are less effective 
than the classical drugs in these patients. We perform or will perform similar studies 
comparing other antidepressants such as an SSRI and for instance venlafa..'<ine to 
TCAs in our inpatient groups. 
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Summary 
This thesis is concerned with the pharmacotherapy of inpatients with a major 
depressive disorder. In Chapter 1 the background of the present study is given. 
Successively, epidemiological aspects of unipolar depression, evidence on the 
efficacy of various classes of antidepressants in inpatients, lithium addition in 
treatment resistant depressive patients, and trait anxiety level as a possible predictor 
of response are discussed. 
In many studies comparing a ne\.v antidepressant '\vith a tricyclic antidepressant 
(Iel\), the statistical "no difference" conclusion has been taken as an indication of 
therapeutic equivalence with the TCA. In the majority of studies, however, a possible 
difference in efficacy between the drugs may have stayed undetected as a result of 
methodological shortcomings and/or a too low statistical power by too small sample 
size. One of the methodological problems is the dose design of many studies. 
Dosing of TeAs without blood level control voill not result in an adequate blood 
level of the antidepressant in 30%-50% of the patients. In a dose design without 
blood level control, flexible dosing of TeAs is more problematic than fL,ed dosing 
because disturbing side effects could result in doses below the therapeutic level, 
which may lead to response rates below the real potentials of these drugs. The 
majority of trials comparing antidepressants used a flexible dose design without 
blood level control. This may have lowered the efficacy of the TeAs used in these 
trials, which implicates that real differences between TeAs and other antidepressants 
may have been missed. Another problem is the study population of many inpatient 
studies. Patients vo~th typical inpatient characteristics were often excluded in these 
studies. The characteristics in these study populations are more similar to those of 
outpatients than of inpatients. In view of the selection of these patient groups, it is 
unlikely that the results of these studies could be generalised to other inpatient 
groups vo~th typical inpatient characteristics such as melancholic features, psychotic 
features, suicidality, treatment resistance and a relatively long duration of the current 
episode of depression. 
Given the low number of studies on the newer antidepressants in inpatients and 
given the methodological weaknesses of most of these studies, the efficacy of these 
drugs compared to the TeAs in inpatients is still uncertain. 
In addition to the issue regarding the optimal antidepressant treatment, there is 
the question 'Nith respect to the strategy in treatment resistant depressive patients. 
Lithium addition appears to be an effective strategy in patients with treatment-
129 
Summary 
resistant depression. The treatment "vith an antidepressant and the addition of 
lithium, however, are often regarded separate, unrelated treatment decisions. Thus, in 
prescribing an antidepressant, the efficacy of possible lithium addition to that 
specific antidepressant is not taken into account. Therefore, comparison of the 
overall effectiveness of treatment strategies of different antidepressants and 
subsequent lithium addition of the respective non-responders is of interest. 
Predictors of response, which would be useful in identifying patients who would 
best be treated with a certain antidepressant, have been scarcely established. Patients 
with a history of (trait) an.."<iety often develop a depression later in their life, which 
may be phenomenologically similar to depressions of patients without a history of 
anxiety. Disorders with different aetiology may show differential response to specific 
treatments. Therefore, it may be useful to explore the predictive value of trait an.~ety 
in depressive patients with respect to the specific response to different 
antidepressants. 
The main purpose of the present study was to compare the efficacy of 
mirtazapine, a new antidepressant 'Vv;th supposed strong anxiolytic properties, to the 
efficacy of imipramine, a standard TCA, among inpatients with a major depressive 
disorder, including patients 'With typical inpatient characteristics. The subgroup of 
psychotic depressed patients is of particular interest because these patients have been 
reported to show a weak response to treatment v.rith antidepressants alone. A 
randomised controlled clinical trial was performed, which was designed to avoid 
methodological problems such as inadequate dosing of the reference drug, a high 
dropout rate and concomitant treatment with other psychotropic drugs. Thus, the 
purpose of this design was to minimise the chance of type-2 errors and to maximise 
the chance to observe quantitative and qualitative differences between the treatment 
outcomes of the two drugs. 
The specific aims of this study, as stated a priori in the study protocol, were the 
following: 
Primary aims: (1) To compare the efficacy of mirtazapine and imipramine in 
inpatients with major depressive disorder. (2) To determine the value of trait anxiety 
level as a predictor for response to mirtazapine and impramine, respectively. 
Secondary aims: (3) To compare the efficacy of treatment of psychotic depressed 
patients with that of non-psychotic depressed patients in the total study population 
and in the mirtazapine and the imipramine group, respectively. (4) To compare the 
overall efficacy of two treatment strategies for depressed inpatients: mirtazapine and 
subsequently lithium addition for non-responders, or imipramine and subsequently 
lithium addition for non-responders (not stated a prion). (5) To determine clinical, 
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personality and biological variables which could help to distinguish patients with 
different levels of trait anxiety. 
In Chapter 2, the pharmacological properties of mirtazapine are discussed. 
Subsequendy, the design of this randomised, double blind study with inpatients and 
the selected patient population, are described in detail. Patients "'-:lth a DSM-III-R 
diagnosis of major depression and a Hamilton (17 -item) score of 2: 18 were selected. 
After a drug-free and a placebo washout period of 7 days in total, 107 patients still 
fulfilling the HRSD criterion of 2: 18 started on active treatment. The dose was 
adjusted to a predefined fi.,ed blood level to avoid sub-optimal dosing of 
imipramine. In the total study population, after 4 weeks' treatment on the predefined 
blood level, there was a considerable difference in antidepressive efficacy between 
mirtazapine and imipramine in favour of the last. This difference was significant 
according to all a priori defined outcome criteria. The subgroup of psychotic patients 
showed an even larger superiority~ of imipramine over m.irtazapine, response 
percentages being around 60-70% for imipramine and around 20-30% for 
mirtazapine, depending on the analysis performed. Most of these results were 
significant, even with the small number of psychotic patients studied. These results 
are discussed in the light of the data on this issue from the literature and in the light 
of the applied methodology. 
In Chapter 3, we focus on the response to imipramine in a group of patients with 
psychotic depression and compare this to patients without psychotic features. Most 
studies report a poor response of psychotic depressed patients to tricyclic 
antidepressants in comparison "vith non-psychotic depressed patients and in 
comparison ,;vith treatment with tricyclic antidepressants in combination Vlith 
antipsychotics. However, the issue of optimal treatment of psychotic depressed 
patients has not been resolved as yet. Our aim in presenting these findings was to 
contribute to the discussion on the optimal treatment of psychotic depressed 
patients. Fifty-two patients "'-:lth a unipolar major depression, comprising 15 patients 
with mood-congruent psychotic features and 37 with no psychotic features, were 
commenced on treatment "\\lith imipramine. After 4 weeks of treatment on 
predetermined blood level, a high response rate of 69% (9/13 completers) was 
observed in our patients with psychotic depression who were treated with 
imipramine "\vi.th no adjuvant antipsychotic medication. This contrasted "vith a much 
lower response rate of 43% (14/32 completers) to the same treatment in our non-
psychotic patients. Throughout the entire treatment period the steeper response 
131 
Summary 
curve of the psychotic depressed patients in the present study was clear. Possible 
confounding factors did not account for this result. Most reports in the literature 
conclude that combination of an antidepressant 'Jl'ith an antipsychotic is the 
treatment of choice in psychotic depressed patients in view of the poor response to 
mono-therapy 'Wi.th an antidepressant. In our patient group, however, the fust choice 
treatment is mono-therapy with imipramine with blood level control because of the 
high success rate, the more so since subsequent lithium addition for psychotic 
depressed patients with unsatisfactory response increased the response rate from 
69% to 100%. Differences with data from the literature on this issue are discussed 
and possible causes of these differences are evaluated. 
In Chapter 4, the results of an analysis of different symptom clusters and their 
course during treatment "vith mirtazapine and imipramine, respectively, are reported. 
Total HRSD scores and 7 symptom clusters were analysed in the 85/107 patients 
(79%) ,-vho were not receiving any co-medication. Imipramine was more effective for 
symptoms such as depression, guilt, and retardation, which can be regarded as the 
core symptoms of depression and it had an effect on all of the symptoms, which 
progressively increased during treatment. Mirtazapine, on the other hand, had a more 
restricted effect on sleep and anxiety symptoms, to which tolerance developed. 
Differences in response patterns have not previously been observed in studies 
comparing antidepressants, despite the wealth of such studies and numerous efforts 
to discover differences between antidepressants. These findings suggest that 
mirtazapine may have an...aolytic and sedative properties and fewer antidepressant 
properties than imipramine in severely depressed inpatients. The implications of 
these results "vi.th respect to possible differences in mechanism of action bet\"Veen the 
two drugs are discussed. 
In Chapter 5, the comparison of 2 treatment strategies for depressed inpatients is 
reported: mirtazapine (phase 1) and subsequently lithium addition for non-
responders (phase 2) or imipramine (phase 1) and subsequently lithium addition for 
non-responders (phase 2). The design of phase 2 of the study is described in detail. 
Non-responders had lithium added to the double-blind mirtazapine or imipramine 
medication. The dose was adjusted to obtain a blood level of 0.5 to 1.0 mmo1/1. 
Treatment effects were evaluated weekly by the Montgomery-Asberg Depression 
Rating Scale (MADRS) for up to 2 weeks on this lithium blood level. A survival 
analysis of the total patient group intent-to-treat showed a significant difference in 
favour of the treatment strategy with imipramine and subsequent lithium addition, 
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indicating that patients who are starting treatment with an antidepressant and who 
are treated v,."ith lithium addition to that antidepressant in case of non-response, have 
a higher probability to recover and also recover sooner when started on imipramine. 
In Chapter 6 the results of our analysis of the value of trait anxiety level as a 
predictor for response to mirtazapine and imipramine, respectively, are described. 
No relation was found bet\\leen trait anxiety level and treatment response to either 
imipramine or mirtazapine. Our hypothesis that mirtazapine, an antidepressant \\lith 
supposed strong anxiolytic properties, would be more effective in patients '-v-ith a 
high trait anxiety level and that the standard antidepressant imipramine would be 
more effective in patients \-vith a lo'\v trait anxiety level, '\vas not confirmed. In 
addition, no variables were found which could help to distinguish patients with 
different levels of trait anxiety, except for the diazepam test. The most important 
finding of this part of the study is the significant differential response to the 
diazepam test in the 101 unipolar patients: Depressive patients with high trait anxiety 
sho'\ved predominantly disappearance of depressive symptoms \.vithout sedation and 
depressive patients \-,,1.th lo\.v trait anxiety showed predominantly sedation '\..'\t1.thout 
disappearance of depressive symptoms. The opposite response to the diazepam test 
in patients ,,~th a different history of trait anxiety in spite of similar depressive 
symptomatology is suggestive for differences in underlying pathophysiologic 
mechanisms. 
In Chapter 7. the results of the study and clinical implications are discussed, and 
finally, recommendations for future research are given. 
The most important fmding in the present study is the considerable difference in 
efficacy behveen mirtazapine and .i.m.ipramine. This difference was even more 
pronounced in the subgroup of psychotic depressed patients. In addition, we found 
significant differences in the response patterns between the two drugs. Such 
differences beh\ ... een antidepressants have not been reported before. The 
combination of the methodological strengths regarding study population, dose 
design, concomitant medication, and dropout rate appear to have resulted in the 
fmding of true drug/drug differences which otherwise might have been missed. 
Adjustment of the dose to therapeutic blood levels seems to be the most important 
aspect in this respect. Such a dose design appears to be very emcient due to the large 
inter-individual variability in blood level of TCAs at a given dose. 
These results apply to unipolar depressed inpatients with typical inpatient 
characteristics such as suicidality, melancholic and psychotic features, long duration 
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of the current episode and/or adequate pre-treatment with an antidepressant during 
the current episode. Adding the results of the present study to the results of studies 
on the efficacy of the Selective Serotonin Reuptake Inhibitors (SSRIs) and the newer 
antidepressants as reviewed in Chapter 1, it can be concluded that treatment \Vith a 
TeA with dose adjustment to therapeutic plasma levels is the treatment of choice for 
unipolar depressed inpatients, because this treatment is most evidence based and 
probably the most effective pharmacotherapy in depressed inpatients. The results of 
the present study emphasise the value of lithium addition to tricyclics in case of non-
response, especially for patients 'Wi.th mood congruent psychotic depressions, as has 
been suggested in earlier reports. 
In view of the design and the results of the present study. it is essential to 
perform more double-blind, random1sed studies with dose adjustment of, at least, 
the reference drug to therapeutic plasma levels, and with control of use of 
concomitant psychotropic medication and dropout rate among large inpatient 
samples that are representative of inpatients. Actually, the same principles also apply 
to outpatient groups. These aspects minimise the chance of type-2 error and 
ma:illnise the probability to detect true drug/drug differences. The persistent lack of 
trials "vith such a methodology may ultimately lead to more and more antidepressants 
being used in certain groups of depressed patients although they in fact are less 
effective than the classical drugs in these patients. 
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Dit proefschrift gaat over de farmacotherapie van opgenomen patienten met een 
depressieve stoomis. In hoofdrtuk 1 wordt de achtergrond van elit onderzoek 
gepresenteerd. Achtereenvolgens worden besproken: epidemiologische aspecten van 
unipolaire depressie, het be'\vijsmateriaal betreffende de effectiv-iteit van verschillende 
soorten antidepressiva bij opgenomen patienten, lithiumadelitie bij therapieresistente 
depressieve patienten en het "trait anxiety" ruveau als mogelijke voorspeller van 
respons. 
In veel onderzoeken, '\vaarin een nieuw antidepressivum met een tricyclisch 
antidepressivum (TeA) werd vergeleken, heeft men aangenomen dat de statistische 
"geen verschil" -conclusie een teken is van therapeutische gelijk"Waarcligheid tussen 
het TeA en het nieuwe antidepressivum. Bij het merendeel van deze onderzoeken 
ecliter, kan een mogelijk verschil in effectiviteit tussen de middelen onontdekt 
gebleven zijn ten gevolge van methodologische tekortkomingen en/of een te kleine 
statistische "power" door een te klein amtal patienten. Een van de methodologische 
problemen in veel onderzoeken is het doseringsschema. Het doseren van TeAs 
zonder bloedspiegelcontrole resulteert in 30% tot 50% van de parienten ruet in een 
adequate bloedspiegel van het antidepressivum. Bij een doseringsschema zonder 
bloedspiegelcontrole geeft flexibel doseren meer problemen dan doseren met een 
vaste dosis, omdat hinderlijke bijwerkingen zouden kunnen resulteren in 
subtherapeutische doseringen, hetgeen kan leiden tot responspercentages die lager 
liggen dan de werkelijke mogelijkheden van deze middelen. Bij de meeste 
onderzoeken, waarbij de effectiviteit van verschillende antidepressiva wordt 
vergeleken, wordt gewerkt met flexibele doseringen zonder bloedspiegelcontrole. Dit 
kan de gemeten effectiviteit van de bij deze onderzoeken gebruikte TCAs 
verminderd hebben, hetgeen betekent dat in werkelijkheid bestaande verschillen 
tussen TeAs en andere antidepressiva onopgemerkt gebleven zijn. Een tweede 
probleem is de onderzoekspopulatie van veel onderzoeken bij opgenomen patienten. 
Patienten met kenmerken die juist vaak voorkomen bij opgenomen patienten werden 
vaak uitgesloten bij deze onderzoeken. Derhalve is het onwaarschijnlijk, dat de 
resultaten van deze onderzoeken gegeneraliseerd h.-unnen worden ten aanzien van 
andere patientengroepen met typische eigenschappen van opgenomen patienten 
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zoals vitale kenmerken, psychotische kenmerken, sillcidaliteit, therapieresistentie en 
een relatief lange duur van de aanwezige depressieve episode. 
Gezien het ger:inge aantal onderzoeken met nieuwere antidepressiva bij 
opgenomen patienten en gezien de methodologische tekortkomingen van de meeste 
van deze onderzoeken, is de effectiviteit van deze middelen bij opgenomen patienten 
in vergelijking met de TCAs nog onzeker. 
Naast het probleem betreffende de optimale antidepressieve behandeling is er 
ook de bvestie van het beleid bij therapieresistente depressieve patienten. 
Lithiumadelitie blijkt een effectieve aanpak te zijn bij deze patienten. De behandeling 
met een antidepressivum en de additie van lithium worden echter vaak gezien rus los 
van elkaar staande behandelingsbeslissingen. Dat \<1.1 zeggen dat men de effectiviteit 
van lithiumadelitie bij een bepaald antidepressivum in geval van non-respons niet 
mee laat wegen bij de keuze van een antidepressivum. Vergelijking van de totale 
effectiviteit van behandelingsstrategieen met verschillende antidepressiva en daarop-
volgende lithiumadelitie bij de respectievelijke non-responders is daarom van belang. 
Er zijn nau"\velijks factoren bekend, die respons voorspellen en die van nut 
zouden kunnen zijn bij het vaststellen welke parienten men het best met een bepaald 
antidepressivum kan behandelen. Patienten met (trait) angst in de voorgeschiedenis 
ontwikkelen later in hun !even vaak een depressie die qua verschijningsvorm 
hetzelfde kan zijn als depressies van patienten zonder angst in de voorgeschiedenis. 
Desondanks reageren stoorn1ssen met verschillende eriologie misschien verschillend 
op bepaalde behandelingen. Het lijkt dan ook zinvol om bij depressieve patienten te 
onderzoeken of het "trait anxiety" -niveau de specifiek.e respons op verschillende 
antidepressiva kan voorspellen. 
Het belangrijkste doel van elit onderzoek was om, bij een groep opgenomen 
depressieve patienten met de typische klinische kenmerken elie bij elie groep horen, 
de effectiviteit van mirtazapine, een nieuw antidepressivum met naar aangenomen 
wordt sterk anxiolytische eigenschappen, te vergelijken met de effectiviteit van 
imipramine, een standaard TCA. De subgroep van depressieve patienten met 
psychotische kenmerken is hierbij van speciaal belang, omdat deze patienten volgens 
de literatuw: slecht zouden reageren op behandeling met antidepressiva alleen. \vij 
voerden een gecontroleerd gerandomiseerd klinisch onderzoek uit, dat qua opzet tot 
doel had 20 veel mogelijk methodologische problemen te voorkomen, zoals 
inadequaat doseren van het referenriemiddel, een hoog percentage uitvallers en co-
meelicatie met psychotrope middelen. Het was dus de bedoeling om de kans op type-
2 errors zo klein mogelijk te maken en om de kans op het vinden van h."'V,,'antitatieve 
138 
Samenvatting 
en 1...-u,>aJ.itatieve verschillen tussen de behandelingsresultaten van de tw"ee middelen 20 
groot mogelijk te maken. 
Meer specifiek gesteld waren de doelen van dit onderzoek, zoals a priori 
omschreven in het onderzoeksprotocol, de volgende: 
Primaire ekekn: (1) Het vergelijken van de effectiviteit van mirtazapine en 
imipramine bij opgenomen patienten met een depressieve stoornis. (2) Het bepalen 
van de voorspellende waarde van "trait anxiety" -mveau veor respons op 
respectievelijk mirtazapine en imipramine. 
S ecundaire eke/en: (3) Het vergelijken van de effectiviteit van de behandeling bij 
depressieve patienten met psychotische kenmerken met die bij depressieve patienten 
zander psychotische kenmerken in de totale onderzoeksgroep en in de 
respectievelijke mirtazapine- en imipramine-groep afzonderlijk. (4) Het vergelijken 
van de totale effectiviteit van t\vee behandelingsstrategieen voor opgenomen 
depressieve patienten: mirtazapine en venrolgens lithiumadditie bij de non-
responders of imipramine en vervolgens lithiumadditie bij de non-responders (niet a 
priori beschreven). (5) Het bepalen van klinische, persoonlijkheids- en biologische 
variabelen, die rnlsschien van nut zouden kunnen zijn bij het onderscheiden van 
patienten met verschillend "'trait anxiety,." -ruveau. 
In hoofdrtuk 2 worden de farmacologische eigenschappen van mirtazapine 
besproken. Vervolgens worden de opzet van dit gerandorniseerde dubbelblinde 
onderzoek en de geselecteerde onderzoekspopulatie gedetailleerd beschreven. 
Ingesloten werden patienten met een DSM-III-R diagnose "depressieve episode" en 
een Hamilton Rating Scale for Depression (HRSD, 17 -item) score van ;::: 18. N a een 
medicatievrije en placeboperiode van in totaal 7 dagen kregen 107 patienten, die nog 
steeds voldeden aan het insluitingscriterium van een HRSD score van 2:: 18, 
onderzoeksmeclicatie voorgeschreven. De dosis werd aangepast om een tevoren 
bepaalde therapeutische bloedspiegel te bereiken en zo een te !age doseting van 
imipramine te voorkomen. Na 4 weken behandeling op therapeutische bloedspiegels 
bleek imipramine in de totale onderzoekspopulatie aanmerkelijk effectiever te zijn 
dan mirtazapine. Dit verschil was significant volgens aile a priori bepaalde 
responscriteria. In de subgroep van de psychotische patienten was het verschil tussen 
imipramine en mirtazapine nog groter, met responspercentages van rond de 60% tot 
70% voor imipramine en rond de 20%-30% voor mirtazapine, afhankelijk van de 
uitgevoerde analyse. De meeste van deze resultaten waren significant, ondanks het 
kleine aantal psychotische patienten waarom het hier ging. Deze resultaten werden 
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besproken in het hcht van de gegevens op elit gebied uit de hteratuur en in het hcht 
van de toegepaste methodologie. 
Hoofdstuk 3 gaat over de respons op imipramine bij psychotisch depressieve 
patienten in vergelijk1ng met patienten zender psychotische kenmerken. De meeste 
onderzoekers rapporteren een slechte respons van psychotisch depressieve patienten 
op TeAs vergeleken met niet-psychotisch depressieve patienten en vergeleken met 
behandeling met TCAs in combinatie met antipsychotica. De kwestie van de 
optimale behandeling van psychotisch depressieve patienten is echter nog ruet 
opgelost. Ons doel met het presenteren van deze resultaten was om bij te dragen aan 
de discussie over de oprimale behandeling van psycho tisch depressieve patienten. 
Tweeenvijftig patienten met een unipolaire depressie, waaxonder 15 psychotische 
patienten met stemmingscongruente ,-vanen en 37 patienten zonder psychotische 
kenmerken, werden behandeld met imipramine. N a 4 weken behandeling op 
therapeutische bloedspiegels was er een hoog responspercentage bij 69% (9/13 
"completers ") van de psychotische patienten die werden behandeld met imipramine 
zender toevoeging van antipsychotische medicatie. Dit stond in contrast tot het veel 
lagere respons percentage van 43 % (14/32 "completers") op dezelfde behandeling 
bij de ruet-psychotische patienten. Gedurende de gehele behandeling was de steilere 
responscurve van de psychotische patienten duidehjk. Dit resultaat bleek ruet te 
"\vijten te zijn aan invloed van mogelijke verstorende vanabelen. De meeste 
onderzoeksverslagen in de literatuur concluderen, dat combinacie van een 
ancidepressivum met een ancipsychoticurn de behandeling van eerste keus is bij 
psychotisch depressieve patienten. In onze patientengroep echter is, vanwege het 
hoge responspercentage, de eerste keus behandeling monotherapie met imipramine 
onder bloedspiegelcontrole. Dit geldt des te meer gezien het feit dat de vervolgens 
toegepaste hthiumadelitie bij psychotisch depressieve patienten met onvoldoende 
reaccie op imipramine het responspercentage verhoogde van 69% naar 100%. De 
verschillen met de gegevens in de literatuur over rut onderwerp worden besproken 
en mogelijke oorzaken van deze verschillen worden geevalueerd. 
In hooJdstuk 4 wordt een onderzoeksverslag gegeven van een analyse van 
verschillende symptoomclusters en hun beloop tijdens behandeling met 
respectievelijk mirtazapine en imipramine. De totale HRSD scores en 7 
symptoomclusters werden geanalyseerd bij de 85/107 patienten (79%) elie geen co-
meclicatie voorgeschreven hadden gekregen. Imipramine was effectiever bij 
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symptomen zoals depressie, schuldgevoel en psychomotore remmmg; symptomen 
die beschouwd kunnen worden als de kerns}rmptomen van de depressieve stoorms. 
Daarnaast beinvloedde imipramine alie symptomen, hetgeen progressief toenam 
gedurende de behandeling. Het effect van mirtazapine, aan de andere kant, beperkte 
zich meer tot slaap- en angstsymptomen, maar hiervoor ontstond tolerantie. 
Verschillen in responspatronen werden ruet eerder waargenomen in onderzoeken 
waarbij antidepressiva werden vergeleken ondanks de overvloed aan zulke 
onderzoeken en ondanks de talioze pogingen om verschillen tussen ancidepressiva te 
ontdekken. Deze bevindingen suggereren dat mirtazapine bij emstig depressieve 
patienten rnlsschien anxiolycische en sedatieve eigenschappen heeft en in mlndere 
mate ancidepressieve eigenschappen dan imipramine. De implicaties van deze 
resultaten voor de theorie over de mogelijke verschillen in werkingsmechanisme 
tussen de Nlee rnlddelen worden besproken. 
In hoofcistuk 5 wordt een onderzoeksverslag gegeven van de vergelijking van 2 
behandelingsstrategieen voor opgenomen depressieve patienten: mirtazapine (fase 1) 
en vervolgens lithiumadditie voor non-responders (fase 2) of imipramine (fase 1) en 
vervolgens lithiumadditie voor non-responders (fase 2). De opzet van fase 2 van het 
onderzoek wordt gedetailleerd beschreven. Bij non-responders werd lithium 
toegevoegd aan de dubbelblinde mirtazapine- of imipramine-medicatie. De dosis 
werd aangepast om een bloedspiegel van 0.5 tot 1.0 mmo1/1 te bereiken. De 
behandelingseffecten werden wekelijks gemeten met de Montgomery-Asberg 
Depression Rating Scale (MllDRS) totdat de patient 2 weken behandeld was op deze 
lithium-bloedspiegel. Een sunrival-analyse van de totale patientengroep (intent-to-
treat) toonde een significant verschil ten gunste van de behandelingsstrategie met 
imipramine en vervolgens lithiumadditie, ten teken dat patienten~ die beginnen met 
een antidepressivum en daar in geval van non-response lithium aan toegevoegd 
krijgen, een grotere kans hebben om te genezen en ook sneller genezen wanneer zij 
imipramine voorgeschreven krijgen. 
In hoofds/uk 6 worden de resultaten beschreven van het onderzoek naar de 
voorspellende waarde van het "trait anxiety'~ -ruveau v~~r res pons op respectievelijk 
mirtazapine en imipramine. Er werd geen relatie gevonden tussen "trait anxiety"-
niveau en behandelingsrespons 01' mirtazapine of imipramine. Onze hypothese dat 
mirtazapine, een an tidepressivum met naar men aanneemt sterk anxiolytische 
eigenschappen~ effectiever zou zijn bij patienten met een hoog "trait an....a.ety" -ruveau 
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en dat het standaard antidepressivurn imipramine effectiever ZQU zijn bij patienten 
met een laag "trait anxiety" -niveau, werd niet bevestigd. Bovendien ,-verden geen 
vanabelen gevonden die van nut zouden kunnen zijn bij het onderscheiden van 
patienten met verschillend "trait anxiety" -niveau, met uitzondering van de diazepam-
test. De belangrijkste bevinding van dit deel van het onderzoek is de significant 
verschillende respons op de diazepam-test in de 101 unipolaire patienten. Hierbij 
werd eenmalig een hoge dosis diazepam toegediend. Depressieve patienten met een 
hoog "trait anxiety" -niveau vertoonden voomamelijk een verd"'W'ijnen van de 
deptessieve symptomen zender sedatie en depressieve patienten met een laag "trait 
anxiety" -niveau vertoonden voomamelijk sedatie zonder verdwijnen van de 
depressieve symptomen. De tegengestelde reactie op de diazepam-test bij patienten 
met een verschillende voorgeschiedenis wat betreft "trait an.-..ciety", ondanks 
gelijkende depressieve symptomatologie, suggereert verschillen in onderliggende 
pathofysiologische mechanismen. 
In hoofdtuk 7 worden de resultaten van het onderzoek en de klinische implicaties 
ervan besproken en tenslotte worden aanbevelingen gedaan v~~r toekomstig 
onderzoek. 
De belangrijkste bevinding bij dit onderzoek is het aanmerkelijke verschil in 
effectiviteit tussen rnirtazapine en imipramine in de totale groep van opgenomen 
depressieve patienten Dit verschil was nog groter in de subgroep van psychotisch 
depressieve patienten. Bovendien vonden Vlij significante verschillen in respons-
patronen tussen de t\vee middelen. Dit soort verschillen tussen antidepressiva werd 
niet eerder gerapporteerd. De combinatie van een aantal sterke methodologische 
"pecten wat betreft onderzoekspopulatie, doseringsschema, co-medicatie en 
uitvallerspercentage lijkt geresulteerd te hebben in het vinden van werkelijke 
verschillen tussen de middelen, die anders misscruen onopgernerkt gebleven zouden 
zijn. Het aanpassen van de dosis totdat therapeutische bloedspiegels bereikt zijn, lijkt 
wat dit betreft het belangrijkste aspect te zijn. Een dergelijk doseringsscherna blijkt 
zeer efficient te zijn vanwege de grote interindividuele spreiding van bloedspiegels 
van TeAs bij een bepaalde dosering. 
Deze resultaten zijn van toepassing op opgenomen unipolair depressieve 
patienten met de typische klinische kenmerken die deze patienten vaak hebben, zoals 
sulcidaliteit, vitale en psychotische kerunerken, lange duur van de huidige depressieve 
episode en/of adequate voorbehandeling met een antidepressivum gedurende de 
huidige depressieve episode. Wanneer v.~j de resultaten van dit onderzoek voegen bij 
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de resultaten van de in hoofdstuk 1 besproken onderzoeken naar de effectiviteit van 
SSRls en de nieuwere antidepressiva dan h:unnen ,,~j concluderen, dat behandeling 
met een TeA. op therapeutische bloedspiegels de behandeling van eerste keuze is 
voor opgenomen unipolaix depressieve patienten, omdat deze behandeling het meest 
"evidence based" is en waarschijnlijk de meest effec'tieve farmacotherapie voor deze 
patientengroep. De resultaten van deze studie benadrukken de \vaarde van 
lithiumadditie bij TeAs in geval van non-respons, speciaal bij patienten met een 
stemrningscongruente psychotische depressie, zoals dat ook al in eerdere 
onderzoeksverslagen naar voren is gekomen. 
Gezien de opzet en de resultaten van dit onderzoek is het essentieel dat er meer 
dubbelblinde gerandomiseerde onderzoeken komen met behandeling op 
therapeutische bloedspiegels van tenminste het referentiemiddel en met controle van 
de co-medicatie en het uitvallerspercentage onder grote groepen opgenomen 
depressieve patienten met klinische kenmerken, die represenratief zijn voor deze 
groep patienten. Eigenlijk gelden dezelfde onderzoeksprincipes ook voor arnbulante 
patienten. Deze aspecten maken de kans op type-2 errors zo klein mogelijk en de 
kans dat er in werkelijkheid bestaande verschillen tussen middelen worden gevonden 
zo groot mogelijk. \Vanneer het tekort aan onderzoeken met een dergelijke 
methodologie voortduurt, zal dit bij bepaalde groepen depressieve patienten 
uiteindelijk miss chien leiden tot het gebruik van steeds meer verschillende 
antidepressiva, die bij deze patienten eigenlijk minder effectief zijn dan de klassieke 
middelen. 
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Dankwoord 
Graag \vil ik iedereen, die aan dit onderzoek en aan het tot stand komen van mijn 
proefschrift heeft bijgedxagen, bedanken . 
• AJlereerst "il ik alle patii'nten bedanken elie, opgenomen op de afdeling Psychiatrie 
van het i\cademisch Ziekenhuis Rotterdam-Dijkzigt, dee!genomen hebben aan elit 
onderzoek. Tenvijl zij in een buitengewoon moeilijke periode \varen, hebben zij ons 
als behandelteam hun vertrouwen gegeven. Het feit dat de meeste van hen na kortere 
of langere tijd de kliniek in goede toestand konden verlaten, \vas voor ons een extra 
stimulans om door te gaan. 
Peter Moleman, beste copromotor, jij bent er vanaf de eerste plannen voor een 
onderzoeksprotocoi tot de iaatste hoofdstukken van het proefschrift bij betrokken 
geweest. Peter, jouw grote deskundigheid maar vooral ook jouw enthousiasme en 
wezenlijke interesse voor wetenschappelijk onderzoek zijn voor mij steeds zeer 
inspirerend geweest. Ik denk met veel piezier terug aan de vele gesprekken elie wij 
gedurende het gehele traject hadden. 
Prof. Frank Verhulst en Prof. Wi//em Nolen !':".ramen eigenlijk pas in het hatste 
stadium in bee!d. Frank en Willem, ik ben jullie bijzonder erkentelijk dat jullie, toen 
er een moeilijke situatie op onze afdeling ontstaan was, op verzoek van Prof. 
Verv;roerd, decaan van de faculteit, als promotor hebben \villen optreden. De 
snelheid waannee jullie de manuscripten, voorzien van gedegen en deskundige 
feedback, retourneerden \vas voor mij ongekend en motiveerde mij extra om deze 
laatste fase sne! af te maken. Ook Prof Verwoerd ",il ik bedanken voor zijn inzet in 
deze. De promotiecommissie dank ik voor het beoordelen van het proefschrift. 
Bij het uit'lloeren van het onderzoek ben ik bijgestaan door veel mens en. 
Allereerst ",il ik alle jec/en van het behandelteam van Dp-2, dat toen nog 5-Zuid heette, 
van harte bedanken voor hun inzet. Dit patientgebonden onderzoek was ruet 
mogeJijk geweest zonder de steun en de betrokkenheid van de verpieegkuneligen, 
arts-assistenten, vaktherapeuten, maatschappe1ijk werkende en psycholoog van deze 
"depressie" -unit. Met name onze verpleegkundigen wil ik speciaal noemen. De 
begeleicling van ernstig zieke depressieve patienten binnen een onderzoeksprotocoi 
met medicatievrije obsenratie en vervolgens monotherapie met antidepressiva vraagt 
veel van de bege!eidende verpieegkuneligen. Ik heb bewondering voor jullie 
toewijcling en expertise op dit gebied en ben jullie erkenteJijk voor jullie inzet Siska 
Verploegh, jij bent onze onvolprezen research-assistente. Dank voor al je hulp. 
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Halverwege dit onderzoek L-wam jij op de unit en hie!p op onnavolgbare 'W-ijze met 
de orgarusatie van dit project en van de onderzoeksprojecten die volgden. Ben van de 
Weten·ng, ik dank je voor je steun gedurende de eerste jaren toen ik begon met 
patientgebonden onderzoek op 5-Zuid. Anne Marie van Hulst, samen hebben wij bij 
alle patienten een gestandaardiseerd psychiatrisch onderzoek afgenomen. Hoe druk 
je het ook had, je vond altijd gelegenheid om dit op de v~~r jou zo kenmerkende 
zorgvuldige en kritische wijze te doen. Ik heb dat zeer gewaardeerd. Roos van der Mast, 
jij waakte als een cerberus over de bloedspiege!s van de patienten. Ik dank je voor de 
efficiente regeling van deze bloedspiege!s onder strikte handhaving van dubbelblinde 
condities, jaar in jaar uit. Marga Bosbaan leverde hieriToor steeds de uitslagen aan, 
waarvoor vee! dank. Walter van den Broek, vanaf het moment dat jij de fakke! ovemam 
van Ben, heb jij je geldentificeerd met het patientgebonden onderzoek op onze 
research-unit en heb je mij geholpen bij het afmaken van dit onderzoek. Ik ben je 
daar zeer erkentelijk voor. Hayo Graatsma van de ziekenhuisapotheek (hoofd: Peter 
Roos) wil ik bedanken v~~r de zorgvuldige verstrekking van de dubbelblinde 
medicatie. Rita Brouwer en Rens Zwang van de afdeling Klinische Chemie (hoofd: Jan 
Lindemans) zorgden voor de '\vekelijkse efficiente en nau'\vkeurige bepating van de 
bloedspiege!s, waarvoor vee! dank. Godfried van Kempen en zijn medewerkers Erik 
Musch en Jolanda Schouten wil ik bedanken voor het bepalen van de MAO-activiteit in 
hun laboratorium, dat onderdeel is van het Psychiatrisch Ziekenhuis Endegeest. 
Theo Broekman heeft op zeer kundige wijze de data-base voor dit onderzoek 
ontworpen en later ook de data-validering verzorgd. Ik ben hern hier zeer erkentelijk 
voor. Ineke Verschoor ben ik veel dank verschulcligd voor het invoeren van de 
eindeloze hoeveelheid data. Organon wil ik bedanken v~~r de financiele 
ondersteuning van de data-base, inclusief de data-invoer. 
SPSS is tegenwoordig onder Windows te bedienen, tengevolge waarvan ook 
clinici zich '\vagen aan de statistische analyse van hun onderzoeksgegevens. Het is van 
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dank. 
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